WO2013009781A2 - Communication system with remote activation - Google Patents

Communication system with remote activation Download PDF

Info

Publication number
WO2013009781A2
WO2013009781A2 PCT/US2012/046118 US2012046118W WO2013009781A2 WO 2013009781 A2 WO2013009781 A2 WO 2013009781A2 US 2012046118 W US2012046118 W US 2012046118W WO 2013009781 A2 WO2013009781 A2 WO 2013009781A2
Authority
WO
WIPO (PCT)
Prior art keywords
unit
control module
signal
sealed housing
impedance
Prior art date
Application number
PCT/US2012/046118
Other languages
French (fr)
Other versions
WO2013009781A3 (en
Inventor
Jeffrey Berkman
Mark J. Zdeblick
Patricia Johnson
Hooman Hafezi
Jonathan Withrington
Original Assignee
Proteus Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2014520263A priority Critical patent/JP2014522695A/en
Priority to CN201280043374.0A priority patent/CN103781411B/en
Priority to CA2841904A priority patent/CA2841904A1/en
Priority to RU2014104519/14A priority patent/RU2014104519A/en
Priority to EP12811425.3A priority patent/EP2731497B1/en
Priority to AU2012282776A priority patent/AU2012282776B2/en
Priority to IN509CHN2014 priority patent/IN2014CN00509A/en
Priority to KR1020147003474A priority patent/KR20140066996A/en
Application filed by Proteus Biomedical, Inc. filed Critical Proteus Biomedical, Inc.
Priority to MX2014000482A priority patent/MX337132B/en
Priority to BR112014000624A priority patent/BR112014000624A2/en
Publication of WO2013009781A2 publication Critical patent/WO2013009781A2/en
Publication of WO2013009781A3 publication Critical patent/WO2013009781A3/en
Priority to HK14109909.5A priority patent/HK1196239A1/en
Priority to AU2017202754A priority patent/AU2017202754B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/07Endoradiosondes
    • A61B5/073Intestinal transmitters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0538Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7285Specific aspects of physiological measurement analysis for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/007Marking tablets or the like
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/27Adaptation for use in or on movable bodies
    • H01Q1/273Adaptation for carrying or wearing by persons or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0204Operational features of power management
    • A61B2560/0214Operational features of power management of power generation or supply
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/18Shielding or protection of sensors from environmental influences, e.g. protection from mechanical damage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0004Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
    • A61B5/0008Temperature signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/03Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs
    • A61B5/036Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs by means introduced into body tracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4836Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery

Definitions

  • the present invention is related to communication systems for detection of an event. More specifically, the present disclosure includes a system that includes a device with various power sources and communication schemes.
  • Ingestible devices that include electronic circuitry have been proposed for use in a variety of different medical applications, including both diagnostic and therapeutic applications. These devices typically require an internal power supply for operation.
  • ingestible devices are ingestible electronic capsules which collect data as they pass through the body, and transmit the data to an external receiver system.
  • An example of this type of electronic capsule is an in- vivo video camera.
  • the swallowable capsule includes a camera system and an optical system for imaging an area of interest onto the camera system.
  • the transmitter transmits the video output of the camera system and the reception system receives the transmitted video output.
  • Other examples include an ingestible imaging device, which has an internal and self-contained power source, which obtains images from within body lumens or cavities.
  • the electronic circuit components of the device are enclosed by an inert indigestible housing (e.g. glass housing) that passes through the body internally.
  • an inert indigestible housing e.g. glass housing
  • Other examples include an ingestible data recorder capsule medical device.
  • the electronic circuits of the disclosed device e.g. sensor, recorder, battery etc.
  • RFID tags are used in drug ingestion monitoring applications.
  • each application/tag requires an internal power supply.
  • the RFID tags are antenna structures that are configured to transmit a radio-frequency signal through the body.
  • the present disclosure includes a system for producing a unique signature that indicates the occurrence of an event.
  • the system includes circuitry and components that can be placed within certain environments that include a conducting fluid.
  • a conducting fluid such as a sealed bag with a solution, which includes an IV bag.
  • Another example is within the body of a living organism, such as an animal or a human.
  • the systems are ingestible and/or digestible or partially digestible.
  • the system includes dissimilar materials positioned on the framework such that when a conducting fluid comes into contact with the dissimilar materials, a voltage potential difference is created. The voltage potential difference, and hence the voltage, is used to power up control logic that is positioned within the framework. Ions or current flows from the first dissimilar material to the second dissimilar material via the control logic and then through the conducting fluid to complete a circuit.
  • the control logic controls the conductance between the two dissimilar materials and, hence, controls or modulates the conductance of the system.
  • the ingestible circuitry is made up of ingestible, and even digestible, components
  • the ingestible circuitry results in little, if any, unwanted side effects, even when employed in chronic situations.
  • Examples of the range of components that may be included are: logic and/or memory elements; effectors; a signal transmission element; and a passive element, such as a resistor or inductor.
  • the one or more components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided. All of the components and the support of the ingestible circuitry are ingestible, and in certain instances digestible or partially digestible.
  • Fig. 1 shows a pharmaceutical product with an event indicator system according to the teaching of the present invention, wherein the product and the event indicator system combination are within the body.
  • Fig. 2A shows the pharmaceutical product of Fig. 1 with the event indicator system on the exterior of the pharmaceutical product.
  • Fig. 2B shows the pharmaceutical product of Fig. 1 with the event indicator system positioned inside the pharmaceutical product.
  • Fig. 2C shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
  • Fig. 2D shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
  • Fig. 2E shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
  • Fig. 2F is an exploded view of the event indicator system.
  • Fig. 3 is a block diagram representation of one aspect of the event indicator system with dissimilar metals positioned on opposite ends.
  • Fig. 4 is a block diagram representation of another aspect of the event indicator system with dissimilar metals positioned on the same end and separated by a non-conducting material.
  • Fig. 5 shows ionic transfer or the current path through a conducting fluid when the event indicator system of Fig. 3 is in contact with conducting liquid and in an active state.
  • Fig. 5A shows an exploded view of the surface of dissimilar materials of Fig. 5.
  • Fig. 5B shows the event indicator system of Fig. 5 with a pH sensor unit.
  • Fig. 6 is a block diagram illustration of one aspect of the control device used in the system of Figs. 3 and 4.
  • Fig 7. is a functional block diagram of a demodulation circuit that performs coherent demodulation that may be present in a receiver, according to one aspect.
  • Fig 8 illustrates a functional block diagram for a beacon module within a receiver, according to one aspect.
  • Fig 9 is a block diagram of the different functional modules that may be present in a receiver, according to one aspect
  • Fig 10 is a block diagram of a receiver, according to one aspect.
  • Fig 1 1 provides a block diagram of a high frequency signal chain in a receiver, according to one aspect.
  • Fig 12 provides a diagram of how a system that includes a signal receiver and an ingestible event marker may be employed, according to one aspect.
  • the present disclosure includes multiple aspects for indicating the occurrence of an event.
  • a system of the present invention is used with a conducting fluid to indicate the event marked by contact between the conducting fluid and the system.
  • the system of the present disclosure may be used with pharmaceutical product and the event that is indicated is when the product is taken or ingested.
  • the term "ingested” or “ingest” or “ingesting” is understood to mean any introduction of the system internal to the body.
  • ingesting includes simply placing the system in the mouth all the way to the descending colon.
  • the term ingesting refers to any instant in time when the system is introduced to an environment that contains a conducting fluid.
  • Another example would be a situation when a non-conducting fluid is mixed with a conducting fluid. In such a situation the system would be present in the non- conduction fluid and when the two fluids are mixed, the system comes into contact with the conducting fluid and the system is activated. Yet another example would be the situation when the presence of certain conducting fluids needed to be detected. In such instances, the presence of the system, which would be activated, within the conducting fluid could be detected and, hence, the presence of the respective fluid would be detected.
  • the device comes into contact with the conducting liquid of the body.
  • the system of the present invention comes into contact with the body fluid, a voltage potential is created and the system is activated.
  • a portion of the power source is provided by the device, while another portion of the power source is provided by the conducting fluid, which is discussed in detail below.
  • an ingestible product 14 that includes a system of the present invention is shown inside the body.
  • the product 14 is configured as an orally ingestible pharmaceutical formulation in the form of a pill or capsule.
  • the pill moves to the stomach.
  • stomach fluid 18 Upon reaching the stomach, the product 14 is in contact with stomach fluid 18 and undergoes a chemical or electrochemical reaction with the various materials in the stomach fluid 18, such as hydrochloric acid and other digestive agents.
  • the system of the present invention is discussed in reference to a pharmaceutical environment. However, the scope of the present invention is not limited thereby.
  • the present invention can be used in any environment e.g., outside a body, where a conducting fluid is present or becomes present through mixing of two or more components that result in a conducting liquid.
  • a pharmaceutical product 10 similar to the product 14 of Fig. 1 , is shown with a system 12, such as an ingestible event marker or an ionic emission module (IEM).
  • IEM ionic emission module
  • the product 10 can be a capsule, a time-release oral dosage, a tablet, a gel cap, a sub-lingual tablet, or any oral dosage product that can be combined with the system 12.
  • the product 10 has the system 12 secured to the exterior using known methods of securing micro-devices to the exterior of pharmaceutical products.
  • Example of methods for securing the micro-device to the product is disclosed in US Provisional Application No. 12/741 ,583 filed on January 5, 2010 and entitled “HIGH-THROUGHPUT PRODUCTION OF INGESTIBLE EVENT MARKERS” also filed as PCT Application No. PCT/US10/20142 dated January 5, 2010 and published as WO 2010/080765 dated July 15, 2010 as well as US Provisional Application No. 61 /177,61 1 filed on May 12, 2009 and entitled “INGESTIBLE EVENT MARKERS COMPRISING AN IDENTIFIER AND AN INGESTIBLE COMPONENT", also filed as PCT Application No.
  • the system 12 may be coated with a shielding material or protective layer. The layer is dissolved over a period of time, thereby allowing the system 12 to be activated when the product 10 has reached a target location.
  • a pharmaceutical product 20 similar to the product 14 of Fig. 1 , is shown with a system 22, such as an ingestible event marker or an identifiable emission module.
  • a system 22 such as an ingestible event marker or an identifiable emission module.
  • the scope of the present invention is not limited by the environment to which the system 22 is introduced.
  • the system 22 can be enclosed in a capsule that is taken in addition to/independently from the pharmaceutical product.
  • the capsule may be simply a carrier for the system 22 and may not contain any product.
  • the scope of the present invention is not limited by the shape or type of product 20.
  • the product 20 can be a capsule, a time-release oral dosage, a tablet, a gel capsule, a sub-lingual tablet, or any oral dosage product.
  • the product 20 has the system 22 positioned inside or secured to the interior of the product 20.
  • the system 22 is secured to the interior wall of the product 20.
  • the content of the gel capsule is a non-conducting gel-liquid.
  • the system 22 is coated with a protective cover to prevent unwanted activation by the gel capsule content.
  • the system 22 is positioned or placed within the capsule. If the product 20 is a tablet or hard pill, then the system 22 is held in place inside the tablet. Once ingested, the product 20 containing the system 22 is disintegrated and/or dissolved. The system 22 comes into contact with body liquids and the system 22 is activated. Depending on the product 20, the system 22 may be positioned in either a near-central or near- perimeter position depending on the desired activation delay between the time of initial ingestion and activation of the system 22. For example, a central position for the system 22 means that it will take longer for the system 22 to be in contact with the conducting liquid and, hence, it will take longer for the system 22 to be activated. Therefore, it will take longer for the occurrence of the event to be detected.
  • a capsule 1 1 is shown with a cavity 1 1 a therein.
  • the capsule 1 1 is shown as an empty capsule in accordance with one aspect of the present invention.
  • a system 12a Inside the cavity is a system 12a, which is similar to the systems 12 and 22 of Figs. 2A and 2B, respectively.
  • the capsule 1 1 breaks apart or disintegrates or dissolves to allow the system to be released from the environment.
  • the capsule 1 1 is shown with the system 12a along with a material 13 inserted into the cavity 1 1 a.
  • the material 13 can be activated to expand and cause the capsule 1 1 to break apart.
  • the activation of the material 13 is controlled by the system 12a.
  • the system 12a receives a signal from an external source which may be inside the body, on the body or outside the body and in response to the signal, is able to activate the material 13 to cause the material 12 to expand.
  • the material 13 is an electroactive material that is selected to be reactive to an electrical signal such that the properties change when exposed to a voltage potential or current.
  • An electroactive material or matrix includes a material whose properties, such as physical dimensions or solubility, change in response to an applied voltage or current.
  • electroactive materials include: polyvinylidene fluoride (PVDF), perfluorinated sulfouic acid (Nation TM), perfluorinated carboxylic acid (Flemion TM), cellulose, a polymer matrix (for example polyethylene oxide or cellulose) containing a salt (eg a salt containing a multivalent ion such as Fe 3+ ) or a protein.
  • the system 12a includes a plunger that releases a chemical or compound into the material 1 1 a to cause a chemical reaction that causes the material 1 1 a to expand.
  • the capsule 1 1 is shown with the system 12a in greater detail.
  • the system 12a includes a unit 12b secured to the system 12a.
  • the unit 12b includes a housing that defines a cavity 12c.
  • the cavity 12c can be filled with a chemical or a compound that is released into the cavity 1 1 a when the cavity 1 1 a is filled with the material 13 to initiate a reaction that causes the material 13 to expand.
  • the cavity 12c includes a solid object that acts like a needle or a rod. The object is mechanically pushed out of the cavity 12c in the direction AA as shown.
  • the object is then able to push through the wall of the capsule 1 1 and cause the wall to tear or break apart. This facilitates separation of the system 12a from the capsule 1 1 and allows the system 12a to come into contact with the surrounding environment and become activated.
  • the unit 12b is able to control activation of the system 12a.
  • the unit 12b includes a communication module that can either receive, transmit, or receive and transmit.
  • the unit 12b can act as a secondary communication module, as discussed in detail below with respect to Fig. 5 and element 75.
  • the unit 12b can receive control signals from and external source, in accordance with one aspect of the present invention.
  • the unit 12b can send signals to an external source.
  • the unit 12b acts as a transceiver and is able to receive and send signals to external devices.
  • the unit 12b is also in communication with the other components of the system 12a as discussed in detail below.
  • system 30 in one aspect, the systems 12 and 22 of Figs. 2A and 2B, respectively, are shown in more detail as system 30.
  • the system 30 can be used in association with any pharmaceutical product, as mentioned above, to determine when a patient ingests the pharmaceutical product.
  • the scope of the present invention is not limited by the environment and the product that is used with the system 30.
  • the system 30 may be placed within a capsule and the capsule is placed within the conducting liquid. The capsule would then dissolve over a period of time and release the system 30 into the conducting liquid.
  • the capsule would contain the system 30 and no product.
  • Such a capsule may then be used in any environment where a conducting liquid is present and with any product.
  • the capsule may be dropped into a container filled with jet fuel, salt water, tomato sauce, motor oil, or any similar product.
  • the capsule containing the system 30 may be ingested at the same time that any pharmaceutical product is ingested in order to record the occurrence of the event, such as when the product was taken.
  • the system 30 is activated.
  • the system 30 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken.
  • the system 30 includes a resistance 31 between the V high and ground 52.
  • the resistive element includes a known quantity and represents a voltage drop between V high and ground. This known quantity is used to determine the impedance of the surrounding environment as noted with respect to Fig. 5 below and unit 75a.
  • the system 30 includes a framework 32.
  • the framework 32 is a chassis for the system 30 and multiple components are attached to, deposited upon, or secured to the framework 32.
  • an ingestible or digestible material 34 is physically associated with the framework 32.
  • the material 34 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as "deposit" with respect to the framework 32.
  • the material 34 is deposited on one side of the framework 32.
  • the materials of interest that can be used as material 34 include, but are not limited to: Cu or Cul.
  • the material 34 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols.
  • the material 34 may be from about 0.05 to about 500 ⁇ thick, such as from about 5 to about 100 ⁇ thick.
  • the shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 30 may contain two or more electrically unique regions where the material 34 may be deposited, as desired.
  • Another digestible material 36 is deposited, such that materials 34 and 36 are dissimilar and are insulated from each other.
  • the different side selected may be the side next to the side selected for the material 34.
  • the scope of the present invention is not limited by the side selected and the term "different side" can mean any of the multiple sides that are different from the first selected side.
  • the shape of the system is shown as a square, the shape maybe any geometrically suitable shape.
  • Material 34 and 36 are selected such that they produce a voltage potential difference when the system 30 is in contact with conducting liquid, such as body fluids.
  • the materials of interest for material 36 include, but are not limited to: Mg, Zn, or other electronegative metals.
  • the material 36 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework. Also, an adhesion layer may be necessary to help the material 36 (as well as material 34 when needed) to adhere to the framework 32. Typical adhesion layers for the material 36 are Ti, TiW, Cr or similar material. Anode material and the adhesion layer may be deposited by physical vapor deposition, electrodeposition or plasma deposition. The material 36 may be from about 0.05 to about 500 ⁇ thick, such as from about 5 to about 100 ⁇ thick. However, the scope of the present invention is not limited by the thickness of any of the materials nor by the type of process used to deposit or secure the materials to the framework 32.
  • the materials 34 and 36 can be any pair of materials with different electrochemical potentials. Additionally, in the aspects wherein the system 30 is used in-vivo, the materials 34 and 36 may be vitamins that can be absorbed. More specifically, the materials 34 and 36 can be made of any two materials appropriate for the environment in which the system 30 will be operating. For example, when used with an ingestible product, the materials 34 and 36 are any pair of materials with different electrochemical potentials that are ingestible. An illustrative example includes the instance when the system 30 is in contact with an ionic solution, such as stomach acids.
  • Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuCI or Cul).
  • a metal such as Mg
  • a salt such as CuCI or Cul
  • any pairing of substances - metals, salts, or intercalation compounds - with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.
  • Materials and pairings of interest include, but are not limited to, those reported in Table 1 below.
  • one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage potential created between the materials as they come into contact with a conducting liquid.
  • Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like.
  • the materials are copper iodine (Cul) as the anode and magnesium (Mg) as the cathode. Aspects of the present invention use electrode materials that are not harmful to the human body.
  • Copper salts Copper salts: iodide, chloride, bromide, sulfate, formate, (other anions possible)
  • Fe 3+ salts e.g. orthophosphate, pyrophosphate, (other anions possible)
  • a current path is formed through the conducting liquid between material 34 and 36.
  • a control device 38 is secured to the framework 32 and electrically coupled to the materials 34 and 36.
  • the control device 38 includes electronic circuitry, for example control logic that is capable of controlling and altering the conductance between the materials 34 and 36.
  • the voltage potential created between the materials 34 and 36 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system.
  • the system operates in direct current mode.
  • the system controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current.
  • a receiver not shown, can detect the presence of the current and recognize that the system 30 has been activate and the desired event is occurring or has occurred. Illustrative examples of such receivers are further described with respect to Figs. 7 to 12, as described hereinafter.
  • the two materials 34 and 36 are similar in function to the two electrodes needed for a direct current power source, such as a battery.
  • the conducting liquid acts as the electrolyte needed to complete the power source.
  • the completed power source described is defined by the electrochemical reaction between the materials 34 and 36 of the system 30 and enabled by the fluids of the body.
  • the completed power source may be viewed as a power source that exploits electrochemical conduction in an ionic or a conducting solution such as gastric fluid, blood, or other bodily fluids and some tissues.
  • the environment may be something other than a body and the liquid may be any conducting liquid.
  • the conducting fluid may be salt water or a metallic based paint.
  • these two materials are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials are exposed to the target site, a voltage potential is generated.
  • the complete power source or supply is one that is made up of active electrode materials, electrolytes, and inactive materials, such as current collectors, packaging, etc.
  • the active materials are any pair of materials with different electrochemical potentials. Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as Cul).
  • a metal such as Mg
  • a salt such as Cul
  • any pairing of substances - metals, salts, or intercalation compounds - with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.
  • electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the system of the identifier.
  • the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1 .0 volts or higher, where in certain aspects, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.
  • the materials 34 and 36 provide the voltage potential to activate the control device 38.
  • the control device 38 can alter conductance between the materials 34 and 36 in a unique manner.
  • the control device 38 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 30. This produces a unique current signature that can be detected and measured by a receiver (not shown), which can be positioned internal or external to the body.
  • non-conducting materials, membrane, or “skirt" are used to increase the "length" of the current path and, hence, act to boost the conductance path, as disclosed in the U.S.
  • the system 30 may be surrounded entirely or partially by the skirt and the skirt maybe positioned along a central axis of the system 30 or off-center relative to a central axis.
  • the scope of the present invention as claimed herein is not limited by the shape or size of the skirt.
  • the materials 34 and 36 may be separated by one skirt that is positioned in any defined region between the materials 34 and 36.
  • the system 40 includes a framework 42.
  • the framework 42 is similar to the framework 32 of Fig. 3.
  • a digestible or dissolvable material 44 is deposited on a portion of one side of the framework 42.
  • another digestible material 46 is deposited, such that materials 44 and 46 are dissimilar. More specifically, materials 44 and 46 are selected such that they form a voltage potential difference when in contact with a conducting liquid, such as body fluids.
  • a current path is formed through the conducting liquid between material 44 and 46.
  • a control device 48 is secured to the framework 42 and electrically coupled to the materials 44 and 46.
  • the control device 48 includes electronic circuitry that is capable of controlling part of the conductance path between the materials 44 and 46.
  • the materials 44 and 46 are separated by a non-conducting skirt 49.
  • Various examples of the skirt 49 are disclosed in US Provisional Application No. 61 /173,51 1 filed on April 28, 2009 and entitled "HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS OF USING SAME" also filed as PCT Application No.
  • the control device 48 can alter conductance between the materials 44 and 46.
  • the control device 48 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 40.
  • a unique current signature that is associated with the system 40 can be detected by a receiver (not shown) to mark the activation of the system 40. Illustrative examples of receivers are found in Figs.7 to 12 , as described hereinafter.
  • the size and/or characteristics of the skirt 49 is altered. The longer the current path, the easier it may be for the receiver to detect the current.
  • FIG. 5 the system 30 of Fig. 3 is shown in an activated state and in contact with conducting liquid.
  • the system 30 is grounded through ground contact 52.
  • the conducting fluid provides the ground.
  • the system 30 also includes a sensor module 74, which is described in greater detail with respect to Fig. 6.
  • Ion or current paths 50 are formed between material 34 to material 36 and through the conducting fluid in contact with the system 30.
  • the voltage potential created between the material 34 and 36 is created through chemical reactions between materials 34/36 and the conducting fluid.
  • the system 30 also includes a unit 75.
  • the unit 75 includes aspects that enable communication functions and in accordance with the various aspects of the present invention can act as any of the following: a receiver, a transmitter, or a transceiver.
  • another device that is external to the system 30, such as a cell phone, an implanted device, a device attached to the user's body, or a device placed under the user's skin, may communicate, e.g. to, from or both, the system 30 through the unit 75.
  • the unit 75 is also electrically connected to the materials 34 and 36.
  • any device that is external to the system 30 may communicate with either the unit 75 or the control module 38 using current flow through the environment surrounding the system 30.
  • a patch or receiver that is attached to the user's body, a cell phone or device being held by the user, or an implanted device are examples of devices which can generate a current signature through the user's body.
  • the current signature can include information that is encoded therein.
  • the current signature is detected by the system 30, using the unit 75 or the control module 38, and decoded to allow communication to the system 30 from the device external to system 30. Accordingly, the external device can send a signal to the unit 75, either wirelessly or through transconduction, that controls the activation of the system 30.
  • the unit 75 can also measure the surrounding environment, either directly or through the sensor module 74, to determine is the system 30 should be deactivate due to unfavorable environmental conditions.
  • the unit 75 may include an impedance measurement unit 75a that is able to measure impedance of the environment around the system 30.
  • the unit 75a measures impedance by transmitting or applying voltage to one output terminal, such as the material 34.
  • the unit 75a measures impedance (using the resistance 31 of Fig. 3). With a known quantity of resistance and the known voltage, the unit 75a is able to determine the impedance of the surrounding environment.
  • the received signal at the receiver is directly proportional to the current output of the system 30.
  • the current output of the system 30 will be proportional to 1 /(R+Z), where R is the value of the variable resistor and Z, the local impedance of the solution or stomach environment around the system 30. Therefore, the detected signal will be equal to:
  • Vreceievd k / (R + Z)
  • the system 30 can be designed with a variable resistor that cycles between 2 or more levels during transmission. This results in a received signal that will vary according the above equation. When detected, the signal is used to generate a linear plot to fit :
  • the slope will have a value 1/k and the intercept, Z/k. This allows both k and the local impedance of the system 30 to be determined, independent of the actual voltage or current draw from the system 30 because the value of the variable resistor is know from the design parameters.
  • the impedance measurement may be used to monitor hydration state of the patient, presence of drug, Gastro-intestinal motility/waves, gastric transit time, presence of certain types of tissue (tumors) or bleeding.
  • the impedance measurement is also a useful diagnostic tool for monitoring performance of the system 30. For example, if the impedance of the surrounding environment would prevent effective communication, then the system 30 can be deactivated or activated with a delay.
  • the unit 75 sends a signal to the control device 38.
  • control device 38 can alter the conductance, and hence the impedance, between the materials 34 and 36 to reduce the rate of chemical reaction between materials 34 and 36 and the surrounding environment and thereby cause the system 30 to reach a deactivated mode, state, or condition. In this way, even though there is some chemical reaction, it is sufficiently low to preserve the power of the system 30 for later use, while still allowing operation of sensing and measurement of the nearby environment.
  • the unit 75 sends a signal to the control device 38 to alter the conductance between the materials 34 and 36 to allow for communication using the current signature of the system 30.
  • the system 30 can be activated again.
  • the unit 75 sends a signal to the control device 38 to alter the conductance between the materials 34 and 36 to allow for communication using the current signature of the system 30.
  • the system 30 can be activated again.
  • Fig. 5A shows an exploded view of the surface of the material 34.
  • the surface of the material 34 is not planar, but rather an irregular surface.
  • the irregular surface increases the surface area of the material and, hence, the area that comes in contact with the conducting fluid.
  • there is an electrochemical reaction between the material 34 and the surrounding conducting fluid such that mass is exchanged with the conducting fluid.
  • masses as used here includes any ionic or non-ionic species that may be added or removed from the conductive fluid as part of the electrochemical reactions occurring on material 34.
  • One example includes the instant where the material is CuCI and when in contact with the conducting fluid, CuCI is converted to Cu metal (solid) and CI- is released into the solution.
  • the flow of positive ions into the conducting fluid is depicted by the current path 50.
  • Negative ions flow in the opposite direction.
  • the release of negative ions at the material 34 and release of positive ions by the material 36 are related to each other through the current flow that is controlled by the control device 38.
  • the rate of reaction and hence the ionic emission rate or current is controlled by the control device 38.
  • the control device 38 can increase or decrease the rate of ion flow by altering its internal conductance, which alters the impedance, and therefore the current flow and reaction rates at the materials 34 and 36.
  • the system 30 can encode information in the ionic flow.
  • the system 30 encodes information using ionic emission or flow.
  • the control device 38 can vary the duration of ionic flow or current while keeping the current or ionic flow magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 38 can vary the level of the ionic flow rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 38 encodes information in the current or the ionic flow. For example, the control device 38 may use, but is not limited to any of the following techniques, including Binary Phase- Shift Keying (PSK), Frequency modulation, Amplitude modulation, on-off keying, and PSK with on-off keying.
  • PSK Binary Phase- Shift Keying
  • the various aspects disclosed herein include electronic components as part of the control device 38 or the control device 48.
  • Components that may be present include but are not limited to: logic and/or memory elements, an integrated circuit, an inductor, a resistor, and sensors for measuring various parameters.
  • Each component may be secured to the framework and/or to another component.
  • the components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided.
  • the system such as control devices 30 and 40, control the conductance between the dissimilar materials and, hence, the rate of ionic flow or current.
  • the system is capable of encoding information in the ionic flow and the current signature.
  • the ionic flow or the current signature is used to uniquely identify the specific system.
  • the systems 30 and 40 are capable of producing various different unique patterns or signatures and, thus, provide additional information.
  • a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment.
  • a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.
  • the control device 38 includes a control module 62, a counter or clock 64, and a memory 66. Additionally, the device 38 is shown to include a sensor module 72 as well as the sensor module 74, which was referenced in Fig. 5.
  • the control module 62 has an input 68 electrically coupled to the material 34 and an output 70 electrically coupled to the material 36.
  • the control module 62, the clock 64, the memory 66, and the sensor modules 72/74 also have power inputs (some not shown). The power for each of these components is supplied by the voltage potential produced by the chemical reaction between materials 34 and 36 and the conducting fluid, when the system 30 is in contact with the conducting fluid.
  • the control module 62 controls the conductance through logic that alters the overall impedance of the system 30.
  • the control module 62 is electrically coupled to the clock 64.
  • the clock 64 provides a clock cycle to the control module 62. Based upon the programmed characteristics of the control module 62, when a set number of clock cycles have passed, the control module 62 alters the conductance characteristics between materials 34 and 36. This cycle is repeated and thereby the control device 38 produces a unique current signature characteristic.
  • the control module 62 is also electrically coupled to the memory 66. Both the clock 64 and the memory 66 are powered by the voltage potential created between the materials 34 and 36.
  • the control module 62 is also electrically coupled to and in communication with the sensor modules 72 and 74.
  • the sensor module 72 is part of the control device 38 and the sensor module 74 is a separate component.
  • either one of the sensor modules 72 and 74 can be used without the other and the scope of the present invention is not limited by the structural or functional location of the sensor modules 72 or 74.
  • any component of the system 30 may be functionally or structurally moved, combined, or repositioned without limiting the scope of the present invention as claimed.
  • the sensor modules 72 or 74 can include any of the following sensors: temperature, pressure, pH level, and conductivity.
  • the sensor modules 72 or 74 gather information from the environment and communicate the analog information to the control module 62.
  • the control module then converts the analog information to digital information and the digital information is encoded in the current flow or the rate of the transfer of mass that produces the ionic flow.
  • the sensor modules 72 or 74 gather information from the environment and convert the analog information to digital information and then communicate the digital information to control module 62.
  • the sensor module 74 is shown as being electrically coupled to the material 34 and 36 as well as the control device 38.
  • the sensor module 74 is electrically coupled to the control device 38 at connection 78.
  • the connection 78 acts as both a source for power supply to the sensor module 74 and a communication channel between the sensor module 74 and the control device 38.
  • the system 30 includes a pH sensor module 76 connected to a material 39, which is selected in accordance with the specific type of sensing function being performed.
  • the pH sensor module 76 is also connected to the control device 38.
  • the material 39 is electrically isolated from the material 34 by a non-conductive barrier 55.
  • the material 39 is platinum.
  • the pH sensor module 76 uses the voltage potential difference between the materials 34/36.
  • the pH sensor module 76 measures the voltage potential difference between the material 34 and the material 39 and records that value for later comparison.
  • the pH sensor module 76 also measures the voltage potential difference between the material 39 and the material 36 and records that value for later comparison.
  • the pH sensor module 76 calculates the pH level of the surrounding environment using the voltage potential values.
  • the pH sensor module 76 provides that information to the control device 38.
  • the control device 38 varies the rate of the transfer of mass that produces the ionic transfer and the current flow to encode the information relevant to the pH level in the ionic transfer, which can be detected by a receiver (not shown).
  • the system 30 can determine and provide the information related to the pH level to a source external to the environment.
  • control device 38 can be programmed in advance to output a pre-defined current signature.
  • system can include a receiver system that can receive programming information when the system is activated.
  • switch 64 and the memory 66 can be combined into one device.
  • FIG. 7 provides a functional block diagram of how a receiver may implement a coherent demodulation protocol, according to one aspect of the invention. It should be noted that only a portion of the receiver is shown in FIG. 7.
  • FIG. 7 illustrates the process of mixing the signal down to baseband once the carrier frequency (and carrier signal mixed down to carrier offset) is determined.
  • a carrier signal 2221 is mixed with a second carrier signal 2222 at mixer 2223.
  • a narrow low-pass filter 2220 is applied of appropriate bandwidth to reduce the effect of out-of-bound noise.
  • Demodulation occurs at functional blocks 2225 in accordance with the coherent demodulation scheme of the present invention.
  • the unwrapped phase 2230 of the complex signal is determined.
  • the structure of the packet is then leveraged to determine the beginning of the coding region of the BPSK signal at block 2240. Mainly, the presence of the sync header, which appears as an FM porch in the amplitude signal of the complex demodulated signal is used to determine the starting bounds of the packet. Once the starting point of the packet is determined the signal is rotated at block 2250 on the IQ plane and standard bit identification and eventually decoded at block 2260.
  • the transbody communication module may include a forward error correction module, which module provides additional gain to combat interference from other unwanted signals and noise.
  • Forward error correction functional modules of interest include those described in PCT Application Serial No. PCT/US2007/024225 and published as WO 2008/063626, the disclosure of which is herein incorporated by reference.
  • the forward error correction module may employ any convenient protocol, such as Reed-Solomon, Golay, Hamming, BCH, and Turbo protocols to identify and correct (within bounds) decoding errors.
  • the receiver includes a beacon module as shown in the functional block diagram of FIG. 8.
  • the scheme outlined in FIG. 8 outlines one technique for identifying a valid beacon.
  • the incoming signal 2360 represents the signals received by electrodes, bandpass filtered (such as from 10 KHz to 34 KHz) by a high frequency signaling chain (which encompasses the carrier frequency), and converted from analog to digital.
  • the signal 2360 is then decimated at block 2361 and mixed at the nominal drive frequency (such as, 12.5 KHz, 20 KHz, etc.) at mixer 2362.
  • the resulting signal is decimated at block 2364 and low-pass filtered (such as 5 KHz BW) at block 2365 to produce the carrier signal mixed down to carrier offset- signal 2369.
  • Signal 2369 is further processed by blocks 2367 (fast Fourier transform and then detection of two strongest peaks) to provide the true carrier frequency signal 2368. This protocol allows for accurate determination of the carrier frequency of the transmitted beacon.
  • FIG. 9 provides a block functional diagram of an integrated circuit component of a signal receiver according to an aspect of the invention.
  • receiver 2700 includes electrode input 2710. Electrically coupled to the electrode input 2710 are transbody conductive communication module 2720 and physiological sensing module 2730.
  • transbody conductive communication module 2720 is implemented as a high frequency (HF) signal chain and physiological sensing module 2730 is implemented as a low frequency (LF) signal chain.
  • CMOS temperature sensing module 2740 for detecting ambient temperature
  • Receiver 2700 also includes a processing engine 2760 (for example, a microcontroller and digital signal processor), non-volatile memory 2770 (for data storage) and wireless communication module 2780 (for data transmission to another device, for example in a data upload action).
  • processing engine 2760 for example, a microcontroller and digital signal processor
  • non-volatile memory 2770 for data storage
  • wireless communication module 2780 for data transmission to another device, for example in a data upload action.
  • FIG. 10 provides a more detailed block diagram of a circuit configured to implement the block functional diagram of the receiver depicted in FIG. 9, according to one aspect of the invention.
  • receiver 2800 includes electrodes e1 , e2 and e3 (281 1 , 2812 and 2813) which, for example, receive the conductively transmitted signals by an I EM and/or sense physiological parameters or biomarkers of interest.
  • the signals received by the electrodes 281 1 , 2812, and 2813 are multiplexed by multiplexer 2820 which is electrically coupled to the electrodes.
  • Multiplexer 2820 is electrically coupled to both high band pass filter 2830 and low band pass filter 2840.
  • the high and low frequency signal chains provide for programmable gain to cover the desired level or range.
  • high band pass filter 2830 passes frequencies in the 10 KHz to 34 KHz band while filtering out noise from out-of-band frequencies. This high frequency band may vary, and may include, for example, a range of 3 KHz to 300 KHz.
  • the passing frequencies are then amplified by amplifier 2832 before being converted into a digital signal by converter 2834 for input into high power processor 2880 (shown as a DSP) which is electrically coupled to the high frequency signal chain.
  • DSP digital signal processor
  • Low band pass filter 2840 is shown passing lower frequencies in the range of 0.5 Hz to 150 Hz while filtering out out-of-band frequencies.
  • the frequency band may vary, and may include, for example, frequencies less than 300 Hz, such as less than 200 Hz, including less than 150 Hz.
  • the passing frequency signals are amplified by amplifier 2842.
  • accelerometer 2850 electrically coupled to second multiplexer 2860.
  • Multiplexer 2860 multiplexes the signals from the accelerometer with the amplified signals from amplifier 2842.
  • the multiplexed signals are then converted to digital signals by converter 2864 which is also electrically coupled to low power processor 2870.
  • a digital accelerometer (such as one manufactured by Analog Devices), may be implemented in place of accelerometer 2850.
  • the digital accelerometer may include a FIFO buffer to help control the flow of data sent to the low power processor 2870. For instance, data may be buffered in the FIFO until full, at which time the processor may be triggered to turn awaken from an idle state and receive the data.
  • Low power processor 2870 may be, for example, an MSP430 microcontroller from Texas Instruments.
  • Low power processor 2870 of receiver 2800 maintains the idle state, which as stated earlier, requires minimal current draw ⁇ e.g., 10 .mu.A or less, or 1 .mu.A or less.
  • High power processor 2880 may be, for example, a VC5509 digital signal process from Texas Instruments. The high power processor 2880 performs the signal processing actions during the active state. These actions, as stated earlier, require larger amounts of current than the idle state ⁇ e.g., currents of 30 .mu.A or more, such as 50 .mu.A or more--and may include, for example, actions such as scanning for conductively transmitted signals, processing conductively transmitted signals when received, obtaining and/or processing physiological data, etc.
  • flash memory 2890 electrically coupled to high power processor 2880.
  • flash memory 2890 may be electrically coupled to low power processor 2870, which may provide for better power efficiency.
  • Wireless communication element 2895 is shown electrically coupled to high power processor 2880 and may include, for example, a BLUETOOTH. TM. wireless communication transceiver.
  • wireless communication element 2895 is electrically coupled to high power processor 2880.
  • wireless communication element 2895 is electrically coupled to high power processor 2880 and low power processor 2870.
  • wireless communication element 2895 may be implemented to have its own power supply so that it may be turned on and off independently from other components of the receiver ⁇ e.g., by a microprocessor.
  • Receiver 2800 is configured such that low power processor 2870 is in an inactive state (such as idle state) and high power processor 2880 is in an inactive state (such as idle state), and circuit blocks related to peripheral circuitry and their power supplies required during various active states remain off (for example, wireless communication module 2895 and the analog front end).
  • the low power processor may have a 32 KHz oscillator active and may consume a few .mu.A current or less, including 0.5 .mu.A or less.
  • the low power processor 2870 may, for example, wait for a signal to transfer to an active state.
  • the signal might be external such as an interrupt or internally generated by one of the device's peripherals, such as a timer.
  • the high power processor may, for example, be running off a 32 KHz watch crystal.
  • the high power processor may, for example, wait for a signal to transfer to active state.
  • low power processor 2870 is in an idle state and high power processor 2880 is in an idle state.
  • the beacon signal module may implement various types of sniff signals to achieve low power efficiency.
  • a higher power demodulate and decode state may be entered.
  • low power processor 2870 is in an active state
  • high power processor 2880 is in an active state.
  • High power processor 2880 may, for example, be running from a 12 MHz or near crystal oscillator with a PLL-based clock multiplier giving the device a 108 MHz clock speed.
  • the low power processor 2870 may, for example, run off an internal R-C oscillator in the range of 1 MHz to 20 MHz and consume power in the range of 250 to 300 uA per MHz clock speed during active states.
  • the active state allows for processing and any transmissions that may follow. Required transmissions may trigger the wireless communication module to cycle from off to on.
  • the high power processor 2880 is in an in idle state during collection, and in an active state (for example, running from a 12 MHz or near crystal oscillator with a PLL-based clock multiplier giving the device a 108 MHz clock speed) during processing and transmission.
  • the low power processor 2870 is in an active state during this state and may run off an internal R-C oscillator in the range of 1 MHz to 20 MHz and consume power in the range of 250 to 300 uA per MHz clock speed.
  • the low power processor e.g., MSP shown in FIG. 10
  • high power processor e.g., DSP shown in FIG. 10
  • SPI bus serial peripheral interface bus
  • FIG. 1 1 provides a view of a block diagram of hardware in a receiver according to an aspect of the invention related to the high frequency signal chain.
  • receiver 2900 includes receiver probes (for example in the form of electrodes 291 1 , 2912 and 2913) electrically coupled to multiplexer 2920.
  • high pass filter 2930 and low pass filter 2940 to provide for a band pass filter which eliminates any out-of-band frequencies.
  • a band pass of 10 KHz to 34 KHz is provided to pass carrier signals falling within the frequency band.
  • Example carrier frequencies may include, but are not limited to, 12.5 KHz and 20 KHz.
  • One or more carriers may be present.
  • receiver 2900 includes analog to digital converter 2950 ⁇ for example, sampling at 500 KHz.
  • the digital signal can thereafter be processed by the DSP.
  • Shown in this aspect is DMA to DSP unit 2960 which sends the digital signal to dedicated memory for the DSP.
  • the direct memory access provides the benefit of allowing the rest of the DSP to remain in a low power mode.
  • system 3500 includes a pharmaceutical composition 3510 that comprises an ingestible device such as an ingestible event marker, " I EM.” Also present in system 3500 is signal receiver 3520.
  • Signal receiver 3520 is configured to detect a signal emitted from the identifier of the I EM 3510.
  • Signal receiver 3520 also includes physiologic sensing capability, such as ECG and movement sensing capability.
  • Signal receiver 3520 is configured to transmit data to a patient's an external device or PDA 3530 (such as a smart phone or other wireless communication enabled device), which in turn transmits the data to a server 3540.
  • PDA 3530 such as a smart phone or other wireless communication enabled device
  • Server 3540 may be configured as desired, e.g., to provide for patient directed permissions.
  • server 3540 may be configured to allow a family caregiver 3550 to participate in the patient's therapeutic regimen, e.g., via an interface (such as a web interface) that allows the family caregiver 3550 to monitor alerts and trends generated by the server 3540, and provide support back to the patient, as indicated by arrow 3560.
  • the server 3540 may also be configured to provide responses directly to the patient, e.g., in the form of patient alerts, patient incentives, etc., as indicated by arrow 3565 which are relayed to the patient via PDA 3530.
  • Server 3540 may also interact with a health care professional (e.g., RN, physician) 3555, which can use data processing algorithms to obtain measures of patient health and compliance, e.g., wellness index summaries, alerts, cross-patient benchmarks, etc., and provide informed clinical communication and support back to the patient, as indicated by arrow 3580.
  • a health care professional e.g., RN, physician
  • measures of patient health and compliance e.g., wellness index summaries, alerts, cross-patient benchmarks, etc.
  • the system 30 may also include one or other electronic components.
  • Electrical components of interest include, but are not limited to: additional logic and/or memory elements, e.g., in the form of an integrated circuit; a power regulation device, e.g., battery, fuel cell or capacitor; a sensor, a stimulator, etc. ; a signal transmission element, e.g., in the form of an antenna, electrode, coil, etc. ; a passive element, e.g., an inductor, resistor, etc.
  • the ingestible circuitry includes a coating layer.
  • the purpose of this coating layer can vary, e.g., to protect the circuitry, the chip and/or the battery, or any components during processing, during storage, or even during ingestion.
  • a coating on top of the circuitry may be included.
  • coatings that are designed to protect the ingestible circuitry during storage, but dissolve immediately during use For example, coatings that dissolve upon contact with an aqueous fluid, e.g. stomach fluid, or the conducting fluid as referenced above.
  • protective processing coatings that are employed to allow the use of processing steps that would otherwise damage certain components of the device.
  • the product needs to be diced.
  • the dicing process can scratch off the dissimilar material, and also there might be liquid involved which would cause the dissimilar materials to discharge or dissolve.
  • a protective coating on the materials prevents mechanical or liquid contact with the component during processing can be employed.
  • Another purpose of the dissolvable coatings may be provided to delay activation of the device. For example, the coating that sits on the dissimilar material and takes a certain period of time, e.g., five minutes, to dissolve upon contact with stomach fluid may be employed.
  • the coating can also be an environmentally sensitive coating, e.g., a temperature or pH sensitive coating, or other chemically sensitive coating that provides for dissolution in a controlled fashion and allows one to activate the device when desired. Coatings that survive the stomach but dissolve in the intestine are also of interest, e.g., where one desires to delay activation until the device leaves the stomach.
  • An example of such a coating is a polymer that is insoluble at low pH, but becomes soluble at a higher pH.
  • pharmaceutical formulation protective coatings e.g., a gel cap liquid protective coating that prevents the circuit from being activated by liquid of the gel cap.
  • Identifiers of interest include two dissimilar electrochemical materials, which act similar to the electrodes (e.g., anode and cathode) of a power source.
  • the reference to an electrode or anode or cathode are used here merely as illustrative examples.
  • the scope of the present invention is not limited by the label used and includes the aspect wherein the voltage potential is created between two dissimilar materials.
  • reference is made to an electrode, anode, or cathode it is intended as a reference to a voltage potential created between two dissimilar materials.
  • a potential difference that is, a voltage
  • a potential difference is generated between the electrodes as a result of the respective oxidation and reduction reactions incurred to the two electrode materials.
  • a voltaic cell, or battery can thereby be produced.
  • such power supplies are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated.
  • one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery.
  • Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like.
  • a device for communication including circuitry and components which function in conducting fluid, which device is ingestible and/or digestible, the device comprising: [091] a communication unit, which communication unit comprises; [092] a support structure;
  • a second material deposited onto the support structure and electrically isolated from the first material, wherein the first material and the second material are selected to have a voltage potential difference when in contact with a conducting fluid to provide power to activate the device;
  • a control module associated with the support structure and electrically connected to the first material and the second material for controlling the conductance between the first material and the second material such that a change in conductance between the first material and the second material alters the device's current signature and thereby encodes information in the current signature;
  • a unit in communication with the control module and associated with the support structure to at least either receive a signal from an external source or send a signal to the external source.
  • the unit comprises an impedance measurement unit coupled to the first material at one output and coupled to the second material at another output to measure the impedance of the surrounding environment and to control the device.
  • System comprising a device according to any of the clauses 1 -18 and a receiver, for receiving communications from the device.

Abstract

The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.

Description

COMMUNICATION SYSTEM WITH REMOTE ACTIVATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This application is a continuation-in-part of application serial no. 13/180,516 filed on July 1 1 , 201 1 and entitled "Communication System with Remote Activation", which application is a continuation-in-part of U.S. Patent Application No. 12/564,017, filed on Sept 21 , 2009 and entitled "Communication System with Partial Power Source", published on April 1 , 2010 as U.S. Publication No. 2010-0081894A1 , which is a continuation-in-part application of U.S. Patent Application No. 1 1 /912,475 filed June 23, 2008 and entitled "Pharma-lnformatics System", published on November 20, 2008 as U.S. Publication No. 2008-0284599A1 which application is a 371 application of PCT Application No. PCT/US06/16370 filed April 28, 2006 and entitled "Pharma-lnformatics System"; published on November 2, 2006 as WO Publication No. WO 2006/1 16718 which application pursuant to 35 U.S.C. § 1 19 (e), claims priority to the filing dates of: United States Provisional Patent Application Serial No. 60/676,145 filed April 28, 2005 and entitled "Pharma-lnformatics System"; United States Provisional Patent Application Serial No. 60/694,078, filed June 24, 2005, and entitled "Pharma-lnformatics System"; United States Provisional Patent Application Serial No. 60/713,680 filed September 1 , 2005 and entitled "Medical Diagnostic And Treatment Platform Using Near-Field Wireless Communication Of Information Within A Patient's Body"; and United States Provisional Patent Application Serial No. 60/790,335 filed April 7, 2006 and entitled "Pharma- lnformatics System"; the disclosures of which are herein incorporated by reference.
[002] This application is related to the following US Applications filed concurrently herewith, the disclosures of which are incorporated herein by reference: US Application Serial No. 13/180,498 COMMUNICATION SYSTEM WITH MULTIPLE SOURCES OF POWER; US Application Serial No. 13/180,539 COMMUNICATION SYSTEM USING AN IMPLANTABLE DEVICE; US Application Serial No. 13/180,525 COMMUNICATION SYSTEM WITH ENHANCED PARTIAL POWER AND METHOD OF MANUFACTURING SAME; US Application Serial No. 13/180,538 POLYPHARMACY CO-PACKAGED MEDICATION DOSING UNIT INCLUDING COMMUNICATION SYSTEM THEREFOR; and US Application Serial No. 13/180,507 COMMUNICATION SYSTEM INCORPORATED IN AN INGESTIBLEPRODUCT.
FIELD
[003] The present invention is related to communication systems for detection of an event. More specifically, the present disclosure includes a system that includes a device with various power sources and communication schemes.
INTRODUCTION
[004] Ingestible devices that include electronic circuitry have been proposed for use in a variety of different medical applications, including both diagnostic and therapeutic applications. These devices typically require an internal power supply for operation. Examples of such ingestible devices are ingestible electronic capsules which collect data as they pass through the body, and transmit the data to an external receiver system. An example of this type of electronic capsule is an in- vivo video camera. The swallowable capsule includes a camera system and an optical system for imaging an area of interest onto the camera system. The transmitter transmits the video output of the camera system and the reception system receives the transmitted video output. Other examples include an ingestible imaging device, which has an internal and self-contained power source, which obtains images from within body lumens or cavities. The electronic circuit components of the device are enclosed by an inert indigestible housing (e.g. glass housing) that passes through the body internally. Other examples include an ingestible data recorder capsule medical device. The electronic circuits of the disclosed device (e.g. sensor, recorder, battery etc.) are housed in a capsule made of inert materials.
[005] In other examples, fragile radio frequency identification (RFID) tags are used in drug ingestion monitoring applications. In order for the RFID tags to be operational, each application/tag requires an internal power supply. The RFID tags are antenna structures that are configured to transmit a radio-frequency signal through the body.
[006] The problem these existing devices pose is that the power source is internal to device and such power sources are bulky, costly to produce and potentially harmful to the surrounding environment if the power source leaks or is damaged. Additionally, having antennas extending from the device is a concern as related to the antennas getting damaged or causing a problem when the device is used in- vivo. Therefore, what is needed is suitable system with circuitry that eliminates the need for an internal power source and antennas.
SUMMARY
[007] The present disclosure includes a system for producing a unique signature that indicates the occurrence of an event. The system includes circuitry and components that can be placed within certain environments that include a conducting fluid. One example of such an environment is inside a container that houses the conducting fluid, such as a sealed bag with a solution, which includes an IV bag. Another example is within the body of a living organism, such as an animal or a human. The systems are ingestible and/or digestible or partially digestible. The system includes dissimilar materials positioned on the framework such that when a conducting fluid comes into contact with the dissimilar materials, a voltage potential difference is created. The voltage potential difference, and hence the voltage, is used to power up control logic that is positioned within the framework. Ions or current flows from the first dissimilar material to the second dissimilar material via the control logic and then through the conducting fluid to complete a circuit. The control logic controls the conductance between the two dissimilar materials and, hence, controls or modulates the conductance of the system.
[008] As the ingestible circuitry is made up of ingestible, and even digestible, components, the ingestible circuitry results in little, if any, unwanted side effects, even when employed in chronic situations. Examples of the range of components that may be included are: logic and/or memory elements; effectors; a signal transmission element; and a passive element, such as a resistor or inductor. The one or more components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided. All of the components and the support of the ingestible circuitry are ingestible, and in certain instances digestible or partially digestible.
BRI EF DESCRI PTION OF THE FIGURES
[009] Fig. 1 shows a pharmaceutical product with an event indicator system according to the teaching of the present invention, wherein the product and the event indicator system combination are within the body.
[010] Fig. 2A shows the pharmaceutical product of Fig. 1 with the event indicator system on the exterior of the pharmaceutical product.
[011] Fig. 2B shows the pharmaceutical product of Fig. 1 with the event indicator system positioned inside the pharmaceutical product.
[012] Fig. 2C shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
[013] Fig. 2D shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
[014] Fig. 2E shows a capsule with the event indicator system positioned inside in accordance with one aspect of the present invention.
[015] Fig. 2F is an exploded view of the event indicator system.
[016] Fig. 3 is a block diagram representation of one aspect of the event indicator system with dissimilar metals positioned on opposite ends.
[017] Fig. 4 is a block diagram representation of another aspect of the event indicator system with dissimilar metals positioned on the same end and separated by a non-conducting material.
[018] Fig. 5 shows ionic transfer or the current path through a conducting fluid when the event indicator system of Fig. 3 is in contact with conducting liquid and in an active state.
[019] Fig. 5A shows an exploded view of the surface of dissimilar materials of Fig. 5. [020] Fig. 5B shows the event indicator system of Fig. 5 with a pH sensor unit.
[021] Fig. 6 is a block diagram illustration of one aspect of the control device used in the system of Figs. 3 and 4.
[022] Fig 7. is a functional block diagram of a demodulation circuit that performs coherent demodulation that may be present in a receiver, according to one aspect. Fig 8 illustrates a functional block diagram for a beacon module within a receiver, according to one aspect.
[023] Fig 9 is a block diagram of the different functional modules that may be present in a receiver, according to one aspect
[024] Fig 10 is a block diagram of a receiver, according to one aspect.
[025] Fig 1 1 provides a block diagram of a high frequency signal chain in a receiver, according to one aspect.
[026] Fig 12 provides a diagram of how a system that includes a signal receiver and an ingestible event marker may be employed, according to one aspect.
DETAILED DESCRIPTION
[027] The present disclosure includes multiple aspects for indicating the occurrence of an event. As described in more detail below, a system of the present invention is used with a conducting fluid to indicate the event marked by contact between the conducting fluid and the system. For example, the system of the present disclosure may be used with pharmaceutical product and the event that is indicated is when the product is taken or ingested. The term "ingested" or "ingest" or "ingesting" is understood to mean any introduction of the system internal to the body. For example, ingesting includes simply placing the system in the mouth all the way to the descending colon. Thus, the term ingesting refers to any instant in time when the system is introduced to an environment that contains a conducting fluid. Another example would be a situation when a non-conducting fluid is mixed with a conducting fluid. In such a situation the system would be present in the non- conduction fluid and when the two fluids are mixed, the system comes into contact with the conducting fluid and the system is activated. Yet another example would be the situation when the presence of certain conducting fluids needed to be detected. In such instances, the presence of the system, which would be activated, within the conducting fluid could be detected and, hence, the presence of the respective fluid would be detected.
[028] Referring again to the instance where the system is used with the product that is ingested into the living organism, when the product that includes the system is taken or ingested, the device comes into contact with the conducting liquid of the body. When the system of the present invention comes into contact with the body fluid, a voltage potential is created and the system is activated. A portion of the power source is provided by the device, while another portion of the power source is provided by the conducting fluid, which is discussed in detail below.
[029] Referring now to Fig. 1 , an ingestible product 14 that includes a system of the present invention is shown inside the body. The product 14 is configured as an orally ingestible pharmaceutical formulation in the form of a pill or capsule. Upon ingestion, the pill moves to the stomach. Upon reaching the stomach, the product 14 is in contact with stomach fluid 18 and undergoes a chemical or electrochemical reaction with the various materials in the stomach fluid 18, such as hydrochloric acid and other digestive agents. The system of the present invention is discussed in reference to a pharmaceutical environment. However, the scope of the present invention is not limited thereby. The present invention can be used in any environment e.g., outside a body, where a conducting fluid is present or becomes present through mixing of two or more components that result in a conducting liquid.
[030] Referring now to Fig. 2A, a pharmaceutical product 10, similar to the product 14 of Fig. 1 , is shown with a system 12, such as an ingestible event marker or an ionic emission module (IEM). The scope of the present invention is not limited by the shape or type of the product 10. For example, it will be clear to one skilled in the art that the product 10 can be a capsule, a time-release oral dosage, a tablet, a gel cap, a sub-lingual tablet, or any oral dosage product that can be combined with the system 12. In the referenced aspect, the product 10 has the system 12 secured to the exterior using known methods of securing micro-devices to the exterior of pharmaceutical products. Example of methods for securing the micro-device to the product is disclosed in US Provisional Application No. 12/741 ,583 filed on January 5, 2010 and entitled "HIGH-THROUGHPUT PRODUCTION OF INGESTIBLE EVENT MARKERS" also filed as PCT Application No. PCT/US10/20142 dated January 5, 2010 and published as WO 2010/080765 dated July 15, 2010 as well as US Provisional Application No. 61 /177,61 1 filed on May 12, 2009 and entitled "INGESTIBLE EVENT MARKERS COMPRISING AN IDENTIFIER AND AN INGESTIBLE COMPONENT", also filed as PCT Application No. PCT/US10/34186 dated May 10, 2010 and published as WO 2010/132331 dated Nov 18, 2010 the entire disclosure of each is incorporated herein by reference. Once ingested, the system 12 comes into contact with body liquids and the system 12 is activated. The system 12 uses the voltage potential difference to power up and thereafter modulates conductance to create a unique and identifiable current signature. Upon activation, the system 12 controls the conductance and, hence, current flow to produce the current signature.
[031] There are various reasons for delaying the activation of the system 12. In order to delay the activation of the system 12, the system 12 may be coated with a shielding material or protective layer. The layer is dissolved over a period of time, thereby allowing the system 12 to be activated when the product 10 has reached a target location.
[032] Referring now to Fig. 2B, a pharmaceutical product 20, similar to the product 14 of Fig. 1 , is shown with a system 22, such as an ingestible event marker or an identifiable emission module. The scope of the present invention is not limited by the environment to which the system 22 is introduced. For example, the system 22 can be enclosed in a capsule that is taken in addition to/independently from the pharmaceutical product. The capsule may be simply a carrier for the system 22 and may not contain any product. Furthermore, the scope of the present invention is not limited by the shape or type of product 20. For example, it will be clear to one skilled in the art that the product 20 can be a capsule, a time-release oral dosage, a tablet, a gel capsule, a sub-lingual tablet, or any oral dosage product. In the referenced aspect, the product 20 has the system 22 positioned inside or secured to the interior of the product 20. In one aspect, the system 22 is secured to the interior wall of the product 20. When the system 22 is positioned inside a gel capsule, then the content of the gel capsule is a non-conducting gel-liquid. On the other hand, if the content of the gel capsule is a conducting gel-liquid, then in an alternative aspect, the system 22 is coated with a protective cover to prevent unwanted activation by the gel capsule content. If the content of the capsule is a dry powder or microspheres, then the system 22 is positioned or placed within the capsule. If the product 20 is a tablet or hard pill, then the system 22 is held in place inside the tablet. Once ingested, the product 20 containing the system 22 is disintegrated and/or dissolved. The system 22 comes into contact with body liquids and the system 22 is activated. Depending on the product 20, the system 22 may be positioned in either a near-central or near- perimeter position depending on the desired activation delay between the time of initial ingestion and activation of the system 22. For example, a central position for the system 22 means that it will take longer for the system 22 to be in contact with the conducting liquid and, hence, it will take longer for the system 22 to be activated. Therefore, it will take longer for the occurrence of the event to be detected.
[033] Referring now to Fig. 2C, in accordance with one aspect of the present invention, a capsule 1 1 is shown with a cavity 1 1 a therein. The capsule 1 1 is shown as an empty capsule in accordance with one aspect of the present invention. Inside the cavity is a system 12a, which is similar to the systems 12 and 22 of Figs. 2A and 2B, respectively. As the capsule 1 1 is introduced to or comes into contact with a conducting fluid, the capsule 1 1 breaks apart or disintegrates or dissolves to allow the system to be released from the environment.
[034] Referring now to Fig. 2D, the capsule 1 1 is shown with the system 12a along with a material 13 inserted into the cavity 1 1 a. The material 13 can be activated to expand and cause the capsule 1 1 to break apart. In accordance with one aspect of the present invention, the activation of the material 13 is controlled by the system 12a. The system 12a, as shown in Fig. 2E below, receives a signal from an external source which may be inside the body, on the body or outside the body and in response to the signal, is able to activate the material 13 to cause the material 12 to expand. For example, in accordance with one aspect of the present invention, the material 13 is an electroactive material that is selected to be reactive to an electrical signal such that the properties change when exposed to a voltage potential or current. An electroactive material or matrix includes a material whose properties, such as physical dimensions or solubility, change in response to an applied voltage or current. Examples of electroactive materials include: polyvinylidene fluoride (PVDF), perfluorinated sulfouic acid (Nation TM), perfluorinated carboxylic acid (Flemion TM), cellulose, a polymer matrix (for example polyethylene oxide or cellulose) containing a salt (eg a salt containing a multivalent ion such as Fe3+ ) or a protein. In accordance with another aspect of the present invention, the system 12a includes a plunger that releases a chemical or compound into the material 1 1 a to cause a chemical reaction that causes the material 1 1 a to expand.
[035] Referring now to Fig. 2E, the capsule 1 1 is shown with the system 12a in greater detail. The system 12a includes a unit 12b secured to the system 12a. In accordance with one aspect of the present invention, the unit 12b includes a housing that defines a cavity 12c. In one example, the cavity 12c can be filled with a chemical or a compound that is released into the cavity 1 1 a when the cavity 1 1 a is filled with the material 13 to initiate a reaction that causes the material 13 to expand. Referring now also to Fig. 2F, in another example, the cavity 12c includes a solid object that acts like a needle or a rod. The object is mechanically pushed out of the cavity 12c in the direction AA as shown. The object is then able to push through the wall of the capsule 1 1 and cause the wall to tear or break apart. This facilitates separation of the system 12a from the capsule 1 1 and allows the system 12a to come into contact with the surrounding environment and become activated. Thus, the unit 12b is able to control activation of the system 12a.
[036] In accordance with one aspect of the present invention, the unit 12b includes a communication module that can either receive, transmit, or receive and transmit. Thus, the unit 12b can act as a secondary communication module, as discussed in detail below with respect to Fig. 5 and element 75. The unit 12b can receive control signals from and external source, in accordance with one aspect of the present invention. In accordance with another aspect, the unit 12b can send signals to an external source. In accordance with yet another aspect of the present invention, the unit 12b acts as a transceiver and is able to receive and send signals to external devices. The unit 12b is also in communication with the other components of the system 12a as discussed in detail below.
[037] Referring now to Fig. 3, in one aspect, the systems 12 and 22 of Figs. 2A and 2B, respectively, are shown in more detail as system 30. The system 30 can be used in association with any pharmaceutical product, as mentioned above, to determine when a patient ingests the pharmaceutical product. As indicated above, the scope of the present invention is not limited by the environment and the product that is used with the system 30. For example, the system 30 may be placed within a capsule and the capsule is placed within the conducting liquid. The capsule would then dissolve over a period of time and release the system 30 into the conducting liquid. Thus, in one aspect, the capsule would contain the system 30 and no product. Such a capsule may then be used in any environment where a conducting liquid is present and with any product. For example, the capsule may be dropped into a container filled with jet fuel, salt water, tomato sauce, motor oil, or any similar product. Additionally, the capsule containing the system 30 may be ingested at the same time that any pharmaceutical product is ingested in order to record the occurrence of the event, such as when the product was taken.
[038] In the specific example of the system 30 combined with the pharmaceutical product, as the product or pill is ingested, the system 30 is activated. The system 30 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken. The system 30 includes a resistance 31 between the Vhigh and ground 52. The resistive element includes a known quantity and represents a voltage drop between Vhigh and ground. This known quantity is used to determine the impedance of the surrounding environment as noted with respect to Fig. 5 below and unit 75a.
[039] The system 30 includes a framework 32. The framework 32 is a chassis for the system 30 and multiple components are attached to, deposited upon, or secured to the framework 32. In this aspect of the system 30, an ingestible or digestible material 34 is physically associated with the framework 32. The material 34 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as "deposit" with respect to the framework 32. The material 34 is deposited on one side of the framework 32. The materials of interest that can be used as material 34 include, but are not limited to: Cu or Cul. The material 34 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols. The material 34 may be from about 0.05 to about 500 μιτι thick, such as from about 5 to about 100 μιτι thick. The shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 30 may contain two or more electrically unique regions where the material 34 may be deposited, as desired.
[040] At a different side, which is the opposite side as shown in Fig. 3, another digestible material 36 is deposited, such that materials 34 and 36 are dissimilar and are insulated from each other. Although not shown, the different side selected may be the side next to the side selected for the material 34. The scope of the present invention is not limited by the side selected and the term "different side" can mean any of the multiple sides that are different from the first selected side. Furthermore, even though the shape of the system is shown as a square, the shape maybe any geometrically suitable shape. Material 34 and 36 are selected such that they produce a voltage potential difference when the system 30 is in contact with conducting liquid, such as body fluids. The materials of interest for material 36 include, but are not limited to: Mg, Zn, or other electronegative metals. As indicated above with respect to the material 34, the material 36 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework. Also, an adhesion layer may be necessary to help the material 36 (as well as material 34 when needed) to adhere to the framework 32. Typical adhesion layers for the material 36 are Ti, TiW, Cr or similar material. Anode material and the adhesion layer may be deposited by physical vapor deposition, electrodeposition or plasma deposition. The material 36 may be from about 0.05 to about 500 μιτι thick, such as from about 5 to about 100 μιτι thick. However, the scope of the present invention is not limited by the thickness of any of the materials nor by the type of process used to deposit or secure the materials to the framework 32. [041] According to the disclosure set forth, the materials 34 and 36 can be any pair of materials with different electrochemical potentials. Additionally, in the aspects wherein the system 30 is used in-vivo, the materials 34 and 36 may be vitamins that can be absorbed. More specifically, the materials 34 and 36 can be made of any two materials appropriate for the environment in which the system 30 will be operating. For example, when used with an ingestible product, the materials 34 and 36 are any pair of materials with different electrochemical potentials that are ingestible. An illustrative example includes the instance when the system 30 is in contact with an ionic solution, such as stomach acids. Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuCI or Cul). With respect to the active electrode materials, any pairing of substances - metals, salts, or intercalation compounds - with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.
[042] Materials and pairings of interest include, but are not limited to, those reported in Table 1 below. In one aspect, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage potential created between the materials as they come into contact with a conducting liquid. Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like. In another aspect, the materials are copper iodine (Cul) as the anode and magnesium (Mg) as the cathode. Aspects of the present invention use electrode materials that are not harmful to the human body.
TABLE 1
Anode Cathode
Metals Magnesium, Zinc
Sodium, Lithium
Iron
Salts Copper salts: iodide, chloride, bromide, sulfate, formate, (other anions possible)
Fe3+ salts: e.g. orthophosphate, pyrophosphate, (other anions possible)
Oxygen or Hydrogen ion (H+)on platinum, gold or other catalytic surfaces
Intercalation Graphite with Li, K, Ca, Vanadium oxide
compounds Na, Mg Manganese oxide
[043] Thus, when the system 30 is in contact with the conducting liquid, a current path, an example is shown in Fig. 5, is formed through the conducting liquid between material 34 and 36. A control device 38 is secured to the framework 32 and electrically coupled to the materials 34 and 36. The control device 38 includes electronic circuitry, for example control logic that is capable of controlling and altering the conductance between the materials 34 and 36.
[044] The voltage potential created between the materials 34 and 36 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system. In one aspect, the system operates in direct current mode. In an alternative aspect, the system controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current. As the system reaches the conducting fluid or the electrolyte, where the fluid or electrolyte component is provided by a physiological fluid, e.g., stomach acid, the path for current flow between the materials 34 and 36 is completed external to the system 30; the current path through the system 30 is controlled by the control device 38. Completion of the current path allows for the current to flow and in turn a receiver, not shown, can detect the presence of the current and recognize that the system 30 has been activate and the desired event is occurring or has occurred. Illustrative examples of such receivers are further described with respect to Figs. 7 to 12, as described hereinafter.
[045] In one aspect, the two materials 34 and 36 are similar in function to the two electrodes needed for a direct current power source, such as a battery. The conducting liquid acts as the electrolyte needed to complete the power source. The completed power source described is defined by the electrochemical reaction between the materials 34 and 36 of the system 30 and enabled by the fluids of the body. The completed power source may be viewed as a power source that exploits electrochemical conduction in an ionic or a conducting solution such as gastric fluid, blood, or other bodily fluids and some tissues. Additionally, the environment may be something other than a body and the liquid may be any conducting liquid. For example, the conducting fluid may be salt water or a metallic based paint.
[046] In certain aspects, these two materials are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials are exposed to the target site, a voltage potential is generated.
[047] In certain aspects, the complete power source or supply is one that is made up of active electrode materials, electrolytes, and inactive materials, such as current collectors, packaging, etc. The active materials are any pair of materials with different electrochemical potentials. Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as Cul). With respect to the active electrode materials, any pairing of substances - metals, salts, or intercalation compounds - with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.
[048] A variety of different materials may be employed as the materials that form the electrodes. In certain aspects, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the system of the identifier. In certain aspects, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1 .0 volts or higher, where in certain aspects, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.
[049] Referring again to Fig. 3, the materials 34 and 36 provide the voltage potential to activate the control device 38. Once the control device 38 is activated or powered up, the control device 38 can alter conductance between the materials 34 and 36 in a unique manner. By altering the conductance between materials 34 and 36, the control device 38 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 30. This produces a unique current signature that can be detected and measured by a receiver (not shown), which can be positioned internal or external to the body. In addition to controlling the magnitude of the current path between the materials, non-conducting materials, membrane, or "skirt" are used to increase the "length" of the current path and, hence, act to boost the conductance path, as disclosed in the U.S. Patent Application Serial No. 12/238,345 entitled, "In-Body Device with Virtual Dipole Signal Amplification" filed September 25, 2008, and published as 2009-0082645 A1 dated March 26, 2009 the entire content of which is incorporated herein by reference. Alternatively, throughout the disclosure herein, the terms "non-conducting material", "membrane", and "skirt" are used interchangeably with the term "current path extender" without impacting the scope or the present aspects and the claims herein. The skirt, shown in portion at 35 and 37, respectively, may be associated with, e.g., secured to, the framework 32. Various shapes and configurations for the skirt are contemplated as within the scope of the present invention. For example, the system 30 may be surrounded entirely or partially by the skirt and the skirt maybe positioned along a central axis of the system 30 or off-center relative to a central axis. Thus, the scope of the present invention as claimed herein is not limited by the shape or size of the skirt. Furthermore, in other aspects, the materials 34 and 36 may be separated by one skirt that is positioned in any defined region between the materials 34 and 36.
[050] Referring now to Fig. 4, in another aspect, the systems 12 and 22 of Figs. 2A and 2B, respectively, are shown in more detail as system 40. The system 40 includes a framework 42. The framework 42 is similar to the framework 32 of Fig. 3. In this aspect of the system 40, a digestible or dissolvable material 44 is deposited on a portion of one side of the framework 42. At a different portion of the same side of the framework 42, another digestible material 46 is deposited, such that materials 44 and 46 are dissimilar. More specifically, materials 44 and 46 are selected such that they form a voltage potential difference when in contact with a conducting liquid, such as body fluids. Thus, when the system 40 is in contact with and/or partially in contact with the conducting liquid, then a current path, an example is shown in Fig. 5, is formed through the conducting liquid between material 44 and 46. A control device 48 is secured to the framework 42 and electrically coupled to the materials 44 and 46. The control device 48 includes electronic circuitry that is capable of controlling part of the conductance path between the materials 44 and 46. The materials 44 and 46 are separated by a non-conducting skirt 49. Various examples of the skirt 49 are disclosed in US Provisional Application No. 61 /173,51 1 filed on April 28, 2009 and entitled "HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS OF USING SAME" also filed as PCT Application No. PCT/US10/32590 dated April 27, 2010 and published as WO 2010/129288.. dated Nov 1 1 , 2010 and US Provisional Application No. 61/173,564 filed on April 28, 2009 and entitled "INGESTIBLE EVENT MARKERS HAVING SIGNAL AMPLIFIERS THAT COMPRISE AN ACTIVE AGENT" also filed as PCT Application No. PCT/US10/32590 dated April 27, 2010 and published as WO 2010/129288. dated Nov 1 1 , 2010 ; as well as U.S. Application No. 12/238,345 filed September 25, 2008 and entitled "IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION" and published as US Publication No. 2009-0082645 A1 dated March 26, 2009; the entire disclosure of each is incorporated herein by reference.
[051] Once the control device 48 is activated or powered up, the control device 48 can alter conductance between the materials 44 and 46. Thus, the control device 48 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 40. As indicated above with respect to system 30, a unique current signature that is associated with the system 40 can be detected by a receiver (not shown) to mark the activation of the system 40. Illustrative examples of receivers are found in Figs.7 to 12 , as described hereinafter. In order to increase the "length" of the current path the size and/or characteristics of the skirt 49 is altered. The longer the current path, the easier it may be for the receiver to detect the current.
[052] Referring now to Fig. 5, the system 30 of Fig. 3 is shown in an activated state and in contact with conducting liquid. The system 30 is grounded through ground contact 52. For example, when the system 30 is in contact with a conducting fluid, the conducting fluid provides the ground. The system 30 also includes a sensor module 74, which is described in greater detail with respect to Fig. 6. Ion or current paths 50 are formed between material 34 to material 36 and through the conducting fluid in contact with the system 30. The voltage potential created between the material 34 and 36 is created through chemical reactions between materials 34/36 and the conducting fluid.
[053] The system 30 also includes a unit 75. The unit 75 includes aspects that enable communication functions and in accordance with the various aspects of the present invention can act as any of the following: a receiver, a transmitter, or a transceiver. Thus, another device that is external to the system 30, such as a cell phone, an implanted device, a device attached to the user's body, or a device placed under the user's skin, may communicate, e.g. to, from or both, the system 30 through the unit 75. The unit 75 is also electrically connected to the materials 34 and 36. In accordance with one aspect of the present invention, any device that is external to the system 30 may communicate with either the unit 75 or the control module 38 using current flow through the environment surrounding the system 30. For example, a patch or receiver that is attached to the user's body, a cell phone or device being held by the user, or an implanted device, are examples of devices which can generate a current signature through the user's body. The current signature can include information that is encoded therein. The current signature is detected by the system 30, using the unit 75 or the control module 38, and decoded to allow communication to the system 30 from the device external to system 30. Accordingly, the external device can send a signal to the unit 75, either wirelessly or through transconduction, that controls the activation of the system 30. [054] In accordance with one aspect of the present invention, the unit 75 can also measure the surrounding environment, either directly or through the sensor module 74, to determine is the system 30 should be deactivate due to unfavorable environmental conditions. For example, the unit 75 may include an impedance measurement unit 75a that is able to measure impedance of the environment around the system 30. The unit 75a measures impedance by transmitting or applying voltage to one output terminal, such as the material 34. The unit 75a then measures impedance (using the resistance 31 of Fig. 3). With a known quantity of resistance and the known voltage, the unit 75a is able to determine the impedance of the surrounding environment. The received signal at the receiver is directly proportional to the current output of the system 30. If a variable resistance is added at the output terminal of the system 30, such as resistance 31 , then the current output of the system 30 will be proportional to 1 /(R+Z), where R is the value of the variable resistor and Z, the local impedance of the solution or stomach environment around the system 30. Therefore, the detected signal will be equal to:
Vreceievd = k / (R + Z)
[055] The system 30 can be designed with a variable resistor that cycles between 2 or more levels during transmission. This results in a received signal that will vary according the above equation. When detected, the signal is used to generate a linear plot to fit :
1/V received vs R
[056] and determine the slope and intercept. The slope will have a value 1/k and the intercept, Z/k. This allows both k and the local impedance of the system 30 to be determined, independent of the actual voltage or current draw from the system 30 because the value of the variable resistor is know from the design parameters.
[057] The impedance measurement may be used to monitor hydration state of the patient, presence of drug, Gastro-intestinal motility/waves, gastric transit time, presence of certain types of tissue (tumors) or bleeding. The impedance measurement is also a useful diagnostic tool for monitoring performance of the system 30. For example, if the impedance of the surrounding environment would prevent effective communication, then the system 30 can be deactivated or activated with a delay. In accordance with one aspect of the present invention, the unit 75 sends a signal to the control device 38. In response, the control device 38 can alter the conductance, and hence the impedance, between the materials 34 and 36 to reduce the rate of chemical reaction between materials 34 and 36 and the surrounding environment and thereby cause the system 30 to reach a deactivated mode, state, or condition. In this way, even though there is some chemical reaction, it is sufficiently low to preserve the power of the system 30 for later use, while still allowing operation of sensing and measurement of the nearby environment.
[058] If the conditions of the environment change to become favorable to communication, as determine by the measurements of the environment, then the unit 75 sends a signal to the control device 38 to alter the conductance between the materials 34 and 36 to allow for communication using the current signature of the system 30. Thus, if the system 30 has been deactivated and the impedance if the environment is suitable for communication, then the system 30 can be activated again.
[059] If the conditions of the environment change to become favorable to communication, as determined by the measurements of the environment, then the unit 75 sends a signal to the control device 38 to alter the conductance between the materials 34 and 36 to allow for communication using the current signature of the system 30. Thus, if the system 30 has been deactivated and the impedance of the environment is suitable for communication, then the system 30 can be activated again.
[060] Referring now to Fig. 5A, this shows an exploded view of the surface of the material 34. In one aspect, the surface of the material 34 is not planar, but rather an irregular surface. The irregular surface increases the surface area of the material and, hence, the area that comes in contact with the conducting fluid. In one aspect, at the surface of the material 34, there is an electrochemical reaction between the material 34 and the surrounding conducting fluid such that mass is exchanged with the conducting fluid. The term "mass" as used here includes any ionic or non-ionic species that may be added or removed from the conductive fluid as part of the electrochemical reactions occurring on material 34. One example includes the instant where the material is CuCI and when in contact with the conducting fluid, CuCI is converted to Cu metal (solid) and CI- is released into the solution. The flow of positive ions into the conducting fluid is depicted by the current path 50. Negative ions flow in the opposite direction. In a similar manner, there is an electrochemical reaction involving the material 36 that results in ions released or removed from the conducting fluid. In this example, the release of negative ions at the material 34 and release of positive ions by the material 36 are related to each other through the current flow that is controlled by the control device 38. The rate of reaction and hence the ionic emission rate or current, is controlled by the control device 38. The control device 38 can increase or decrease the rate of ion flow by altering its internal conductance, which alters the impedance, and therefore the current flow and reaction rates at the materials 34 and 36. Through controlling the reaction rates, the system 30 can encode information in the ionic flow. Thus, the system 30 encodes information using ionic emission or flow.
[061] The control device 38 can vary the duration of ionic flow or current while keeping the current or ionic flow magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 38 can vary the level of the ionic flow rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 38 encodes information in the current or the ionic flow. For example, the control device 38 may use, but is not limited to any of the following techniques, including Binary Phase- Shift Keying (PSK), Frequency modulation, Amplitude modulation, on-off keying, and PSK with on-off keying.
[062] As indicated above, the various aspects disclosed herein, such as systems 30 and 40 of Figs. 3 and 4, respectively, include electronic components as part of the control device 38 or the control device 48. Components that may be present include but are not limited to: logic and/or memory elements, an integrated circuit, an inductor, a resistor, and sensors for measuring various parameters. Each component may be secured to the framework and/or to another component. The components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided.
[063] As indicated above, the system, such as control devices 30 and 40, control the conductance between the dissimilar materials and, hence, the rate of ionic flow or current. Through altering the conductance in a specific manner the system is capable of encoding information in the ionic flow and the current signature. The ionic flow or the current signature is used to uniquely identify the specific system. Additionally, the systems 30 and 40 are capable of producing various different unique patterns or signatures and, thus, provide additional information. For example, a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment. To further illustrate, a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.
[064] Referring now to Fig. 6, a block diagram representation of the control device 38 is shown. The control device 38 includes a control module 62, a counter or clock 64, and a memory 66. Additionally, the device 38 is shown to include a sensor module 72 as well as the sensor module 74, which was referenced in Fig. 5. The control module 62 has an input 68 electrically coupled to the material 34 and an output 70 electrically coupled to the material 36. The control module 62, the clock 64, the memory 66, and the sensor modules 72/74 also have power inputs (some not shown). The power for each of these components is supplied by the voltage potential produced by the chemical reaction between materials 34 and 36 and the conducting fluid, when the system 30 is in contact with the conducting fluid. The control module 62 controls the conductance through logic that alters the overall impedance of the system 30. The control module 62 is electrically coupled to the clock 64. The clock 64 provides a clock cycle to the control module 62. Based upon the programmed characteristics of the control module 62, when a set number of clock cycles have passed, the control module 62 alters the conductance characteristics between materials 34 and 36. This cycle is repeated and thereby the control device 38 produces a unique current signature characteristic. The control module 62 is also electrically coupled to the memory 66. Both the clock 64 and the memory 66 are powered by the voltage potential created between the materials 34 and 36.
[065] The control module 62 is also electrically coupled to and in communication with the sensor modules 72 and 74. In the aspect shown, the sensor module 72 is part of the control device 38 and the sensor module 74 is a separate component. In alternative aspects, either one of the sensor modules 72 and 74 can be used without the other and the scope of the present invention is not limited by the structural or functional location of the sensor modules 72 or 74. Additionally, any component of the system 30 may be functionally or structurally moved, combined, or repositioned without limiting the scope of the present invention as claimed. Thus, it is possible to have one single structure, for example a processor, which is designed to perform the functions of all of the following modules: the control module 62, the clock 64, the memory 66, and the sensor module 72 or 74. On the other hand, it is also within the scope of the present invention to have each of these functional components located in independent structures that are linked electrically and able to communicate.
[066] Referring again to Fig. 6, the sensor modules 72 or 74 can include any of the following sensors: temperature, pressure, pH level, and conductivity. In one aspect, the sensor modules 72 or 74 gather information from the environment and communicate the analog information to the control module 62. The control module then converts the analog information to digital information and the digital information is encoded in the current flow or the rate of the transfer of mass that produces the ionic flow. In another aspect, the sensor modules 72 or 74 gather information from the environment and convert the analog information to digital information and then communicate the digital information to control module 62. In the aspect shown in Figs. 5, the sensor module 74 is shown as being electrically coupled to the material 34 and 36 as well as the control device 38. In another aspect, as shown in Fig. 6, the sensor module 74 is electrically coupled to the control device 38 at connection 78. The connection 78 acts as both a source for power supply to the sensor module 74 and a communication channel between the sensor module 74 and the control device 38.
[067] Referring now to Fig. 5B, the system 30 includes a pH sensor module 76 connected to a material 39, which is selected in accordance with the specific type of sensing function being performed. The pH sensor module 76 is also connected to the control device 38. The material 39 is electrically isolated from the material 34 by a non-conductive barrier 55. In one aspect, the material 39 is platinum. In operation, the pH sensor module 76 uses the voltage potential difference between the materials 34/36. The pH sensor module 76 measures the voltage potential difference between the material 34 and the material 39 and records that value for later comparison. The pH sensor module 76 also measures the voltage potential difference between the material 39 and the material 36 and records that value for later comparison. The pH sensor module 76 calculates the pH level of the surrounding environment using the voltage potential values. The pH sensor module 76 provides that information to the control device 38. The control device 38 varies the rate of the transfer of mass that produces the ionic transfer and the current flow to encode the information relevant to the pH level in the ionic transfer, which can be detected by a receiver (not shown). Thus, the system 30 can determine and provide the information related to the pH level to a source external to the environment.
[068] As indicated above, the control device 38 can be programmed in advance to output a pre-defined current signature. In another aspect, the system can include a receiver system that can receive programming information when the system is activated. In another aspect, not shown, the switch 64 and the memory 66 can be combined into one device.
[069] Examples of sources external to the environment include various receivers and the like. In one example of a receiver, sometimes referred to herein as a "signal receiver", two or more different demodulation protocols may be employed to decode a given received signal. In some instances, both a coherent demodulation protocol and a differential coherent demodulation protocol may be employed. FIG. 7 provides a functional block diagram of how a receiver may implement a coherent demodulation protocol, according to one aspect of the invention. It should be noted that only a portion of the receiver is shown in FIG. 7. FIG. 7 illustrates the process of mixing the signal down to baseband once the carrier frequency (and carrier signal mixed down to carrier offset) is determined. A carrier signal 2221 is mixed with a second carrier signal 2222 at mixer 2223. A narrow low-pass filter 2220 is applied of appropriate bandwidth to reduce the effect of out-of-bound noise. Demodulation occurs at functional blocks 2225 in accordance with the coherent demodulation scheme of the present invention. The unwrapped phase 2230 of the complex signal is determined. An optional third mixer stage, in which the phase evolution is used to estimate the frequency differential between the calculated and real carrier frequency can be applied. The structure of the packet is then leveraged to determine the beginning of the coding region of the BPSK signal at block 2240. Mainly, the presence of the sync header, which appears as an FM porch in the amplitude signal of the complex demodulated signal is used to determine the starting bounds of the packet. Once the starting point of the packet is determined the signal is rotated at block 2250 on the IQ plane and standard bit identification and eventually decoded at block 2260.
[070] In addition to demodulation, the transbody communication module may include a forward error correction module, which module provides additional gain to combat interference from other unwanted signals and noise. Forward error correction functional modules of interest include those described in PCT Application Serial No. PCT/US2007/024225 and published as WO 2008/063626, the disclosure of which is herein incorporated by reference. In some instances, the forward error correction module may employ any convenient protocol, such as Reed-Solomon, Golay, Hamming, BCH, and Turbo protocols to identify and correct (within bounds) decoding errors.
[071] In another example, the receiver includes a beacon module as shown in the functional block diagram of FIG. 8. The scheme outlined in FIG. 8 outlines one technique for identifying a valid beacon. The incoming signal 2360 represents the signals received by electrodes, bandpass filtered (such as from 10 KHz to 34 KHz) by a high frequency signaling chain (which encompasses the carrier frequency), and converted from analog to digital. The signal 2360 is then decimated at block 2361 and mixed at the nominal drive frequency (such as, 12.5 KHz, 20 KHz, etc.) at mixer 2362. The resulting signal is decimated at block 2364 and low-pass filtered (such as 5 KHz BW) at block 2365 to produce the carrier signal mixed down to carrier offset- signal 2369. Signal 2369 is further processed by blocks 2367 (fast Fourier transform and then detection of two strongest peaks) to provide the true carrier frequency signal 2368. This protocol allows for accurate determination of the carrier frequency of the transmitted beacon.
[072] FIG. 9 provides a block functional diagram of an integrated circuit component of a signal receiver according to an aspect of the invention. In FIG. 9, receiver 2700 includes electrode input 2710. Electrically coupled to the electrode input 2710 are transbody conductive communication module 2720 and physiological sensing module 2730. In one aspect, transbody conductive communication module 2720 is implemented as a high frequency (HF) signal chain and physiological sensing module 2730 is implemented as a low frequency (LF) signal chain. Also shown are CMOS temperature sensing module 2740 (for detecting ambient temperature) and a 3-axis accelerometer 2750. Receiver 2700 also includes a processing engine 2760 (for example, a microcontroller and digital signal processor), non-volatile memory 2770 (for data storage) and wireless communication module 2780 (for data transmission to another device, for example in a data upload action).
[073] FIG. 10 provides a more detailed block diagram of a circuit configured to implement the block functional diagram of the receiver depicted in FIG. 9, according to one aspect of the invention. In FIG. 10, receiver 2800 includes electrodes e1 , e2 and e3 (281 1 , 2812 and 2813) which, for example, receive the conductively transmitted signals by an I EM and/or sense physiological parameters or biomarkers of interest. The signals received by the electrodes 281 1 , 2812, and 2813 are multiplexed by multiplexer 2820 which is electrically coupled to the electrodes.
[074] Multiplexer 2820 is electrically coupled to both high band pass filter 2830 and low band pass filter 2840. The high and low frequency signal chains provide for programmable gain to cover the desired level or range. In this specific aspect, high band pass filter 2830 passes frequencies in the 10 KHz to 34 KHz band while filtering out noise from out-of-band frequencies. This high frequency band may vary, and may include, for example, a range of 3 KHz to 300 KHz. The passing frequencies are then amplified by amplifier 2832 before being converted into a digital signal by converter 2834 for input into high power processor 2880 (shown as a DSP) which is electrically coupled to the high frequency signal chain. Low band pass filter 2840 is shown passing lower frequencies in the range of 0.5 Hz to 150 Hz while filtering out out-of-band frequencies. The frequency band may vary, and may include, for example, frequencies less than 300 Hz, such as less than 200 Hz, including less than 150 Hz. The passing frequency signals are amplified by amplifier 2842. Also shown is accelerometer 2850 electrically coupled to second multiplexer 2860. Multiplexer 2860 multiplexes the signals from the accelerometer with the amplified signals from amplifier 2842. The multiplexed signals are then converted to digital signals by converter 2864 which is also electrically coupled to low power processor 2870. In one aspect, a digital accelerometer (such as one manufactured by Analog Devices), may be implemented in place of accelerometer 2850. Various advantages may be achieved by using a digital accelerometer. For example, because the signals the digital accelerometer would produce signals already in digital format, the digital accelerometer could bypass converter 2864 and electrically couple to the low power microcontroller 2870~in which case multiplexer 2860 would no longer be required. Also, the digital signal may be configured to turn itself on when detecting motion, further conserving power. In addition, continuous step counting may be implemented. The digital accelerometer may include a FIFO buffer to help control the flow of data sent to the low power processor 2870. For instance, data may be buffered in the FIFO until full, at which time the processor may be triggered to turn awaken from an idle state and receive the data. Low power processor 2870 may be, for example, an MSP430 microcontroller from Texas Instruments. Low power processor 2870 of receiver 2800 maintains the idle state, which as stated earlier, requires minimal current draw~e.g., 10 .mu.A or less, or 1 .mu.A or less. High power processor 2880 may be, for example, a VC5509 digital signal process from Texas Instruments. The high power processor 2880 performs the signal processing actions during the active state. These actions, as stated earlier, require larger amounts of current than the idle state~e.g., currents of 30 .mu.A or more, such as 50 .mu.A or more--and may include, for example, actions such as scanning for conductively transmitted signals, processing conductively transmitted signals when received, obtaining and/or processing physiological data, etc.
[075] Also shown in FIG. 10 is flash memory 2890 electrically coupled to high power processor 2880. In one aspect, flash memory 2890 may be electrically coupled to low power processor 2870, which may provide for better power efficiency. Wireless communication element 2895 is shown electrically coupled to high power processor 2880 and may include, for example, a BLUETOOTH. TM. wireless communication transceiver. In one aspect, wireless communication element 2895 is electrically coupled to high power processor 2880. In another aspect, wireless communication element 2895 is electrically coupled to high power processor 2880 and low power processor 2870. Furthermore, wireless communication element 2895 may be implemented to have its own power supply so that it may be turned on and off independently from other components of the receiver~e.g., by a microprocessor.
[076] With, for example, an idle state in mind, the following paragraphs provide example configurations of receiver components shown in FIG. 10 during various states of the receiver, according to one aspect of the invention. It should be understood that alternative configurations may be implemented depending on the desired application. In an idle state, for example, the receiver draws minimal current. Receiver 2800 is configured such that low power processor 2870 is in an inactive state (such as idle state) and high power processor 2880 is in an inactive state (such as idle state), and circuit blocks related to peripheral circuitry and their power supplies required during various active states remain off (for example, wireless communication module 2895 and the analog front end). For example, the low power processor may have a 32 KHz oscillator active and may consume a few .mu.A current or less, including 0.5 .mu.A or less. In the idle state, the low power processor 2870 may, for example, wait for a signal to transfer to an active state. The signal might be external such as an interrupt or internally generated by one of the device's peripherals, such as a timer. During the high power processor's idle state, the high power processor may, for example, be running off a 32 KHz watch crystal. The high power processor may, for example, wait for a signal to transfer to active state. When the receiver is in the sniff state, low power processor 2870 is in an idle state and high power processor 2880 is in an idle state. In addition, the circuit blocks relating to the analog front end including A/D converter that is needed for the sniff function are on (in other words, the high frequency signal chain). As stated earlier, the beacon signal module may implement various types of sniff signals to achieve low power efficiency. Upon detection of a transmitted signal, a higher power demodulate and decode state may be entered. When the receiver is in the demodulate and decode state, low power processor 2870 is in an active state and high power processor 2880 is in an active state. High power processor 2880 may, for example, be running from a 12 MHz or near crystal oscillator with a PLL-based clock multiplier giving the device a 108 MHz clock speed. The low power processor 2870 may, for example, run off an internal R-C oscillator in the range of 1 MHz to 20 MHz and consume power in the range of 250 to 300 uA per MHz clock speed during active states. The active state allows for processing and any transmissions that may follow. Required transmissions may trigger the wireless communication module to cycle from off to on.
[077] When the receiver is in collect ECG and accelerometer state, the circuit blocks relating to the accelerometer and/or ECG signal conditioning chain are on. The high power processor 2880 is in an in idle state during collection, and in an active state (for example, running from a 12 MHz or near crystal oscillator with a PLL-based clock multiplier giving the device a 108 MHz clock speed) during processing and transmission. The low power processor 2870 is in an active state during this state and may run off an internal R-C oscillator in the range of 1 MHz to 20 MHz and consume power in the range of 250 to 300 uA per MHz clock speed.
[078] The low power processor (e.g., MSP shown in FIG. 10) and high power processor (e.g., DSP shown in FIG. 10) may communicate with each other using any convenient communication protocol. In some instances, these two elements, when present, communicate with each via a serial peripheral interface bus (hereinafter "SPI bus"). The following description describes the signaling and messaging scheme implemented to allow the high power processor and low power processor to communicate and send messages back and forth along the SPI bus. For the following description of the communication between the processors, "LPP" and "HPP" are used in place of "low power processor" and "high power processor", respectively, to stay consistent with FIG. 10. The discussion, however, may apply to other processors than those shown in FIG. 10.
[079] FIG. 1 1 provides a view of a block diagram of hardware in a receiver according to an aspect of the invention related to the high frequency signal chain. In FIG. 1 1 , receiver 2900 includes receiver probes (for example in the form of electrodes 291 1 , 2912 and 2913) electrically coupled to multiplexer 2920. Also shown are high pass filter 2930 and low pass filter 2940 to provide for a band pass filter which eliminates any out-of-band frequencies. In the aspect shown, a band pass of 10 KHz to 34 KHz is provided to pass carrier signals falling within the frequency band. Example carrier frequencies may include, but are not limited to, 12.5 KHz and 20 KHz. One or more carriers may be present. In addition, receiver 2900 includes analog to digital converter 2950~for example, sampling at 500 KHz. The digital signal can thereafter be processed by the DSP. Shown in this aspect is DMA to DSP unit 2960 which sends the digital signal to dedicated memory for the DSP. The direct memory access provides the benefit of allowing the rest of the DSP to remain in a low power mode.
[080] An example of a system that includes a receiver is shown in FIG. 12. In FIG. 12, system 3500 includes a pharmaceutical composition 3510 that comprises an ingestible device such as an ingestible event marker, " I EM." Also present in system 3500 is signal receiver 3520.. Signal receiver 3520 is configured to detect a signal emitted from the identifier of the I EM 3510. Signal receiver 3520 also includes physiologic sensing capability, such as ECG and movement sensing capability. Signal receiver 3520 is configured to transmit data to a patient's an external device or PDA 3530 (such as a smart phone or other wireless communication enabled device), which in turn transmits the data to a server 3540. Server 3540 may be configured as desired, e.g., to provide for patient directed permissions. For example, server 3540 may be configured to allow a family caregiver 3550 to participate in the patient's therapeutic regimen, e.g., via an interface (such as a web interface) that allows the family caregiver 3550 to monitor alerts and trends generated by the server 3540, and provide support back to the patient, as indicated by arrow 3560. The server 3540 may also be configured to provide responses directly to the patient, e.g., in the form of patient alerts, patient incentives, etc., as indicated by arrow 3565 which are relayed to the patient via PDA 3530. Server 3540 may also interact with a health care professional (e.g., RN, physician) 3555, which can use data processing algorithms to obtain measures of patient health and compliance, e.g., wellness index summaries, alerts, cross-patient benchmarks, etc., and provide informed clinical communication and support back to the patient, as indicated by arrow 3580.
[081] In addition to the above components, the system 30 may also include one or other electronic components. Electrical components of interest include, but are not limited to: additional logic and/or memory elements, e.g., in the form of an integrated circuit; a power regulation device, e.g., battery, fuel cell or capacitor; a sensor, a stimulator, etc. ; a signal transmission element, e.g., in the form of an antenna, electrode, coil, etc. ; a passive element, e.g., an inductor, resistor, etc.
[082] In certain aspects, the ingestible circuitry includes a coating layer. The purpose of this coating layer can vary, e.g., to protect the circuitry, the chip and/or the battery, or any components during processing, during storage, or even during ingestion. In such instances, a coating on top of the circuitry may be included. Also of interest are coatings that are designed to protect the ingestible circuitry during storage, but dissolve immediately during use. For example, coatings that dissolve upon contact with an aqueous fluid, e.g. stomach fluid, or the conducting fluid as referenced above. Also of interest are protective processing coatings that are employed to allow the use of processing steps that would otherwise damage certain components of the device. For example, in aspects where a chip with dissimilar material deposited on the top and bottom is produced, the product needs to be diced. However, the dicing process can scratch off the dissimilar material, and also there might be liquid involved which would cause the dissimilar materials to discharge or dissolve. In such instances, a protective coating on the materials prevents mechanical or liquid contact with the component during processing can be employed. Another purpose of the dissolvable coatings may be provided to delay activation of the device. For example, the coating that sits on the dissimilar material and takes a certain period of time, e.g., five minutes, to dissolve upon contact with stomach fluid may be employed. The coating can also be an environmentally sensitive coating, e.g., a temperature or pH sensitive coating, or other chemically sensitive coating that provides for dissolution in a controlled fashion and allows one to activate the device when desired. Coatings that survive the stomach but dissolve in the intestine are also of interest, e.g., where one desires to delay activation until the device leaves the stomach. An example of such a coating is a polymer that is insoluble at low pH, but becomes soluble at a higher pH. Also of interest are pharmaceutical formulation protective coatings, e.g., a gel cap liquid protective coating that prevents the circuit from being activated by liquid of the gel cap.
[083] Identifiers of interest include two dissimilar electrochemical materials, which act similar to the electrodes (e.g., anode and cathode) of a power source. The reference to an electrode or anode or cathode are used here merely as illustrative examples. The scope of the present invention is not limited by the label used and includes the aspect wherein the voltage potential is created between two dissimilar materials. Thus, when reference is made to an electrode, anode, or cathode it is intended as a reference to a voltage potential created between two dissimilar materials.
[084] When the materials are exposed and come into contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, that is, a voltage, is generated between the electrodes as a result of the respective oxidation and reduction reactions incurred to the two electrode materials. A voltaic cell, or battery, can thereby be produced. Accordingly, in aspects of the invention, such power supplies are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated. [085] In certain aspects, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery. Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like.
[086] It is to be understood that this invention is not limited to particular embodiments or aspects described herein and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[087] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[088] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
[089] Notwithstanding the claims, the invention is also referred to in the following clauses:
[090] 1 . A device for communication, the device including circuitry and components which function in conducting fluid, which device is ingestible and/or digestible, the device comprising: [091] a communication unit, which communication unit comprises; [092] a support structure;
[093] a partial power source having a first material deposited onto the support structure; and
[094] a second material deposited onto the support structure and electrically isolated from the first material, wherein the first material and the second material are selected to have a voltage potential difference when in contact with a conducting fluid to provide power to activate the device;
[095] a control module associated with the support structure and electrically connected to the first material and the second material for controlling the conductance between the first material and the second material such that a change in conductance between the first material and the second material alters the device's current signature and thereby encodes information in the current signature; and
[096] a unit in communication with the control module and associated with the support structure to at least either receive a signal from an external source or send a signal to the external source.
[097] 2. The device of clause 1 , further comprising a sealed housing defining a cavity, wherein the communication unit is positioned within the cavity.
[098] 3. The device of clause 2, further comprising a release material within the cavity, wherein the unit generates a release command to cause the release material to expand and open the sealed housing.
[099] 4. The device of any of the clauses 2 or 3, wherein the unit includes a mechanism that extends outward from the unit to penetrate a wall portion of the sealed housing and allow the communication unit to be separated from the sealed housing.
[0100] 5. The device according to any of the clauses 1 -4 wherein the unit includes a rod that is mechanically activated to tear a wall portion of the sealed housing and cause the sealed housing to open and allow the communication unit to come into contact with the conducting fluid.
[0101] 6. The device according to any of the clauses 1 -5 wherein the unit measures characteristic associated with an environment immediately surrounding the communication unit.
[0102] 7. The device according to any of the clauses 1 -6 further comprising a release apparatus secured to the support structure and in communication with the unit, wherein the release apparatus receives the release command from the unit and in response to the signal causes the device to be exposed to the conducting fluid.
[0103] 8. The device according to any of the clauses 2-7 wherein the cavity includes a material that is in communication with the release apparatus and the release apparatus causes the material to expand within the cavity such that the sealed housing breaks apart.
[0104] 9. The device of clause 7, wherein the release apparatus includes an expanding material that expands within the cavity to cause the sealed housing to break apart.
[0105] 10. The device of clause 7, wherein the release apparatus includes a rod that is mechanically extended from the release apparatus within the cavity of the sealed housing to cause the sealed housing to break apart. [0106] 1 1 . The device according to any of the clauses 1 -10 wherein after the device comes into contact with the conducting fluid, a signal received at the unit is sent to the control module and the control module reduce the power generated by the device by altering the conductance between the first material and the second material.
[0107] 12. The device according to any of the clauses 1 -1 1 wherein the unit sends information associated with the environment of the device to an external source.
[0108] 13. The device according to any of the clauses 1 -12 wherein the unit comprises an impedance measurement unit coupled to the first material at one output and coupled to the second material at another output to measure the impedance of the surrounding environment and to control the device.
[0109] 14. The device of clause 13, wherein the unit sends an impedance signal to the control module and the control module alters the conductance between the first material and the second material upon receipt of the impedance signal, preferably wherein the measuring unit sends the impedance signal to the control module to indicate to the control module that the impedance of the surrounding environment is below the designated value and the device can be activated.
[0110] 15. The device according to any of the preceding clauses wherein the unit receives a deactivate signal from an external source and communicates that information to the control module such that the control module alters the conductance between the first material and the second material in order to prevent generation of a current flow between the first material and second material and thereby deactivate the.
[0111] 16. The device according to any of the preceding clauses further comprising a sealed housing defining a cavity, wherein the communication unit is positioned within the cavity and further comprising an electroactive matrix within the cavity, wherein the unit generates voltage to cause the electroactive matrix to expand and open the sealed housing.
[0112] 17. Device according to any of the preceding clauses further comprising a pharmaceutical product.
[0113] 18. Device according to clause 17 wherein information is encoded in the current signature on ingestion of the pharmaceutical product and/or activation of the device, and/or contacting of the pharmaceutical product with conducting fluid.
[0114] 19. System comprising a device according to any of the clauses 1 -18 and a receiver, for receiving communications from the device.
[0115] 20. Use of a device or a system according to any of the preceding clauses for indicating when a medication has been taken by a patient.
[0116] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0117] It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation. [0118] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
[0119] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[0120] Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and aspects of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary aspects shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

Claims

What is claimed is:
1 . A device for communication, the device comprising:
a communication unit comprising:
a support structure;
a partial power source comprising:
a first material deposited onto the support structure; and
a second material deposited onto the support structure and electrically isolated from the first material, wherein the first material and the second material are selected to have a voltage potential difference when in contact with a conducting fluid to provide power to activate the device;
a control module associated with the support structure and electrically
connected to the first material and the second material for controlling the conductance between the first material and the second material such that a change in conductance between the first material and the second material alters the device's current signature and thereby encodes information in the current signature; and
a unit in communication with the control module and associated with the
support structure to at least either receive a signal from an external source or send a signal to the external source.
2. The device of claim 1 , further comprising a sealed housing defining a cavity, wherein the communication unit is positioned within the cavity.
3. The device of claim 2, further comprising a release material within the cavity, wherein the unit generates a release command to cause the release material to expand and open the sealed housing.
4. The device of claim 3, wherein the unit includes a mechanism that extends outward from the unit to penetrate a wall portion of the sealed housing and allow the communication unit to be separated from the sealed housing.
5. The device of claim 2, wherein the unit includes a rod that is mechanically activated to tear a wall portion of the sealed housing and cause the sealed housing to open and allow the communication unit to come into contact with the conducting fluid.
6. The device of claim 1 wherein the unit measures at least one characteristic associated with an environment immediately surrounding the communication unit.
7. The device of claim 6 further comprising a release apparatus secured to the support structure and in communication with the unit, wherein the release apparatus receives the release command from the unit and in response to the signal causes the device to be exposed to the conducting fluid.
8. The device of claim 7, wherein the cavity includes a material that is in
communication with the release apparatus and the release apparatus causes the material to expand within the cavity such that the sealed housing breaks apart.
9. The device of claim 7, wherein the release apparatus includes an expanding material that expands within the cavity to cause the sealed housing to break apart.
10. The device of claim 7, wherein the release apparatus includes a rod that is mechanically extended from the release apparatus within the cavity of the sealed housing to cause the sealed housing to break apart.
1 1 . The device of claim 1 , wherein after the device comes into contact with the conducting fluid, a signal received at the unit is sent to the control module and the control module reduce the power generated by the device by altering the
conductance between the first material and the second material.
12. The device of claim 1 , wherein the unit sends information associated with the environment of the device to an external source.
13. The device of claim 1 wherein the unit comprises an impedance measurement unit coupled to the first material at one output and coupled to the second material at another output to measure the impedance of the surrounding environment and to control the device.
14. The device of claim 13, wherein the unit sends an impedance signal to the control module and the control module alters the conductance between the first material and the second material upon receipt of the impedance signal.
15. The device of claim of 14 wherein the impedance measuring unit sends the impedance signal to the control module to indicate to the control module that the impedance of the surrounding environment is below the designated value and the device can be activated.
16. The device of claim 1 wherein the unit receives a deactivate signal from an external source and communicates that information to the control module such that the control module alters the conductance between the first material and the second material in order to prevent generation of a current flow between the first material and second material and thereby deactivate the device.
17. The device of claim 1 , further comprising a sealed housing defining a cavity, wherein the communication unit is positioned within the cavity and further comprising an electroactive matrix within the cavity, wherein the unit generates voltage to cause the electroactive matrix to expand and open the sealed housing.
18. The device of claim 1 , wherein after the device comes into contact with the conducting fluid, a signal received at the unit is sent to the control module and the control module adjusts conductance in response to impedance to at least one of maintain a constant power output and maintain power above a minimum threshold.
19. The device of claim 13, wherein after the device comes into contact with the conducting fluid, the impedance measurement is correlated to at least one indicator selected from a group consisting essentially of the following: hydration state, presence of a drug, gastro-intestinal motility/waves, gastric transit time, presence of specific tissue type, and location of specific tissue type.
20. The device of claim 13, wherein the impedance measurement unit measures impedance at multiple frequencies.
PCT/US2012/046118 2011-07-11 2012-07-10 Communication system with remote activation WO2013009781A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IN509CHN2014 IN2014CN00509A (en) 2011-07-11 2012-07-10
CA2841904A CA2841904A1 (en) 2011-07-11 2012-07-10 Communication system with remote activation
RU2014104519/14A RU2014104519A (en) 2011-07-11 2012-07-10 REMOTE ACTIVATION COMMUNICATION SYSTEM
EP12811425.3A EP2731497B1 (en) 2011-07-11 2012-07-10 Communication system with remote activation
AU2012282776A AU2012282776B2 (en) 2011-07-11 2012-07-10 Communication system with remote activation
JP2014520263A JP2014522695A (en) 2011-07-11 2012-07-10 Communication system having remote activation function
KR1020147003474A KR20140066996A (en) 2011-07-11 2012-07-10 Communication system with remote activation
CN201280043374.0A CN103781411B (en) 2011-07-11 2012-07-10 There is the communication system of remote activation
MX2014000482A MX337132B (en) 2011-07-11 2012-07-10 Communication system with remote activation.
BR112014000624A BR112014000624A2 (en) 2011-07-11 2012-07-10 remote activation communication system
HK14109909.5A HK1196239A1 (en) 2011-07-11 2014-10-06 Communication system with remote activation
AU2017202754A AU2017202754B2 (en) 2011-07-11 2017-04-26 Communication system with remote activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/180,516 US8912908B2 (en) 2005-04-28 2011-07-11 Communication system with remote activation
US13/180,516 2011-07-11

Publications (2)

Publication Number Publication Date
WO2013009781A2 true WO2013009781A2 (en) 2013-01-17
WO2013009781A3 WO2013009781A3 (en) 2013-04-04

Family

ID=47506867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/046118 WO2013009781A2 (en) 2011-07-11 2012-07-10 Communication system with remote activation

Country Status (14)

Country Link
US (2) US8912908B2 (en)
EP (1) EP2731497B1 (en)
JP (1) JP2014522695A (en)
KR (1) KR20140066996A (en)
CN (1) CN103781411B (en)
AU (2) AU2012282776B2 (en)
BR (1) BR112014000624A2 (en)
CA (1) CA2841904A1 (en)
HK (1) HK1196239A1 (en)
IN (1) IN2014CN00509A (en)
MX (1) MX337132B (en)
RU (1) RU2014104519A (en)
TW (1) TW201320962A (en)
WO (1) WO2013009781A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
CN101287411B (en) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 Pharma-informatics system
CN105468895A (en) 2006-05-02 2016-04-06 普罗透斯数字保健公司 Patient customized therapeutic regimens
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
CA2676407A1 (en) 2007-02-01 2008-08-07 Proteus Biomedical, Inc. Ingestible event marker systems
CN101636865B (en) 2007-02-14 2012-09-05 普罗秋斯生物医学公司 In-body power source having high surface area electrode
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
SG10201702853UA (en) 2008-07-08 2017-06-29 Proteus Digital Health Inc Ingestible event marker data framework
CA2732309C (en) 2008-07-30 2018-04-10 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
AU2009281876B2 (en) 2008-08-13 2014-05-22 Proteus Digital Health, Inc. Ingestible circuitry
EP2783727B1 (en) 2008-11-12 2016-11-09 Ecole Polytechnique Fédérale de Lausanne Microfabricated neurostimulation device
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
SG196787A1 (en) 2009-01-06 2014-02-13 Proteus Digital Health Inc Ingestion-related biofeedback and personalized medical therapy method and system
SG10201810784SA (en) 2009-04-28 2018-12-28 Proteus Digital Health Inc Highly Reliable Ingestible Event Markers And Methods For Using The Same
TWI517050B (en) 2009-11-04 2016-01-11 普羅托斯數位健康公司 System for supply chain management
WO2011067297A1 (en) 2009-12-01 2011-06-09 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Microfabricated neurostimulation device and methods of making and using the same
CN102946798A (en) 2010-02-01 2013-02-27 普罗秋斯数字健康公司 Data gathering system
WO2011121089A1 (en) 2010-04-01 2011-10-06 Ecole Polytechnique Federale De Lausanne (Epfl) Device for interacting with neurological tissue and methods of making and using the same
TWI638652B (en) 2010-04-07 2018-10-21 波提亞斯數位康健公司 Miniature ingestible device
TWI557672B (en) 2010-05-19 2016-11-11 波提亞斯數位康健公司 Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device
WO2012071280A2 (en) 2010-11-22 2012-05-31 Proteus Biomedical, Inc. Ingestible device with pharmaceutical product
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
CN103827914A (en) 2011-07-21 2014-05-28 普罗秋斯数字健康公司 Mobile communication device, system, and method
BR112015001388A2 (en) 2012-07-23 2017-07-04 Proteus Digital Health Inc techniques for making ingestible event markers comprising an ingestible component
AU2013331417B2 (en) 2012-10-18 2016-06-02 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
KR101916418B1 (en) * 2012-11-29 2018-11-08 삼성전자주식회사 Method and apparatus for reducing power consumption of receiver
TWI590818B (en) 2012-12-19 2017-07-11 Otsuka Pharma Co Ltd Medicine tablet, its manufacturing method and its manufacturing device
TWI659994B (en) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 Highly-swellable polymeric films and compositions comprising the same
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
JP6498177B2 (en) 2013-03-15 2019-04-10 プロテウス デジタル ヘルス, インコーポレイテッド Identity authentication system and method
JP6511439B2 (en) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス, インコーポレイテッド Systems, devices, and methods for data collection and outcome assessment
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
EP3047618B1 (en) 2013-09-20 2023-11-08 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10084880B2 (en) * 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
JP6354143B2 (en) 2013-12-10 2018-07-11 Tdk株式会社 Information providing system, electronic device, method and program
EP3476430B1 (en) 2014-05-16 2020-07-01 Aleva Neurotherapeutics SA Device for interacting with neurological tissue
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US20160174842A1 (en) * 2014-12-17 2016-06-23 Elwha Llc Epidermal electronics systems having radio frequency antennas systems and methods
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
EP3411111A1 (en) 2016-02-02 2018-12-12 Aleva Neurotherapeutics SA Treatment of autoimmune diseases with deep brain stimulation
KR102051875B1 (en) 2016-07-22 2019-12-04 프로테우스 디지털 헬스, 인코포레이티드 Electromagnetic detection and detection of ingestible event markers
US20180028069A1 (en) * 2016-07-29 2018-02-01 VivaLnk Inc. Wearable thermometer patch for accurate measurement of human skin temperature
US11026609B2 (en) * 2016-08-09 2021-06-08 Verily Life Sciences Llc Wake-up batteries for invasive biosensors
AU2017348094B2 (en) 2016-10-26 2022-10-13 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
TWI789391B (en) 2017-04-25 2023-01-11 日商大塚製藥股份有限公司 Lisinopril compositions with an ingestible event marker
US10588823B1 (en) * 2017-07-12 2020-03-17 Rakesh Arora System for the tracking, dispensing, and administering of a medicament in a programmable encapsulation
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (802)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1548459A (en) 1923-12-14 1925-08-04 Hammer Charles Metal cap
NL224427A (en) 1956-02-08
US3799802A (en) 1966-06-28 1974-03-26 F Schneble Plated through hole printed circuit boards
US3607788A (en) 1967-11-20 1971-09-21 Robert J Adolph Liquid electrode material
US3589943A (en) 1968-08-29 1971-06-29 Gen Electric Electrochemical battery
US3642008A (en) 1968-09-25 1972-02-15 Medical Plastics Inc Ground electrode and test circuit
US3679480A (en) 1969-05-08 1972-07-25 Dow Chemical Co Electrical cell assembly
US3682160A (en) 1969-10-16 1972-08-08 Matsushita Electric Ind Co Ltd Physiological signal transmitter for use inside the body
US3719183A (en) 1970-03-05 1973-03-06 H Schwartz Method for detecting blockage or insufficiency of pancreatic exocrine function
US3837339A (en) 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US3828766A (en) 1972-08-14 1974-08-13 Jet Medical Prod Inc Disposable medical electrode
US3989050A (en) 1972-09-19 1976-11-02 Gilbert Buchalter Process for utilizing certain gel compositions for electrical stimulation
US3849041A (en) 1973-04-30 1974-11-19 Minnesota Mining & Mfg Apparatus for manufacturing environmental seed cells
US3944064A (en) 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US4106348A (en) 1974-02-20 1978-08-15 U.S. Philips Corporation Device for examination by means of ultrasonic vibrations
US3893111A (en) 1974-03-14 1975-07-01 Albert Albert F System and method for remote monitoring of animal temperature
US3967202A (en) 1974-07-25 1976-06-29 Northern Illinois Gas Company Data transmission system including an RF transponder for generating a broad spectrum of intelligence bearing sidebands
US4090752A (en) 1974-10-07 1978-05-23 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
US4077397A (en) 1974-10-07 1978-03-07 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
ZA755785B (en) 1974-10-07 1976-08-25 Baxter Laboratories Inc Diagnostic electrode assembly
US4062750A (en) 1974-12-18 1977-12-13 James Francis Butler Thin film electrochemical electrode and cell
US4055178A (en) 1976-03-10 1977-10-25 Harrigan Roy Major Drug delivery device for preventing contact of undissolved drug with the stomach lining
US4017856A (en) 1976-03-10 1977-04-12 Westinghouse Electric Corporation Self-calibrating microwave transponder
US4129125A (en) 1976-12-27 1978-12-12 Camin Research Corp. Patient monitoring system
GB1594214A (en) 1977-01-21 1981-07-30 Cardio Tech Body electrodes
US4082087A (en) 1977-02-07 1978-04-04 Isis Medical Instruments Body contact electrode structure for deriving electrical signals due to physiological activity
JPS5475284A (en) 1977-11-29 1979-06-15 Asahi Chemical Ind Threeeterminal magnetic reluctance effect element
US4239046A (en) 1978-09-21 1980-12-16 Ong Lincoln T Medical electrode
US4345588A (en) 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4269189A (en) 1979-07-09 1981-05-26 Consolidated Medical Equipment Inc. Skin conducting electrode assembly
DE2928477C3 (en) 1979-07-14 1982-04-15 Battelle-Institut E.V., 6000 Frankfurt Device for the release of substances at defined locations in the digestive tract
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4578061A (en) 1980-10-28 1986-03-25 Lemelson Jerome H Injection catheter and method
US4418697A (en) 1981-08-17 1983-12-06 Francine Tama Electrode attachment method
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4564363A (en) 1983-07-13 1986-01-14 Smithkline Beckman Corporation Delayed action assembly
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4749575A (en) 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4559950A (en) 1983-11-25 1985-12-24 Graphic Controls Corporation Disposable biomedical and diagnostic electrode
US5000957A (en) 1984-03-19 1991-03-19 Alza Corporation Dispenser comprising hydrophilic osmopolymer
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
JPS6172712U (en) 1984-10-12 1986-05-17
US4681111A (en) 1985-04-05 1987-07-21 Siemens-Pacesetter, Inc. Analog and digital telemetry system for an implantable device
US4654165A (en) 1985-04-16 1987-03-31 Micro Tracers, Inc. Microingredient containing tracer
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4763659A (en) 1985-08-21 1988-08-16 Spring Creek Institute, Inc. Dry electrode system for detection of biopotentials
US4669479A (en) 1985-08-21 1987-06-02 Spring Creek Institute, Inc. Dry electrode system for detection of biopotentials
US4635641A (en) 1985-10-16 1987-01-13 Murray Electronics Associates Limited Multi-element electrode
US4663250A (en) 1986-03-12 1987-05-05 Institute Of Gas Technology Reduction of electrode dissolution
US4725997A (en) 1986-08-22 1988-02-16 Aprex Corporation Contingent dosing device
US4784162A (en) 1986-09-23 1988-11-15 Advanced Medical Technologies Portable, multi-channel, physiological data monitoring system
US4896261A (en) 1986-11-24 1990-01-23 Motorola Inc. System for scheduling serial message transmission on a bus which is adoptable for rescheduling prioritized messages using a doubly-linked list
US4876093A (en) 1987-07-02 1989-10-24 Alza Corporation Dispenser with dispersing member for delivering beneficial agent
DE3723310A1 (en) 1987-07-15 1989-01-26 John Urquhart PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
CA1327838C (en) 1988-06-13 1994-03-15 Fred Zacouto Implantable device to prevent blood clotting disorders
US4975230A (en) 1988-06-17 1990-12-04 Vapor Technologies Inc. Method of making an open pore structure
US4844076A (en) 1988-08-26 1989-07-04 The Johns Hopkins University Ingestible size continuously transmitting temperature monitoring pill
JPH02180265A (en) 1988-12-28 1990-07-13 Nippon Eranko Kk Charging device into capsule
SE466684B (en) 1989-03-07 1992-03-23 Draco Ab DEVICE INHALATOR AND PROCEDURE TO REGISTER WITH THE DEVICE INHALATOR MEDICATION
EP0392032B1 (en) 1989-04-10 1995-01-25 Pacesetter AB Medical implantable apparatus with telematic data transmission means
CA2016517C (en) 1989-05-11 1999-01-12 Dale R. Shackle Solid state electrochemical cell having microroughened current collector
US5281287A (en) 1989-07-21 1994-01-25 Iomed, Inc. Method of making a hydratable bioelectrode
GB8920957D0 (en) 1989-09-15 1989-11-01 Hitech Metal Detectors Ltd Metal detecting apparatus and apparatus for testing metal detecting apparatus
US4987897A (en) 1989-09-18 1991-01-29 Medtronic, Inc. Body bus medical device communication system
US5110441A (en) 1989-12-14 1992-05-05 Monsanto Company Solid state ph sensor
US6749122B1 (en) 1990-05-25 2004-06-15 Broadcom Corporation Multi-level hierarchial radio-frequency system communication system
US6359872B1 (en) 1997-10-28 2002-03-19 Intermec Ip Corp. Wireless personal local area network
US5167626A (en) 1990-10-02 1992-12-01 Glaxo Inc. Medical capsule device actuated by radio-frequency (RF) signal
US5395366A (en) 1991-05-30 1995-03-07 The State University Of New York Sampling capsule and process
US5279607A (en) 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
GB9123638D0 (en) 1991-11-07 1992-01-02 Magill Alan R Apparel & fabric & devices suitable for health monitoring applications
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
JPH05228128A (en) 1992-02-25 1993-09-07 Olympus Optical Co Ltd Capsule for medical treatment
DE69329710T2 (en) 1992-04-03 2001-08-02 Micromedical Ind Ltd ARRANGEMENT FOR MONITORING PHYSIOLOGICAL PARAMETERS
US5263481A (en) 1992-05-21 1993-11-23 Jens Axelgaard Electrode system with disposable gel
US5283136A (en) 1992-06-03 1994-02-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Rechargeable batteries
US5318557A (en) 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
US5261402A (en) 1992-07-20 1993-11-16 Graphic Controls Corporation Snapless, tabless, disposable medical electrode with low profile
US5338625A (en) 1992-07-29 1994-08-16 Martin Marietta Energy Systems, Inc. Thin film battery and method for making same
US7758503B2 (en) 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US5757326A (en) 1993-03-29 1998-05-26 Seiko Epson Corporation Slot antenna device and wireless apparatus employing the antenna device
FR2704969B1 (en) 1993-05-06 1995-07-28 Centre Scient Tech Batiment Acoustic attenuation device with active double wall.
AU676293B2 (en) 1993-06-24 1997-03-06 Wilson Greatbatch Ltd. Electrode covering for electrochemical cells
US5394882A (en) 1993-07-21 1995-03-07 Respironics, Inc. Physiological monitoring system
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5458141A (en) 1993-08-04 1995-10-17 Quinton Instrument Company Abrasive skin electrode
US5443461A (en) 1993-08-31 1995-08-22 Alza Corporation Segmented device for simultaneous delivery of multiple beneficial agents
DE4329898A1 (en) 1993-09-04 1995-04-06 Marcus Dr Besson Wireless medical diagnostic and monitoring device
US5402793A (en) 1993-11-19 1995-04-04 Advanced Technology Laboratories, Inc. Ultrasonic transesophageal probe for the imaging and diagnosis of multiple scan planes
US6390088B1 (en) 1993-12-13 2002-05-21 Boehringer Ingelheim Kg Aerosol inhaler
US5659247A (en) 1994-03-10 1997-08-19 Denver Dynamics, Inc. Device for detecting metal objects passing through an opening
US6231593B1 (en) 1994-03-21 2001-05-15 Dusa Pharmaceuticals, Inc. Patch, controller, and method for the photodynamic therapy of a dermal lesion
US5551020A (en) 1994-03-28 1996-08-27 Flextech Systems, Inc. System for the compacting and logical linking of data blocks in files to optimize available physical storage
US5925066A (en) 1995-10-26 1999-07-20 Galvani, Ltd. Atrial arrythmia sensor with drug and electrical therapy control apparatus
US5600548A (en) 1994-08-11 1997-02-04 Sundstrand Corporation DC content control for an inverter
IE70735B1 (en) 1994-08-15 1996-12-11 Elan Med Tech Orally administrable delivery device
DE9414065U1 (en) 1994-08-31 1994-11-03 Roehm Gmbh Thermoplastic plastic for pharmaceutical casings soluble in intestinal juice
IL111396A (en) 1994-10-25 1997-07-13 Ness Neuromuscular Electrical Stimulation Systems Ltd Electrode system
US5718098A (en) 1994-12-30 1998-02-17 Pharmagraphics L.L.C., Midwest Method for producing sample package
US5485841A (en) 1995-02-14 1996-01-23 Univ Mcgill Ultrasonic lung tissue assessment
US5778882A (en) 1995-02-24 1998-07-14 Brigham And Women's Hospital Health monitoring system
US6374670B1 (en) 1995-03-13 2002-04-23 University Of Washington Non-invasive gut motility monitor
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5645063A (en) 1995-06-05 1997-07-08 Quinton Instrument Company Skin electrode having multiple conductive center members
US5738708A (en) 1995-06-07 1998-04-14 The Regents Of The University Of California Office Of Technology Transfer Composite metal membrane
US6083248A (en) 1995-06-23 2000-07-04 Medtronic, Inc. World wide patient location and data telemetry system for implantable medical devices
US5772575A (en) 1995-09-22 1998-06-30 S. George Lesinski Implantable hearing aid
US5802467A (en) 1995-09-28 1998-09-01 Innovative Intelcom Industries Wireless and wired communications, command, control and sensing system for sound and/or data transmission and reception
US6076016A (en) * 1995-10-19 2000-06-13 Feierbach; Gary F. Galvanic transdermal conduction communication system and method
GB9522872D0 (en) 1995-11-08 1996-01-10 Oxford Medical Ltd Improvements relating to physiological monitoring
US8092224B2 (en) 1995-11-22 2012-01-10 James A. Jorasch Systems and methods for improved health care compliance
SE9504258D0 (en) 1995-11-28 1995-11-28 Pacesetter Ab Device and method for generating a synthesized ECG
US5596302A (en) 1996-01-17 1997-01-21 Lucent Technologies Inc. Ring oscillator using even numbers of differential stages with current mirrors
AU710983B2 (en) 1996-02-15 1999-10-07 Armand P. Neukermans Improved biocompatible transducers
US5868136A (en) 1996-02-20 1999-02-09 Axelgaard Manufacturing Co. Ltd. Medical electrode
US20010044588A1 (en) 1996-02-22 2001-11-22 Mault James R. Monitoring system
US5833603A (en) 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
WO1997036646A1 (en) 1996-04-01 1997-10-09 Valery Ivanovich Kobozev Electrical gastro-intestinal tract stimulator
GB9608268D0 (en) 1996-04-22 1996-06-26 Robertson James L Blister pack
US5864578A (en) 1996-04-29 1999-01-26 Golden Bridge Technology, Inc. Matched filter-based handoff method and apparatus
US5800421A (en) 1996-06-12 1998-09-01 Lemelson; Jerome H. Medical devices using electrosensitive gels
WO1998007364A1 (en) 1996-08-16 1998-02-26 Roche Diagnostics Gmbh Monitoring system for the regular intake of a medicament
SK284388B6 (en) 1996-08-29 2005-02-04 Sanofi-Synthelabo Tablet with controlled release of alfuzosine chlorhydrate
US5792048A (en) 1996-09-03 1998-08-11 Schaefer; Guenter Indentification pill with integrated microchip: smartpill, smartpill with integrated microchip and microprocessor for medical analyses and a smartpill, smartbox, smartplague, smartbadge or smartplate for luggage control on commercial airliners
US5963132A (en) 1996-10-11 1999-10-05 Avid Indentification Systems, Inc. Encapsulated implantable transponder
US6364834B1 (en) 1996-11-13 2002-04-02 Criticare Systems, Inc. Method and system for remotely monitoring multiple medical parameters in an integrated medical monitoring system
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
US8734339B2 (en) 1996-12-16 2014-05-27 Ip Holdings, Inc. Electronic skin patch for real time monitoring of cardiac activity and personal health management
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
US5974124A (en) 1997-01-21 1999-10-26 Med Graph Method and system aiding medical diagnosis and treatment
US6317714B1 (en) 1997-02-04 2001-11-13 Microsoft Corporation Controller and associated mechanical characters operable for continuously performing received control data while engaging in bidirectional communications over a single communications channel
DE69841846D1 (en) 1997-03-17 2010-09-30 Adidas Ag INFORMATION RECONDITIONING SYSTEM FOR PHYSIOLOGICAL SIGNALS
WO1998043537A1 (en) 1997-03-31 1998-10-08 Telecom Medical, Inc. Patient monitoring apparatus
US5981166A (en) 1997-04-23 1999-11-09 Pharmaseq, Inc. Screening of soluble chemical compounds for their pharmacological properties utilizing transponders
DE19717023C2 (en) 1997-04-23 2003-02-06 Micronas Gmbh Device for treating malignant, tumorous tissue areas
US6288629B1 (en) 1997-05-23 2001-09-11 Intermec Ip Corp. Method of using write—ok flag for radio frequency (RF) transponders (RF Tags)
US5984875A (en) 1997-08-22 1999-11-16 Innotek Pet Products, Inc. Ingestible animal temperature sensor
US5862808A (en) 1997-08-26 1999-01-26 Cigar Savor Enterprises Llc Cigar punch
US5948227A (en) 1997-12-17 1999-09-07 Caliper Technologies Corp. Methods and systems for performing electrophoretic molecular separations
GB9801363D0 (en) 1998-01-22 1998-03-18 Danbiosyst Uk Novel dosage form
US6099259A (en) 1998-01-26 2000-08-08 Bristol Compressors, Inc. Variable capacity compressor
US6097927A (en) 1998-01-27 2000-08-01 Symbix, Incorporated Active symbolic self design method and apparatus
US6038464A (en) 1998-02-09 2000-03-14 Axelgaard Manufacturing Co., Ltd. Medical electrode
US7542878B2 (en) 1998-03-03 2009-06-02 Card Guard Scientific Survival Ltd. Personal health monitor and a method for health monitoring
US6141592A (en) 1998-03-06 2000-10-31 Intermedics Inc. Data transmission using a varying electric field
US6579231B1 (en) 1998-03-27 2003-06-17 Mci Communications Corporation Personal medical monitoring unit and system
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
PT1077634E (en) 1998-05-13 2003-12-31 Cygnus Therapeutic Systems MONITORING OF PHYSIOLOGICAL SUBSTANCES TO BE ANALYZED
AU4094599A (en) 1998-05-21 1999-12-06 Telecom Medical, Inc. Patient monitoring apparatus
US6205745B1 (en) 1998-05-27 2001-03-27 Lucent Technologies Inc. High speed flip-chip dispensing
US6477424B1 (en) 1998-06-19 2002-11-05 Medtronic, Inc. Medical management system integrated programming apparatus for communication with an implantable medical device
US6704602B2 (en) 1998-07-02 2004-03-09 Medtronic, Inc. Implanted medical device/external medical instrument communication utilizing surface electrodes
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7548787B2 (en) 2005-08-03 2009-06-16 Kamilo Feher Medical diagnostic and communication system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6333699B1 (en) 1998-08-28 2001-12-25 Marathon Oil Company Method and apparatus for determining position in a pipe
CA2341708A1 (en) 1998-09-04 2000-03-16 Wolfe Research Pty. Ltd. Medical implant system
WO2000017813A1 (en) 1998-09-18 2000-03-30 Hitachi Maxell, Ltd. Noncontact communication semiconductor device
FI116957B (en) 1998-10-29 2006-04-13 Nokia Corp The method of communication between the wireless device and the electronic device and the communication device
US6708060B1 (en) 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
AU1832800A (en) 1998-11-25 2000-06-19 Ball Semiconductor Inc. Method of and system for identifying medical products
US6217744B1 (en) 1998-12-18 2001-04-17 Peter Crosby Devices for testing fluid
DE69909327T2 (en) 1998-12-21 2004-04-22 Sequella, Inc. METHODS OF USE AND COMPILATIONS CONTAINING MONITORING SYSTEM
US6115636A (en) 1998-12-22 2000-09-05 Medtronic, Inc. Telemetry for implantable devices using the body as an antenna
US6269058B1 (en) 1999-01-04 2001-07-31 Texas Instruments Incorporated Wide capture range circuitry
US6358202B1 (en) 1999-01-25 2002-03-19 Sun Microsystems, Inc. Network for implanted computer devices
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
US6494829B1 (en) 1999-04-15 2002-12-17 Nexan Limited Physiological sensor array
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6755783B2 (en) 1999-04-16 2004-06-29 Cardiocom Apparatus and method for two-way communication in a device for monitoring and communicating wellness parameters of ambulatory patients
US6290646B1 (en) 1999-04-16 2001-09-18 Cardiocom Apparatus and method for monitoring and communicating wellness parameters of ambulatory patients
DK1182966T3 (en) 1999-05-25 2004-04-13 Medicotest As Electrode for application to the skin
EP1194903B1 (en) 1999-05-26 2013-11-13 Johnson Controls Technology Company Wireless communications system and method
US6366206B1 (en) 1999-06-02 2002-04-02 Ball Semiconductor, Inc. Method and apparatus for attaching tags to medical and non-medical devices
EP1060704A3 (en) 1999-06-18 2002-09-18 Agilent Technologies, Inc. (a Delaware corporation) Multi-parameter capability transmitter for wireless telemetry systems
JP3402267B2 (en) 1999-06-23 2003-05-06 ソニーケミカル株式会社 Electronic element mounting method
DE19929328A1 (en) 1999-06-26 2001-01-04 Daimlerchrysler Aerospace Ag Device for long-term medical monitoring of people
US6287252B1 (en) 1999-06-30 2001-09-11 Monitrak Patient monitor
US6307468B1 (en) 1999-07-20 2001-10-23 Avid Identification Systems, Inc. Impedance matching network and multidimensional electromagnetic field coil for a transponder interrogator
HN2000000165A (en) 1999-08-05 2001-07-09 Dimensional Foods Corp EDIBLE HOLOGRAPHIC PRODUCTS, PARTICULARLY PHARMACEUTICALS, AND METHODS AND APPLIANCES FOR PRODUCERS.
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US6206702B1 (en) 1999-08-24 2001-03-27 Deborah A. Hayden Methods and devices for treating unilateral neglect
US6526034B1 (en) 1999-09-21 2003-02-25 Tantivy Communications, Inc. Dual mode subscriber unit for short range, high rate and long range, lower rate data communications
US6533733B1 (en) 1999-09-24 2003-03-18 Ut-Battelle, Llc Implantable device for in-vivo intracranial and cerebrospinal fluid pressure monitoring
US6990082B1 (en) 1999-11-08 2006-01-24 Intel Corporation Wireless apparatus having a transceiver equipped to support multiple wireless communication protocols
KR100739357B1 (en) 1999-09-30 2007-07-18 소니 가부시끼 가이샤 Recording apparatus, recording method and recording media
AU778361B2 (en) 1999-10-07 2004-12-02 La Mont, Llc Physiological signal monitoring apparatus and method
US6852084B1 (en) 2000-04-28 2005-02-08 Peter V. Boesen Wireless physiological pressure sensor and transmitter with capability of short range radio frequency transmissions
US6882881B1 (en) 1999-10-19 2005-04-19 The Johns Hopkins University Techniques using heat flow management, stimulation, and signal analysis to treat medical disorders
US6426863B1 (en) 1999-11-25 2002-07-30 Lithium Power Technologies, Inc. Electrochemical capacitor
US6612984B1 (en) 1999-12-03 2003-09-02 Kerr, Ii Robert A. System and method for collecting and transmitting medical data
GB9930000D0 (en) 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US6294999B1 (en) 1999-12-29 2001-09-25 Becton, Dickinson And Company Systems and methods for monitoring patient compliance with medication regimens
US6471645B1 (en) 1999-12-30 2002-10-29 Medtronic, Inc. Communications system for an implantable device and a drug dispenser
US8002700B2 (en) 1999-12-30 2011-08-23 Medtronic, Inc. Communications system for an implantable medical device and a delivery device
GB0000566D0 (en) 2000-01-12 2000-03-01 Willett Int Ltd Apparatus and method
DE60030086T2 (en) 2000-01-20 2007-01-04 Lucent Technologies Inc. Interoperability of Bluetooth and IEEE 802.11
AR026148A1 (en) 2000-01-21 2003-01-29 Osmotica Argentina S A OSMOTIC DEVICE WITH PREFORMED PASSAGE THAT INCREASES SIZE
US6567685B2 (en) 2000-01-21 2003-05-20 Kabushiki Kaisha Toshiba Magnetic resonance imaging apparatus
US6368190B1 (en) 2000-01-26 2002-04-09 Agere Systems Guardian Corp. Electrochemical mechanical planarization apparatus and method
US7039453B2 (en) 2000-02-08 2006-05-02 Tarun Mullick Miniature ingestible capsule
EP1779777B1 (en) 2000-03-08 2011-06-08 Given Imaging Ltd. A device for in vivo imaging
US6526315B1 (en) 2000-03-17 2003-02-25 Tanita Corporation Portable bioelectrical impedance measuring instrument
DE10014588A1 (en) 2000-03-27 2001-10-04 Basf Ag Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone
GB0007617D0 (en) 2000-03-29 2000-05-17 Psion Dacom Plc A short range radio transceiver device
US6757523B2 (en) 2000-03-31 2004-06-29 Zeus Wireless, Inc. Configuration of transmit/receive switching in a transceiver
US6622050B2 (en) 2000-03-31 2003-09-16 Medtronic, Inc. Variable encryption scheme for data transfer between medical devices and related data management systems
US6922592B2 (en) 2000-04-04 2005-07-26 Medtronic, Inc. Implantable medical device controlled by a non-invasive physiological data measurement device
US6654638B1 (en) 2000-04-06 2003-11-25 Cardiac Pacemakers, Inc. Ultrasonically activated electrodes
US6496705B1 (en) 2000-04-18 2002-12-17 Motorola Inc. Programmable wireless electrode system for medical monitoring
US6441747B1 (en) 2000-04-18 2002-08-27 Motorola, Inc. Wireless system protocol for telemetry monitoring
US6561975B1 (en) 2000-04-19 2003-05-13 Medtronic, Inc. Method and apparatus for communicating with medical device systems
US6836862B1 (en) 2000-04-24 2004-12-28 3Com Corporation Method of indicating wireless connection integrity
US7231451B2 (en) 2000-05-08 2007-06-12 Microtune (San Diego), Inc. Transmit-only and receive-only Bluetooth apparatus and method
US6432292B1 (en) 2000-05-16 2002-08-13 Metallic Power, Inc. Method of electrodepositing metal on electrically conducting particles
US6988989B2 (en) 2000-05-19 2006-01-24 Welch Allyn Protocol, Inc. Patient monitoring system
US6680923B1 (en) 2000-05-23 2004-01-20 Calypso Wireless, Inc. Communication system and method
ATE279879T1 (en) 2000-05-29 2004-11-15 Medicotest As ELECTRODE FOR MAKING ELECTRICAL CONTACT WITH THE SKIN
IL143418A (en) 2000-05-31 2004-09-27 Given Imaging Ltd Measurement of electrical characteristics of tissue
US20060122474A1 (en) 2000-06-16 2006-06-08 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
GB0014854D0 (en) 2000-06-16 2000-08-09 Isis Innovation System and method for acquiring data
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
GB0014855D0 (en) 2000-06-16 2000-08-09 Isis Innovation Combining measurements from different sensors
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US7009946B1 (en) 2000-06-22 2006-03-07 Intel Corporation Method and apparatus for multi-access wireless communication
GB0016561D0 (en) 2000-07-05 2000-08-23 Rolls Royce Plc Health monitoring
DE60107685T2 (en) 2000-07-19 2005-10-06 Medicotest A/S SKIN ELECTRODE WITH A BYPASS ELEMENT
EP1304959A1 (en) 2000-07-24 2003-05-02 Motorola, Inc. Ingestible electronic capsule
US6564079B1 (en) 2000-07-27 2003-05-13 Ckm Diagnostics, Inc. Electrode array and skin attachment system for noninvasive nerve location and imaging device
JP4428835B2 (en) 2000-08-09 2010-03-10 昭和電工株式会社 Magnetic recording medium and method for manufacturing the same
US8036731B2 (en) 2001-01-22 2011-10-11 Spectrum Dynamics Llc Ingestible pill for diagnosing a gastrointestinal tract
WO2002018936A2 (en) 2000-08-28 2002-03-07 Cygnus, Inc. Methods of monitoring glucose levels in a subject and uses thereof
US7685005B2 (en) 2000-08-29 2010-03-23 Medtronic, Inc. Medical device systems implemented network scheme for remote patient management
DE60102331T2 (en) 2000-09-08 2005-03-17 Matsushita Electric Works, Ltd., Kadoma Data transmission system using a human body as a signal transmission path
US6720923B1 (en) 2000-09-14 2004-04-13 Stata Labs, Llc Antenna design utilizing a cavity architecture for global positioning system (GPS) applications
US6572636B1 (en) 2000-09-19 2003-06-03 Robert Sean Hagen Pulse sensing patch and associated methods
WO2002027659A2 (en) 2000-09-26 2002-04-04 Advantage 3D Llc Method and system for generation, storage and distribution of omni-directional object views
AU2002224453A1 (en) 2000-10-11 2002-04-22 Microchips, Inc. Microchip reservoir devices and facilitated corrosion of electrodes
US7024248B2 (en) 2000-10-16 2006-04-04 Remon Medical Technologies Ltd Systems and methods for communicating with implantable devices
US7857626B2 (en) 2000-10-23 2010-12-28 Toly Christopher C Medical physiological simulator including a conductive elastomer layer
US6738671B2 (en) 2000-10-26 2004-05-18 Medtronic, Inc. Externally worn transceiver for use with an implantable medical device
US6929636B1 (en) 2000-11-08 2005-08-16 Hewlett-Packard Development Company, L.P. Internal drug dispenser capsule medical device
US6632175B1 (en) 2000-11-08 2003-10-14 Hewlett-Packard Development Company, L.P. Swallowable data recorder capsule medical device
ES2177434B1 (en) 2000-12-05 2004-10-16 Gesimpex Comercial, S.L. PROCEDURE AND CAPSULE FOR REMOTE IDENTIFICATION AND MONITORING OF BIRDS.
US6689117B2 (en) 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US6879810B2 (en) 2000-12-20 2005-04-12 Nokia Corporation Control of short range RF communication
TW567695B (en) 2001-01-17 2003-12-21 Ibm Digital baseband system
JP3927495B2 (en) 2001-02-08 2007-06-06 ミニ−ミッター カンパニー,インコーポレイテッド Skin patch with built-in temperature sensor
US20050208251A1 (en) 2001-02-15 2005-09-22 Integral Technologies, Inc. Low cost electrically conductive tapes and films manufactured from conductive loaded resin-based materials
JP2002263185A (en) 2001-03-12 2002-09-17 Sanyo Electric Co Ltd Medicine administration system and method and medicine administration device
GB0107045D0 (en) 2001-03-21 2001-05-09 Pace Micro Tech Plc Control system for control of power supply for lnb in broadcast data receiving system
JP2002282219A (en) 2001-03-22 2002-10-02 Toshio Chiba Intracorporeal capsule
US6342774B1 (en) 2001-03-27 2002-01-29 Motorola, Inc. Battery having user charge capacity control
JP2002290212A (en) 2001-03-27 2002-10-04 Nec Corp Voltage controlled oscillator
JP2005500869A (en) 2001-03-28 2005-01-13 テレバイタル・インコーポレイテッド System and method for real-time monitoring, judgment, analysis, retrieval and storage of physiological data over a wide area network
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
JP2004527296A (en) 2001-04-02 2004-09-09 エヌ アイ メディカル リミテッド Hemodynamic measurement device
EP1379167A1 (en) 2001-04-06 2004-01-14 Medic4all Inc. A physiological monitoring system for a computational device of a human subject
GR1003802B (en) 2001-04-17 2002-02-08 Micrel �.�.�. ������� ��������� ��������������� ��������� Tele-medicine system
US6694161B2 (en) 2001-04-20 2004-02-17 Monsanto Technology Llc Apparatus and method for monitoring rumen pH
US6801137B2 (en) 2001-04-23 2004-10-05 Cardionet, Inc. Bidirectional communication between a sensor unit and a monitor unit in patient monitoring
US6782290B2 (en) 2001-04-27 2004-08-24 Medtronic, Inc. Implantable medical device with rechargeable thin-film microbattery power source
DE60214698T2 (en) 2001-04-30 2007-09-13 Medtronic, Inc., Minneapolis IMPLANTABLE MEDICAL DEVICE AND PLASTER SYSTEM
KR20030092120A (en) 2001-05-03 2003-12-03 텔쥬트 테크놀로지스, 인크. Wireless medical monitoring apparatus and system
US7039033B2 (en) 2001-05-07 2006-05-02 Ixi Mobile (Israel) Ltd. System, device and computer readable medium for providing a managed wireless network using short-range radio signals
EP1397660B1 (en) 2001-05-20 2013-05-15 Given Imaging Ltd. A floatable in vivo sensing device
GB0113212D0 (en) 2001-05-31 2001-07-25 Oxford Biosignals Ltd Patient condition display
WO2002096347A2 (en) 2001-05-31 2002-12-05 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US20020192159A1 (en) 2001-06-01 2002-12-19 Reitberg Donald P. Single-patient drug trials used with accumulated database: flowchart
US20020179921A1 (en) 2001-06-02 2002-12-05 Cohn Michael B. Compliant hermetic package
AP2004002960A0 (en) 2001-06-19 2004-03-31 Digital Sports Media Physiological monitoring and system
US7160258B2 (en) 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
US7044911B2 (en) 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
EP2159723A1 (en) 2001-07-11 2010-03-03 CNS Response, Inc. Method for remote diagnosis and treatment using electroencephalografy
US7083578B2 (en) 2001-07-12 2006-08-01 Given Imaging Ltd. Device and method for examining a body lumen
US20030017826A1 (en) 2001-07-17 2003-01-23 Dan Fishman Short-range wireless architecture
WO2003009920A1 (en) 2001-07-25 2003-02-06 Biosource, Inc. Electrode array for use in electrochemical cells
FR2827919B1 (en) 2001-07-26 2004-03-05 Thermodyn SEALING FOR COMPRESSOR AND CENTRIFUGAL COMPRESSOR PROVIDED WITH SUCH A SEAL
US6951536B2 (en) 2001-07-30 2005-10-04 Olympus Corporation Capsule-type medical device and medical system
US6747556B2 (en) 2001-07-31 2004-06-08 Medtronic Physio-Control Corp. Method and system for locating a portable medical device
JP2003050867A (en) 2001-08-08 2003-02-21 Nippon Signal Co Ltd:The Method for supporting health check of walker or the like and device therefor
US20030065536A1 (en) 2001-08-13 2003-04-03 Hansen Henrik Egesborg Portable device and method of communicating medical data information
WO2003015890A1 (en) 2001-08-20 2003-02-27 President And Fellows Of Harvard College Fluidic arrays and method of using
JP3962250B2 (en) 2001-08-29 2007-08-22 株式会社レアメタル In vivo information detection system and tag device and relay device used therefor
US6650191B2 (en) 2001-09-07 2003-11-18 Texas Instruments Incorporated Low jitter ring oscillator architecture
US20050137480A1 (en) 2001-10-01 2005-06-23 Eckhard Alt Remote control of implantable device through medical implant communication service band
US20030062551A1 (en) 2001-10-02 2003-04-03 Jds Uniphase Corporation Electrode structure including encapsulated adhesion layer
US6840904B2 (en) 2001-10-11 2005-01-11 Jason Goldberg Medical monitoring device and system
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US6745082B2 (en) 2001-10-22 2004-06-01 Jens Axelgaard Current-controlling electrode with adjustable contact area
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030083559A1 (en) 2001-10-31 2003-05-01 Thompson David L. Non-contact monitor
US6643541B2 (en) 2001-12-07 2003-11-04 Motorola, Inc Wireless electromyography sensor and system
US20030107487A1 (en) 2001-12-10 2003-06-12 Ronen Korman Method and device for measuring physiological parameters at the wrist
GB0130010D0 (en) 2001-12-14 2002-02-06 Isis Innovation Combining measurements from breathing rate sensors
US7016648B2 (en) 2001-12-18 2006-03-21 Ixi Mobile (Israel) Ltd. Method, system and computer readable medium for downloading a software component to a device in a short distance wireless network
US7729776B2 (en) 2001-12-19 2010-06-01 Cardiac Pacemakers, Inc. Implantable medical device with two or more telemetry systems
US7877273B2 (en) 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
WO2003060808A2 (en) 2002-01-11 2003-07-24 Hexalog Sa Systems and methods for medication monitoring
US7519416B2 (en) 2002-02-04 2009-04-14 Heartview, Llc Diagnostic method utilizing standard lead ECG signals
US6958034B2 (en) 2002-02-11 2005-10-25 Given Imaging Ltd. Self propelled device
FR2835730B1 (en) 2002-02-11 2004-12-10 C T M Ct De Transfert Des Micr DEVICE FOR DELIVERY OF SUBSTANCES AND INTRACORPOREAL SAMPLING
US6935560B2 (en) 2002-02-26 2005-08-30 Safety Syringes, Inc. Systems and methods for tracking pharmaceuticals within a facility
US20030162556A1 (en) 2002-02-28 2003-08-28 Libes Michael A. Method and system for communication between two wireless-enabled devices
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US6968153B1 (en) 2002-03-13 2005-11-22 Nokia Corporation Apparatus, method and system for a Bluetooth repeater
US6957107B2 (en) 2002-03-13 2005-10-18 Cardionet, Inc. Method and apparatus for monitoring and communicating with an implanted medical device
US7188767B2 (en) 2002-03-18 2007-03-13 Precision Dynamics Corporation Physical condition or environmental threat detection appliance system
US6850788B2 (en) 2002-03-25 2005-02-01 Masimo Corporation Physiological measurement communications adapter
JP3869291B2 (en) 2002-03-25 2007-01-17 オリンパス株式会社 Capsule medical device
US7376435B2 (en) 2002-04-01 2008-05-20 Intel Corporation Transferring multiple data units over a wireless communication link
US7797033B2 (en) 2002-04-08 2010-09-14 Smart Pill Corporation Method of using, and determining location of, an ingestible capsule
US7645262B2 (en) 2002-04-11 2010-01-12 Second Sight Medical Products, Inc. Biocompatible bonding method and electronics package suitable for implantation
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
EP1356762A1 (en) 2002-04-22 2003-10-29 UbiCom Gesellschaft für Telekommunikation mbH Device for remote monitoring of body functions
US7424268B2 (en) 2002-04-22 2008-09-09 Cisco Technology, Inc. System and method for management of a shared frequency band
IL164685A0 (en) 2002-04-22 2005-12-18 Marcio Marc Aurelio Martins Ab Apparatus and method for measuring biologic parameters
US20030216622A1 (en) 2002-04-25 2003-11-20 Gavriel Meron Device and method for orienting a device in vivo
US7368190B2 (en) 2002-05-02 2008-05-06 Abbott Diabetes Care Inc. Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
US7901939B2 (en) 2002-05-09 2011-03-08 University Of Chicago Method for performing crystallization and reactions in pressure-driven fluid plugs
JP2003325439A (en) 2002-05-15 2003-11-18 Olympus Optical Co Ltd Capsule type medical treatment device
US20030216729A1 (en) 2002-05-20 2003-11-20 Marchitto Kevin S. Device and method for wound healing and uses therefor
GB0211620D0 (en) 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US6847844B2 (en) 2002-06-06 2005-01-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of data communication with implanted device and associated apparatus
US6864692B1 (en) 2002-06-20 2005-03-08 Xsilogy, Inc. Sensor having improved selectivity
US8003179B2 (en) 2002-06-20 2011-08-23 Alcan Packaging Flexible France Films having a desiccant material incorporated therein and methods of use and manufacture
US20040008123A1 (en) 2002-07-15 2004-01-15 Battelle Memorial Institute System and method for tracking medical devices
US20040143182A1 (en) 2002-08-08 2004-07-22 Pavel Kucera System and method for monitoring and stimulating gastro-intestinal motility
US6909878B2 (en) 2002-08-20 2005-06-21 Ixi Mobile (Israel) Ltd. Method, system and computer readable medium for providing an output signal having a theme to a device in a short distance wireless network
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US7294105B1 (en) 2002-09-03 2007-11-13 Cheetah Omni, Llc System and method for a wireless medical communication system
DE60305817T2 (en) 2002-09-04 2007-01-11 Broadcom Corp., Irvine System and method for optimizing power consumption in a mobile environment
US20040049245A1 (en) 2002-09-09 2004-03-11 Volker Gass Autonomous patch for communication with an implantable device, and medical kit for using said patch
US7102508B2 (en) 2002-09-09 2006-09-05 Persephone, Inc. Method and apparatus for locating and tracking persons
GB2393356B (en) 2002-09-18 2006-02-01 E San Ltd Telemedicine system
US7388903B2 (en) 2002-09-18 2008-06-17 Conexant, Inc. Adaptive transmission rate and fragmentation threshold mechanism for local area networks
US7118531B2 (en) 2002-09-24 2006-10-10 The Johns Hopkins University Ingestible medical payload carrying capsule with wireless communication
US6842636B2 (en) 2002-09-27 2005-01-11 Axelgaard Manufacturing Co., Ltd. Medical electrode
US7736309B2 (en) 2002-09-27 2010-06-15 Medtronic Minimed, Inc. Implantable sensor method and system
US7209790B2 (en) 2002-09-30 2007-04-24 Medtronic, Inc. Multi-mode programmer for medical device communication
US7686762B1 (en) 2002-10-03 2010-03-30 Integrated Sensing Systems, Inc. Wireless device and system for monitoring physiologic parameters
AU2003275491A1 (en) 2002-10-09 2004-05-04 Bodymedia, Inc. Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US20040073454A1 (en) 2002-10-10 2004-04-15 John Urquhart System and method of portal-mediated, website-based analysis of medication dosing
US6959217B2 (en) 2002-10-24 2005-10-25 Alfred E. Mann Foundation For Scientific Research Multi-mode crystal oscillator system selectively configurable to minimize power consumption or noise generation
US7027871B2 (en) 2002-10-31 2006-04-11 Medtronic, Inc. Aggregation of data from external data sources within an implantable medical device
US20030126593A1 (en) 2002-11-04 2003-07-03 Mault James R. Interactive physiological monitoring system
EP1437784B1 (en) 2002-11-08 2012-05-30 Honda Motor Co., Ltd. Electrode for solid polymer fuel cell
US20040092801A1 (en) 2002-11-13 2004-05-13 Budimir Drakulic System for, and method of, acquiring physiological signals of a patient
US20050288594A1 (en) 2002-11-29 2005-12-29 Shlomo Lewkowicz Methods, device and system for in vivo diagnosis
US20040115507A1 (en) 2002-12-05 2004-06-17 Potter Curtis N Monolithic fuel cell and method of manufacture
CN1726012A (en) 2002-12-11 2006-01-25 辉瑞产品公司 Controlled-release of an active substance into a high fat environment
US20040167226A1 (en) 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
US20060155174A1 (en) 2002-12-16 2006-07-13 Arkady Glukhovsky Device, system and method for selective activation of in vivo sensors
US7009511B2 (en) 2002-12-17 2006-03-07 Cardiac Pacemakers, Inc. Repeater device for communications with an implantable medical device
EP1590039A1 (en) 2002-12-19 2005-11-02 Koninklijke Philips Electronics N.V. An electrode assembly and a system with impedance control
US7127300B2 (en) 2002-12-23 2006-10-24 Cardiac Pacemakers, Inc. Method and apparatus for enabling data communication between an implantable medical device and a patient management system
US6975174B1 (en) 2002-12-31 2005-12-13 Radioframe Networks, Inc. Clock oscillator
US20060142648A1 (en) 2003-01-07 2006-06-29 Triage Data Networks Wireless, internet-based, medical diagnostic system
US7396330B2 (en) 2003-01-07 2008-07-08 Triage Data Networks Wireless, internet-based medical-diagnostic system
US7512448B2 (en) 2003-01-10 2009-03-31 Phonak Ag Electrode placement for wireless intrabody communication between components of a hearing system
KR100522132B1 (en) 2003-01-25 2005-10-18 한국과학기술연구원 Data receiving method and apparatus in human body communication system
KR100873683B1 (en) 2003-01-25 2008-12-12 한국과학기술연구원 Method and system for data communication in human body and capsule-type endoscope used therein
WO2004066903A2 (en) 2003-01-29 2004-08-12 E-Pill Pharma Ltd. Active drug delivery in the gastrointestinal tract
EP2374406B1 (en) 2003-01-30 2013-06-05 Accenture Global Services Limited Event data acquisition and transmission system
US7002476B2 (en) 2003-01-30 2006-02-21 Leap Of Faith Technologies, Inc. Medication compliance system
US7149581B2 (en) 2003-01-31 2006-12-12 Medtronic, Inc. Patient monitoring device with multi-antenna receiver
US6933026B2 (en) 2003-02-06 2005-08-23 Aradgim Corporation Method to reduce damage caused by irradiation of halogenated polymers
US7215660B2 (en) 2003-02-14 2007-05-08 Rearden Llc Single transceiver architecture for a wireless network
US7392015B1 (en) 2003-02-14 2008-06-24 Calamp Corp. Calibration methods and structures in wireless communications systems
AU2004214420A1 (en) 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
US7653031B2 (en) 2003-03-05 2010-01-26 Timothy Gordon Godfrey Advance notification of transmit opportunities on a shared-communications channel
US7155232B2 (en) 2003-03-05 2006-12-26 Conexant Systems, Inc. Transmit request signaling between transceivers
US7321920B2 (en) 2003-03-21 2008-01-22 Vocel, Inc. Interactive messaging system
WO2004084720A2 (en) 2003-03-21 2004-10-07 Welch Allyn, Inc. Personal status physiologic monitor system and architecture and related monitoring methods
DE10313005B4 (en) 2003-03-24 2007-05-03 Siemens Ag Backup battery and method for its manufacture
IL161096A (en) 2003-03-27 2008-08-07 Given Imaging Ltd Device, system and method for measuring a gradient in-vivo
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
GB0308114D0 (en) 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
JP4593083B2 (en) 2003-04-11 2010-12-08 オリンパス株式会社 Inspection data management method
GB0308467D0 (en) 2003-04-11 2003-05-21 Rolls Royce Plc Method and system for analysing tachometer and vibration data from an apparatus having one or more rotary components
US7972616B2 (en) 2003-04-17 2011-07-05 Nanosys, Inc. Medical device applications of nanostructured surfaces
FI116117B (en) 2003-04-17 2005-09-30 Polar Electro Oy Measuring device and method for measuring heart rate and the method of manufacture of the measuring device
JPWO2004096023A1 (en) 2003-04-25 2006-07-13 オリンパス株式会社 Wireless in-subject information acquisition system and subject external device
US20040218683A1 (en) 2003-05-01 2004-11-04 Texas Instruments Incorporated Multi-mode wireless devices having reduced-mode receivers
US20040225199A1 (en) 2003-05-08 2004-11-11 Evanyk Shane Walter Advanced physiological monitoring systems and methods
TWI226761B (en) 2003-05-08 2005-01-11 Ind Tech Res Inst Dual band transceiver architecture for wireless application
US7031745B2 (en) 2003-05-12 2006-04-18 Shen Ein-Yiao Cellular phone combined physiological condition examination and processing device
WO2004100776A1 (en) 2003-05-14 2004-11-25 Olympus Corporation Capsule medical device
KR100542101B1 (en) 2003-06-02 2006-01-11 삼성전자주식회사 Power control method and bluetooth device using the same
US7188199B2 (en) 2003-06-03 2007-03-06 Silicon Labs Cp, Inc. DMA controller that restricts ADC from memory without interrupting generation of digital words when CPU accesses memory
US20040249257A1 (en) 2003-06-04 2004-12-09 Tupin Joe Paul Article of manufacture for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US7313163B2 (en) 2003-06-17 2007-12-25 Motorola, Inc. Fast synchronization for half duplex digital communications
US20040260154A1 (en) 2003-06-18 2004-12-23 Boris Sidelnik Human physiological and chemical monitoring system
EP2263513B1 (en) 2003-06-24 2013-08-07 Olympus Corporation Capsule type medical device communication system, capsule type medical device, and biological information reception device
CN100542477C (en) 2003-07-16 2009-09-23 皇家飞利浦电子股份有限公司 A kind of portable electric appts that is used to monitor the individual physiological situation and health management system arranged
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US7554452B2 (en) 2003-07-18 2009-06-30 Cary Cole Ingestible tracking and locating device
US7442164B2 (en) 2003-07-23 2008-10-28 Med-El Elektro-Medizinische Gerate Gesellschaft M.B.H. Totally implantable hearing prosthesis
US7653350B2 (en) 2003-07-24 2010-01-26 Sony Ericsson Mobile Communications Ab Wireless terminals and methods for communicating over cellular and enhanced mode bluetooth communication links
JP4038575B2 (en) 2003-07-25 2008-01-30 独立行政法人産業技術総合研究所 Biosensor, biosensor device or biosensor storage method
US7243118B2 (en) 2003-07-30 2007-07-10 Broadcom Corporation Method and apparatus for efficient derivation of modulo arithmetic for frequency selection
US20050055014A1 (en) 2003-08-04 2005-03-10 Coppeta Jonathan R. Methods for accelerated release of material from a reservoir device
EP2008581B1 (en) 2003-08-18 2011-08-17 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
US20050172958A1 (en) 2003-08-20 2005-08-11 The Brigham And Women's Hospital, Inc. Inhalation device and system for the remote monitoring of drug administration
WO2005018432A2 (en) 2003-08-20 2005-03-03 Philometron, Inc. Hydration monitoring
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
JP4398204B2 (en) 2003-08-29 2010-01-13 オリンパス株式会社 In-subject introduction apparatus and wireless in-subject information acquisition system
JP4332152B2 (en) 2003-09-02 2009-09-16 富士通株式会社 Drug administration status management method and drug
JP3993546B2 (en) 2003-09-08 2007-10-17 オリンパス株式会社 In-subject introduction apparatus and wireless in-subject information acquisition system
US20050062644A1 (en) 2003-09-08 2005-03-24 Leci Jonathan Ilan Capsule device to identify the location of an individual
EP3851030B1 (en) 2003-09-11 2024-01-17 Labrador Diagnostics LLC Medical device for analyte monitoring
US7352998B2 (en) 2003-09-12 2008-04-01 Nokia Corporation Method and system for establishing a wireless communications link
US7499674B2 (en) 2003-09-12 2009-03-03 Nokia Corporation Method and system for repeat request in hybrid ultra wideband-bluetooth radio
EP1667579A4 (en) 2003-09-12 2008-06-11 Bodymedia Inc Method and apparatus for measuring heart related parameters
JP4153852B2 (en) 2003-09-18 2008-09-24 オリンパス株式会社 Energy supply coil and wireless in-vivo information acquisition system using the same
US20090157358A1 (en) 2003-09-22 2009-06-18 Hyeung-Yun Kim System for diagnosing and monitoring structural health conditions
WO2005031502A2 (en) 2003-09-22 2005-04-07 Kim Hyeung-Yun Methods for monitoring structural health conditions
US7218967B2 (en) 2003-09-26 2007-05-15 Medtronic, Inc. System and method for real-time remote monitoring of implantable medical devices
JP4503979B2 (en) 2003-10-22 2010-07-14 オリンパス株式会社 Internal devices and medical devices
US20050075145A1 (en) 2003-10-03 2005-04-07 Dvorak Joseph L. Method and system for coordinating use of objects using wireless communications
DE60305505T2 (en) 2003-10-23 2007-04-26 Sony Ericsson Mobile Communications Ab Power control circuitry for a mobile terminal application
US20050096514A1 (en) 2003-11-01 2005-05-05 Medtronic, Inc. Gastric activity notification
US6892590B1 (en) 2003-11-04 2005-05-17 Andermotion Technologies Llc Single-balanced shield electrode configuration for use in capacitive displacement sensing systems and methods
US7101343B2 (en) 2003-11-05 2006-09-05 Temple University Of The Commonwealth System Of Higher Education Implantable telemetric monitoring system, apparatus, and method
US20050101843A1 (en) 2003-11-06 2005-05-12 Welch Allyn, Inc. Wireless disposable physiological sensor
US7415242B1 (en) 2003-11-10 2008-08-19 Sprint Spectrum L.P. Method and system for proximity detection for an in-building wireless repeater
DE102004032812B4 (en) 2003-11-11 2006-07-20 Dräger Safety AG & Co. KGaA Combination sensor for physiological measurements
JP4009581B2 (en) * 2003-11-18 2007-11-14 オリンパス株式会社 Capsule medical system
JP2005158770A (en) 2003-11-20 2005-06-16 Matsushita Electric Ind Co Ltd Laminated substrate and manufacturing method thereof, manufacturing method and apparatus of module using the laminated substrate
WO2005053517A1 (en) 2003-12-01 2005-06-16 Olympus Corporation Endoscope system
US6987691B2 (en) 2003-12-02 2006-01-17 International Business Machines Corporation Easy axis magnetic amplifier
US7427266B2 (en) 2003-12-15 2008-09-23 Hewlett-Packard Development Company, L.P. Method and apparatus for verification of ingestion
US8306592B2 (en) 2003-12-19 2012-11-06 Olympus Corporation Capsule medical device
JP2005185567A (en) 2003-12-25 2005-07-14 Olympus Corp Medical capsule apparatus
JP4198045B2 (en) 2003-12-25 2008-12-17 オリンパス株式会社 In-subject position detection system
US7392091B2 (en) 2003-12-30 2008-06-24 Cochlear Limited Implanted antenna and radio communications link
JP2005193535A (en) 2004-01-07 2005-07-21 Alps Electric Co Ltd Thermal head, method of manufacturing the same, and method of adjusting dot aspect ratio of the thermal head
JP2005192821A (en) 2004-01-07 2005-07-21 Olympus Corp Capsule type medical apparatus
US7176784B2 (en) 2004-01-21 2007-02-13 Battelle Memorial Institute K1-53 Multi-mode radio frequency device
US7342895B2 (en) 2004-01-30 2008-03-11 Mark Serpa Method and system for peer-to-peer wireless communication over unlicensed communication spectrum
US7647112B2 (en) 2004-02-11 2010-01-12 Ethicon, Inc. System and method for selectively stimulating different body parts
US20060154642A1 (en) 2004-02-20 2006-07-13 Scannell Robert F Jr Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses
US20050187789A1 (en) 2004-02-25 2005-08-25 Cardiac Pacemakers, Inc. Advanced patient and medication therapy management system and method
US7904133B2 (en) 2004-02-27 2011-03-08 Koninklijke Philips Electronics N.V. Wearable wireless device for monitoring, analyzing and communicating physiological status
CN1284505C (en) 2004-02-28 2006-11-15 重庆金山科技(集团)有限公司 Radio capsule like endoscope system for medical use
US7406105B2 (en) 2004-03-03 2008-07-29 Alfred E. Mann Foundation For Scientific Research System and method for sharing a common communication channel between multiple systems of implantable medical devices
JP4488315B2 (en) 2004-03-04 2010-06-23 オリンパス株式会社 Capsule medical system
GB0405798D0 (en) 2004-03-15 2004-04-21 E San Ltd Medical data display
EP2574275A3 (en) 2004-03-22 2013-06-26 BodyMedia, Inc. Non-Invasive Temperature Monitoring Device
JP4520198B2 (en) 2004-04-07 2010-08-04 オリンパス株式会社 In-subject position display system
US20050234307A1 (en) 2004-04-15 2005-10-20 Nokia Corporation Physiological event handling system and method
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US9801527B2 (en) 2004-04-19 2017-10-31 Gearbox, Llc Lumen-traveling biological interface device
JP2005304880A (en) 2004-04-23 2005-11-04 Hitachi Ltd In-vivo object management system utilizing non-contact ic tag
WO2005109119A2 (en) 2004-04-24 2005-11-17 Inrange Systems, Inc. Integrated, non-sequential, remote medication management and compliance system
US20050245794A1 (en) 2004-04-29 2005-11-03 Medtronic, Inc. Communication with implantable monitoring probe
GB0410248D0 (en) 2004-05-07 2004-06-09 Isis Innovation Signal analysis method
WO2005110238A1 (en) 2004-05-16 2005-11-24 Medic4All A.G Method and device for measuring physiological parameters at the hand
US20050261559A1 (en) 2004-05-18 2005-11-24 Mumford John R Wireless physiological monitoring system
US7575005B2 (en) 2004-05-18 2009-08-18 Excel-Tech Ltd. Mask assembly with integrated sensors
US7125382B2 (en) 2004-05-20 2006-10-24 Digital Angel Corporation Embedded bio-sensor system
KR100592934B1 (en) 2004-05-21 2006-06-23 한국전자통신연구원 Wearable physiological signal detection module and measurement apparatus with the same
US20050259768A1 (en) 2004-05-21 2005-11-24 Oki Techno Centre (Singapore) Pte Ltd Digital receiver and method for processing received signals
US7653542B2 (en) 2004-05-26 2010-01-26 Verizon Business Global Llc Method and system for providing synthesized speech
US20050267556A1 (en) 2004-05-28 2005-12-01 Allan Shuros Drug eluting implants to prevent cardiac apoptosis
WO2005119610A1 (en) 2004-05-28 2005-12-15 Jan De Geest Communication unit for a person's skin
JP4666951B2 (en) 2004-06-03 2011-04-06 シーケーディ株式会社 Blister packaging machine and pharmaceutical solid preparation
US7289855B2 (en) 2004-06-09 2007-10-30 Medtronic, Inc. Implantable medical device package antenna
US7239918B2 (en) 2004-06-10 2007-07-03 Ndi Medical Inc. Implantable pulse generator for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue
US7697994B2 (en) 2004-06-18 2010-04-13 Medtronic, Inc. Remote scheduling for management of an implantable medical device
JP2006003307A (en) 2004-06-21 2006-01-05 Mitsutoyo Corp Encoder, and signal regulation method therefor
KR100615431B1 (en) 2004-06-22 2006-08-25 한국전자통신연구원 Physiological signal detection module, a multi-channel connector module and physiological signal detection apparatus with the same
JP2006006377A (en) 2004-06-22 2006-01-12 Elquest Corp Powder paper for packing medicine
US7498940B2 (en) 2004-06-22 2009-03-03 Vubiq, Inc. RFID system utilizing parametric reradiated technology
US20050285746A1 (en) 2004-06-25 2005-12-29 Sengupta Uttam K Radio frequency identification based system to track consumption of medication
US7206630B1 (en) 2004-06-29 2007-04-17 Cleveland Medical Devices, Inc Electrode patch and wireless physiological measurement system and method
US20070027383A1 (en) 2004-07-01 2007-02-01 Peyser Thomas A Patches, systems, and methods for non-invasive glucose measurement
US20060001496A1 (en) 2004-07-02 2006-01-05 Abrosimov Igor A Array oscillator and polyphase clock generator
JP4462614B2 (en) 2004-07-05 2010-05-12 ソニー・エリクソン・モバイルコミュニケーションズ株式会社 Short-range wireless communication system, portable terminal device, and wireless communication device
US7343186B2 (en) 2004-07-07 2008-03-11 Masimo Laboratories, Inc. Multi-wavelength physiological monitor
US7505795B1 (en) 2004-07-07 2009-03-17 Advanced Micro Devices, Inc. Power save management with customized range for user configuration and tuning value based upon recent usage
WO2006006158A1 (en) 2004-07-09 2006-01-19 Aerotel Medical Systems (1998) Ltd. Wearable device, system and method for measuring vital parameters
CN1314134C (en) 2004-07-15 2007-05-02 上海交通大学 Method for preparing silicon thin film heterojunction solar cell
WO2006020363A2 (en) 2004-07-21 2006-02-23 Illumina, Inc. Method and apparatus for drug product tracking using encoded optical identification elements
US20080027679A1 (en) 2004-07-21 2008-01-31 Dror Shklarski Wearable Device, System and Method for Measuring Physiological and/or Environmental Parameters
CN100459614C (en) 2004-07-22 2009-02-04 华为技术有限公司 Mobile phone external device and method
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
CN2719214Y (en) * 2004-08-05 2005-08-24 欧阳罗芬 Capsule type gastroscope
US7253716B2 (en) 2004-08-17 2007-08-07 Tagent Corporation Trackable pills with electronic ID tags
US7317378B2 (en) 2004-08-17 2008-01-08 Tagent Corporation Product identification tag device and reader
US20060058602A1 (en) 2004-08-17 2006-03-16 Kwiatkowski Krzysztof C Interstitial fluid analyzer
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
JP5032321B2 (en) 2004-08-31 2012-09-26 ライフスキャン・スコットランド・リミテッド Manufacturing method of automatic calibration sensor
KR100727817B1 (en) 2004-09-07 2007-06-13 한국전자통신연구원 The communication apparatus using the human body with the medium and method for the same
AU2005281502A1 (en) 2004-09-08 2006-03-16 Alertis Medical As Sensor
KR20060023228A (en) 2004-09-09 2006-03-14 이기방 Battery with porous material and fabrication method thereof
GB2418144A (en) 2004-09-17 2006-03-22 Psimedica Ltd Medical device for delivery of beneficial substance
US20060065713A1 (en) 2004-09-24 2006-03-30 John Russell Kingery System and method for monitored administration of medical products to patients
US7618374B2 (en) 2004-09-27 2009-11-17 Siemens Medical Solutions Usa, Inc. Image plane sensing methods and systems for intra-patient probes
US7341560B2 (en) 2004-10-05 2008-03-11 Rader, Fishman & Grauer Pllc Apparatuses and methods for non-invasively monitoring blood parameters
US20060078765A1 (en) 2004-10-12 2006-04-13 Laixia Yang Nano-structured ion-conducting inorganic membranes for fuel cell applications
JP2008011865A (en) 2004-10-27 2008-01-24 Sharp Corp Healthcare apparatus and program for driving the same to function
US7917199B2 (en) 2004-11-02 2011-03-29 Medtronic, Inc. Patient event marking in combination with physiological signals
ATE479387T1 (en) 2004-11-02 2010-09-15 Medtronic Inc TECHNIQUES FOR USER-ACTIVATED DATA RETENTION IN AN IMPLANTABLE MEDICAL DEVICE
IL171772A (en) 2004-11-04 2009-11-18 Given Imaging Ltd Apparatus and method for receiving device selection and combining
KR20060040500A (en) 2004-11-06 2006-05-10 삼성전자주식회사 Method and appratus for measuring bio signal
US7414534B1 (en) 2004-11-09 2008-08-19 Pacesetter, Inc. Method and apparatus for monitoring ingestion of medications using an implantable medical device
US7930064B2 (en) 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
US7214107B2 (en) 2004-11-22 2007-05-08 Cardiodynamics International Corporation Electrical connector apparatus and methods
US8374693B2 (en) 2004-12-03 2013-02-12 Cardiac Pacemakers, Inc. Systems and methods for timing-based communication between implantable medical devices
US7154071B2 (en) 2004-12-07 2006-12-26 Dräger Safety AG & Co. KGaA Device for transmitting an electric signal detected by contact with the skin surface
EP1821432B1 (en) 2004-12-08 2011-07-06 Seiko Instruments Inc. Information transmission through-human-body system and transmitter/receiver
WO2006064397A2 (en) 2004-12-13 2006-06-22 Koninklijke Philips Electronics N.V. Mobile monitoring
US20080275430A1 (en) 2004-12-14 2008-11-06 Ziv Belsky Prolonged Transit Time of Permeability-Enhancing Drug Eluting Pill
US20060136266A1 (en) 2004-12-20 2006-06-22 E-San Limited Medicinal product order processing system
US7249212B2 (en) 2004-12-22 2007-07-24 International Business Machines Corporation Bluetooth association based on docking connection
US7146449B2 (en) 2004-12-22 2006-12-05 International Business Machines Corporation Bluetooth association with simple power connection
DE602005007847D1 (en) 2004-12-30 2008-08-14 Given Imaging Ltd System for localization of an in-vivo signal source
US20060148254A1 (en) 2005-01-05 2006-07-06 Mclean George Y Activated iridium oxide electrodes and methods for their fabrication
ATE514440T1 (en) 2005-01-17 2011-07-15 Novo Nordisk As FLUID DISPENSING DEVICE WITH INTEGRATED MONITORING OF PHYSIOLOGICAL PROPERTIES
WO2006077527A2 (en) 2005-01-18 2006-07-27 Koninklijke Philips Electronics, N.V. Electronically controlled capsule for releasing radiation
JP2008532568A (en) 2005-01-18 2008-08-21 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Electronically controlled capsule
CN101208039A (en) 2005-01-18 2008-06-25 皇家飞利浦电子股份有限公司 Electronically controlled ingestible capsule for sampling fluids in alimentary tract
WO2006077529A2 (en) 2005-01-18 2006-07-27 Koninklijke Philips Electronics, N.V. System for controlling traversal of an ingested capsule
US7686839B2 (en) 2005-01-26 2010-03-30 Lumitex, Inc. Phototherapy treatment devices for applying area lighting to a wound
US8226610B2 (en) 2005-02-01 2012-07-24 Intelliject, Inc. Medical injector with compliance tracking and monitoring
JP4731936B2 (en) 2005-02-09 2011-07-27 本田技研工業株式会社 Rotary variable resistor
JP4099484B2 (en) 2005-02-09 2008-06-11 株式会社カイザーテクノロジー Communications system.
US20090030293A1 (en) 2005-02-11 2009-01-29 The University Court Of The University Of Glasgow Sensing device, apparatus and system, and method for operating the same
US7850645B2 (en) 2005-02-11 2010-12-14 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
US7504954B2 (en) 2005-03-17 2009-03-17 Spaeder Jeffrey A Radio frequency identification pharmaceutical tracking system and method
CN101180093B (en) 2005-03-21 2012-07-18 雅培糖尿病护理公司 Method and system for providing integrated medication infusion and analyte monitoring system
ATE407508T1 (en) 2005-03-22 2008-09-15 Koninkl Philips Electronics Nv ADDRESSING SCHEME FOR INTELLIGENT WIRELESS SENSOR NETWORKS FOR MEDICAL USE
US20060216603A1 (en) 2005-03-26 2006-09-28 Enable Ipc Lithium-ion rechargeable battery based on nanostructures
US20060224326A1 (en) 2005-03-31 2006-10-05 St Ores John W Integrated data collection and analysis for clinical study
WO2006107244A1 (en) 2005-04-07 2006-10-12 St. Jude Medical Ab System and method for radio communication between an implantable medical device and an external base unit
US7270633B1 (en) 2005-04-22 2007-09-18 Cardiac Pacemakers, Inc. Ambulatory repeater for use in automated patient care and method thereof
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US20060247505A1 (en) 2005-04-28 2006-11-02 Siddiqui Waqaas A Wireless sensor system
US7414543B2 (en) 2005-04-28 2008-08-19 Honeywell International Inc. Multiple miniature avionic displays
CN101287411B (en) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 Pharma-informatics system
WO2006118679A2 (en) 2005-04-28 2006-11-09 Second Sight Medical Products, Inc. Package for an implantable neural stimulation device
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US7359674B2 (en) 2005-05-10 2008-04-15 Nokia Corporation Content distribution & communication system for enhancing service distribution in short range radio environment
US20070222556A1 (en) 2005-05-17 2007-09-27 Robbins Gene A Tracking system for distributable objects which are marked in single laser shot events with dynamically variable images
ATE526952T1 (en) 2005-05-20 2011-10-15 Dow Global Technologies Llc MONITORING CORRECT DELIVERY OF ORAL DRUGS USING RADIO FREQUENCY IDENTIFICATION LABELS
US8082919B2 (en) 2005-05-24 2011-12-27 Shl Group Ab Dose counter device for inhaler
US8285205B2 (en) 2005-05-26 2012-10-09 Broadcom Corporation Method and system for a single chip integrated Bluetooth and FM transceiver and baseband processor
US20060273882A1 (en) 2005-06-01 2006-12-07 Intel Corporation RFID tag with separate transmit and receive clocks and related method
US20060276702A1 (en) 2005-06-03 2006-12-07 Mcginnis William Neurophysiological wireless bio-sensor
US7387607B2 (en) 2005-06-06 2008-06-17 Intel Corporation Wireless medical sensor system
KR100695152B1 (en) 2005-06-07 2007-03-14 삼성전자주식회사 electrode for measuring electrocardiogram and device for measuring electrocardiogram comprising the same
WO2006133444A2 (en) 2005-06-09 2006-12-14 Medtronic, Inc. Implantable medical device with electrodes on multiple housing surfaces
US20060282001A1 (en) 2005-06-09 2006-12-14 Michel Noel Physiologic sensor apparatus
WO2006130988A1 (en) 2005-06-10 2006-12-14 Telecommunications Research Laboratories Wireless communication system
ITTO20050407A1 (en) 2005-06-13 2006-12-14 Ist Superiore Mario Boella REMOTE MONITORING SYSTEM FOR PHYSIOLOGICAL PARAMETERS OF AN INDIVIDUAL, PROCEDURE AND IT PRODUCT
US7616111B2 (en) 2005-06-20 2009-11-10 Carestream Health, Inc. System to monitor the ingestion of medicines
US7782189B2 (en) 2005-06-20 2010-08-24 Carestream Health, Inc. System to monitor the ingestion of medicines
US7299034B2 (en) 2005-06-21 2007-11-20 Lawrence Kates System and method for wearable electronics
WO2007002697A2 (en) 2005-06-28 2007-01-04 Mayo Foundation For Medical Education And Research System for monitoring a physical parameter of a subject
FI20055366A0 (en) 2005-06-30 2005-06-30 Gen Electric An electrode for obtaining a biopotential signal
WO2007008494A2 (en) 2005-07-06 2007-01-18 Liebert Corporation Maximized battery run-time in a parallel ups system
US20070016089A1 (en) 2005-07-15 2007-01-18 Fischell David R Implantable device for vital signs monitoring
JP5341513B2 (en) 2005-07-20 2013-11-13 ニール・アール.・イウリアーノ Medication compliance system and related methods
US20100135907A1 (en) 2005-07-22 2010-06-03 Cranley Paul E Oral Drug Compliance Monitoring Using Sound Detection
CN100471445C (en) 2005-08-01 2009-03-25 周常安 Paster style physiological monitoring device, system and network
WO2007021813A2 (en) 2005-08-11 2007-02-22 Eksigent Technologies, Llc Microfluidic system and methods
WO2007021496A2 (en) 2005-08-18 2007-02-22 Walker Digital, Llc Systems and methods for improved health care compliance
US20090124871A1 (en) 2005-08-22 2009-05-14 Khalil Arshak Tracking system
US8116809B2 (en) 2005-08-29 2012-02-14 Intel Corporation Method and apparatus of multiple entity wireless communication adapter
US8827904B2 (en) 2005-08-31 2014-09-09 Medtronic, Inc. Automatic parameter status on an implantable medical device system
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
JP2007068622A (en) 2005-09-05 2007-03-22 Olympus Corp Acquisition system for biological information of subject
US20070135803A1 (en) 2005-09-14 2007-06-14 Amir Belson Methods and apparatus for performing transluminal and other procedures
US20070196456A1 (en) 2005-09-15 2007-08-23 Visible Assets, Inc. Smart patch
US7673679B2 (en) 2005-09-19 2010-03-09 Schlumberger Technology Corporation Protective barriers for small devices
US20080058614A1 (en) 2005-09-20 2008-03-06 Triage Wireless, Inc. Wireless, internet-based system for measuring vital signs from a plurality of patients in a hospital or medical clinic
GB0519837D0 (en) 2005-09-29 2005-11-09 Smartlife Technology Ltd Knitting techniques
GB0519836D0 (en) 2005-09-29 2005-11-09 Smartlife Technology Ltd Contact sensors
US20070078324A1 (en) 2005-09-30 2007-04-05 Textronics, Inc. Physiological Monitoring Wearable Having Three Electrodes
GB0519945D0 (en) 2005-09-30 2005-11-09 Cambridge Silicon Radio Ltd Communication in dual protocol environments
CN100466966C (en) 2005-10-08 2009-03-11 周常安 Physiological signal extracting and monitoring device and system
US7733224B2 (en) 2006-06-30 2010-06-08 Bao Tran Mesh network personal emergency response appliance
US9154616B2 (en) 2005-10-18 2015-10-06 Oia Intellectuals, Inc. Wearable capture and communication
US7720036B2 (en) 2005-10-26 2010-05-18 Intel Corporation Communication within a wireless network using multiple frequency bands
US7499739B2 (en) 2005-10-27 2009-03-03 Smiths Medical Pm, Inc. Single use pulse oximeter
US8515348B2 (en) 2005-10-28 2013-08-20 Electro Industries/Gauge Tech Bluetooth-enable intelligent electronic device
US9067047B2 (en) 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
GB0523447D0 (en) 2005-11-17 2005-12-28 E San Ltd System and method for communicating environmentally-based medical support advice
US8016776B2 (en) 2005-12-02 2011-09-13 Medtronic, Inc. Wearable ambulatory data recorder
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
NL1030608C2 (en) 2005-12-06 2007-06-07 Patrick Antonius Hendri Meeren Blister package, assembly of a blister package and a holder, and method for packaging objects.
CN1985752A (en) 2005-12-19 2007-06-27 周常安 Distributed physiological signal monitor
ATE489079T1 (en) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft MULTI-LAYER TABLET WITH TRIPLE RELEASE COMBINATION
US7678043B2 (en) 2005-12-29 2010-03-16 Given Imaging, Ltd. Device, system and method for in-vivo sensing of a body lumen
US20070156016A1 (en) 2005-12-29 2007-07-05 Ido Betesh Method and system for communication with an ingestible imaging device
US8301254B2 (en) 2006-01-09 2012-10-30 Greatbatch Ltd. Cross-band communications in an implantable device
US20070162089A1 (en) 2006-01-09 2007-07-12 Transoma Medical, Inc. Cross-band communications in an implantable device
US8078278B2 (en) 2006-01-10 2011-12-13 Remon Medical Technologies Ltd. Body attachable unit in wireless communication with implantable devices
EP1979040B1 (en) 2006-01-23 2009-09-02 Koninklijke Philips Electronics N.V. Improved biomedical electrode for extended patient wear featuring a tap, or snap, which is isolated from the retention seal
US20070185393A1 (en) 2006-02-03 2007-08-09 Triage Wireless, Inc. System for measuring vital signs using an optical module featuring a green light source
US7809399B2 (en) 2006-02-10 2010-10-05 Syntek International Holding Ltd. Method and device for providing multiple communication protocols with a single transceiver
US20090023391A1 (en) 2006-02-24 2009-01-22 Koninklijke Philips Electronics N. V. Wireless body sensor network
EP1993437A4 (en) 2006-02-24 2014-05-14 Hmicro Inc A medical signal processing system with distributed wireless sensors
JP2009528909A (en) 2006-03-03 2009-08-13 フィジオウェイヴ インコーポレイテッド Physiological monitoring system and method
US8200320B2 (en) 2006-03-03 2012-06-12 PhysioWave, Inc. Integrated physiologic monitoring systems and methods
WO2007104152A2 (en) 2006-03-14 2007-09-20 Jamie Hackett Long-range radio frequency receiver-controller module and wireless control system comprising same
US8131376B1 (en) 2007-09-11 2012-03-06 Second Sight Medical Products, Inc. Method of inspection of materials for defects
US8920343B2 (en) 2006-03-23 2014-12-30 Michael Edward Sabatino Apparatus for acquiring and processing of physiological auditory signals
US8389003B2 (en) 2006-03-29 2013-03-05 Eatlittle Inc. Ingestible implement for weight control
JP2009532119A (en) 2006-03-30 2009-09-10 ダウ グローバル テクノロジーズ インコーポレイティド Methods and systems for monitoring and analyzing compliance with internal medication regimens
TW200738212A (en) 2006-04-12 2007-10-16 Guo Terry Bo Jau Miniature wireless apparatus for collecting physiological signals of animals
CA2649447A1 (en) 2006-04-25 2007-11-08 Dow Global Technologies Inc. Oral drug compliance monitoring using magnetic-field sensors
US7912537B2 (en) 2006-04-27 2011-03-22 Medtronic, Inc. Telemetry-synchronized physiological monitoring and therapy delivery systems
US7942844B2 (en) 2006-04-28 2011-05-17 Medtronic Minimed, Inc. Remote monitoring for networked fluid infusion systems
CN105468895A (en) 2006-05-02 2016-04-06 普罗透斯数字保健公司 Patient customized therapeutic regimens
GB0608829D0 (en) 2006-05-04 2006-06-14 Husheer Shamus L G In-situ measurement of physical parameters
WO2007128165A1 (en) 2006-05-09 2007-11-15 Fangen Xiong A short-range wireless networks system and erection method which allot time slots with multi-channel rf transceiver
US20080051647A1 (en) 2006-05-11 2008-02-28 Changwang Wu Non-invasive acquisition of large nerve action potentials (NAPs) with closely spaced surface electrodes and reduced stimulus artifacts
US7558622B2 (en) 2006-05-24 2009-07-07 Bao Tran Mesh network stroke monitoring appliance
KR101095589B1 (en) 2006-05-15 2011-12-19 노키아 코포레이션 Contactless programming and testing of memory elements
US7539533B2 (en) 2006-05-16 2009-05-26 Bao Tran Mesh network monitoring appliance
US20080074307A1 (en) 2006-05-17 2008-03-27 Olga Boric-Lubecke Determining presence and/or physiological motion of one or more subjects within a doppler radar system
CN101073494B (en) 2006-05-18 2010-09-08 周常安 Non-invasive life evidence monitor, monitor system and method
US20070279217A1 (en) 2006-06-01 2007-12-06 H-Micro, Inc. Integrated mobile healthcare system for cardiac care
US8562526B2 (en) 2006-06-01 2013-10-22 Resmed Sensor Technologies Limited Apparatus, system, and method for monitoring physiological signs
US7346380B2 (en) 2006-06-16 2008-03-18 Axelgaard Manufacturing Co., Ltd. Medical electrode
US20100081895A1 (en) 2006-06-21 2010-04-01 Jason Matthew Zand Wireless medical telemetry system and methods using radio frequency energized biosensors
EP2032735A4 (en) 2006-06-21 2011-12-21 Proteus Biomedical Inc Implantable medical devices comprising cathodic arc produced structures
US8597278B2 (en) 2006-06-23 2013-12-03 MEDIMETRICS Personalized Drug Delivery B.V. Medicament delivery system and process
US7949404B2 (en) 2006-06-26 2011-05-24 Medtronic, Inc. Communications network for distributed sensing and therapy in biomedical applications
US20080046038A1 (en) 2006-06-26 2008-02-21 Hill Gerard J Local communications network for distributed sensing and therapy in biomedical applications
US20080000804A1 (en) 2006-06-29 2008-01-03 Carey David A Carrier tape with integrated cover tape
EP2037999B1 (en) 2006-07-07 2016-12-28 Proteus Digital Health, Inc. Smart parenteral administration system
US20080020037A1 (en) 2006-07-11 2008-01-24 Robertson Timothy L Acoustic Pharma-Informatics System
US7962174B2 (en) 2006-07-12 2011-06-14 Andrew Llc Transceiver architecture and method for wireless base-stations
US20080021521A1 (en) 2006-07-18 2008-01-24 Cardiac Pacemakers, Inc. Implantable Medical Device Communication System
DE102007020583B4 (en) 2006-07-19 2012-10-11 Erbe Elektromedizin Gmbh Electrode device with an impedance measuring device and method for producing such an electrode device
WO2008018076A2 (en) 2006-08-10 2008-02-14 Given Imaging Ltd. System and method for in vivo imaging
WO2008021524A2 (en) 2006-08-18 2008-02-21 Second Sight Medical Products, Inc. Package for an implantable neural stimulation device
US20080097549A1 (en) 2006-09-01 2008-04-24 Colbaugh Michael E Electrode Assembly and Method of Using Same
US7756573B2 (en) 2006-09-05 2010-07-13 Cardiac Pacemakers, Inc. Implantable medical device diagnostic data acquisition and storage
US20080112885A1 (en) 2006-09-06 2008-05-15 Innurvation, Inc. System and Method for Acoustic Data Transmission
EP2063766B1 (en) 2006-09-06 2017-01-18 Innurvation, Inc. Ingestible low power sensor device and system for communicating with same
CN101516256A (en) 2006-09-18 2009-08-26 皇家飞利浦电子股份有限公司 IP based monitoring and alarming
US20080077028A1 (en) 2006-09-27 2008-03-27 Biotronic Crm Patent Personal health monitoring and care system
US20080077184A1 (en) 2006-09-27 2008-03-27 Stephen Denker Intravascular Stimulation System With Wireless Power Supply
WO2008038246A2 (en) 2006-09-29 2008-04-03 Koninklijke Philips Electronics, N.V. Miniaturized threshold sensor
US20080091114A1 (en) 2006-10-11 2008-04-17 Pacesetter, Inc. Techniques for Correlating Thoracic Impedance with Physiological Status
US20080091089A1 (en) 2006-10-12 2008-04-17 Kenneth Shane Guillory Single use, self-contained surface physiological monitor
ATE535057T1 (en) 2006-10-17 2011-12-15 Proteus Biomedical Inc LOW VOLTAGE OSCILLATOR FOR MEDICAL FACILITIES
US20080097917A1 (en) 2006-10-24 2008-04-24 Kent Dicks Systems and methods for wireless processing and medical device monitoring via remote command execution
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
US20080119705A1 (en) 2006-11-17 2008-05-22 Medtronic Minimed, Inc. Systems and Methods for Diabetes Management Using Consumer Electronic Devices
WO2008063626A2 (en) 2006-11-20 2008-05-29 Proteus Biomedical, Inc. Active signal processing personal health signal receivers
CN101541237A (en) 2006-11-21 2009-09-23 皇家飞利浦电子股份有限公司 Ingestible electronic capsule and in vivo drug delivery or diagnostic system
GB0624085D0 (en) 2006-12-01 2007-01-10 Oxford Biosignals Ltd Biomedical signal analysis method
GB0624081D0 (en) 2006-12-01 2007-01-10 Oxford Biosignals Ltd Biomedical signal analysis method
US20080137566A1 (en) 2006-12-06 2008-06-12 Bojko Marholev Method and System for Shared High-Power Transmit Path for a Multi-Protocol Transceiver
US20080146889A1 (en) 2006-12-13 2008-06-19 National Yang-Ming University Method of monitoring human physiological parameters and safty conditions universally
US8157730B2 (en) 2006-12-19 2012-04-17 Valencell, Inc. Physiological and environmental monitoring systems and methods
TWI334747B (en) 2006-12-22 2010-12-11 Unimicron Technology Corp Circuit board structure having embedded electronic components
US7782991B2 (en) 2007-01-09 2010-08-24 Freescale Semiconductor, Inc. Fractionally related multirate signal processor and method
US20080166992A1 (en) 2007-01-10 2008-07-10 Camillo Ricordi Mobile emergency alert system
CA2671332A1 (en) 2007-01-16 2008-07-24 Christopher Michael Jones Oral drug capsule component incorporating a communication device
WO2008091683A2 (en) 2007-01-25 2008-07-31 Senior Vitals, Inc. System and method for physiological data readings, transmission and presentation
US20080183245A1 (en) 2007-01-31 2008-07-31 Van Oort Geeske Telemetry of external physiological sensor data and implantable medical device data to a central processing system
CA2676407A1 (en) 2007-02-01 2008-08-07 Proteus Biomedical, Inc. Ingestible event marker systems
US20080214985A1 (en) 2007-02-02 2008-09-04 Activatek, Inc. Active transdermal medicament patch
WO2008097652A2 (en) 2007-02-08 2008-08-14 Senior Vitals, Inc. Body patch for none-invasive physiological data readings
CN101636865B (en) 2007-02-14 2012-09-05 普罗秋斯生物医学公司 In-body power source having high surface area electrode
US8932221B2 (en) * 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US20080303638A1 (en) 2007-03-24 2008-12-11 Hap Nguyen Portable patient devices, systems, and methods for providing patient aid and preventing medical errors, for monitoring patient use of ingestible medications, and for preventing distribution of counterfeit drugs
WO2008120128A2 (en) 2007-03-30 2008-10-09 Koninklijke Philips Electronics N.V. System and method for pill communication and control
JP4920478B2 (en) 2007-04-05 2012-04-18 株式会社東芝 MRI equipment
US7998110B2 (en) 2007-04-25 2011-08-16 Hong Kong Polytechnic University Medical device for delivering drug and/or performing physical therapy
KR100895297B1 (en) 2007-04-30 2009-05-07 한국전자통신연구원 A multi channel electrode sensor apparatus for measuring a plurality of physiological signals
WO2008131557A1 (en) 2007-05-01 2008-11-06 Urodynamix Technologies Ltd. Apparatus and methods for evaluating physiological conditions of tissue
GB0709248D0 (en) 2007-05-14 2007-06-20 T & Medical Ltd System for monitoring chemotherapy associated adverse drug reactions
US8412293B2 (en) 2007-07-16 2013-04-02 Optiscan Biomedical Corporation Systems and methods for determining physiological parameters using measured analyte values
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US20080300572A1 (en) 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US20080311852A1 (en) 2007-06-15 2008-12-18 Broadcom Corporation Multiple communication link coordination for shared data transmissions
US8060175B2 (en) 2007-06-15 2011-11-15 General Electric Company System and apparatus for collecting physiological signals from a plurality of electrodes
EP2008584A1 (en) * 2007-06-26 2008-12-31 Julius-Maximilians-Universität Würzburg In vivo device, system and usage thereof
GB2450517A (en) 2007-06-27 2008-12-31 Smartlife Technology Ltd Electrical resistance of yarn or fabric changes with temperature
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
US20090009332A1 (en) 2007-07-03 2009-01-08 Endotronix, Inc. System and method for monitoring ingested medication via rf wireless telemetry
JP5065780B2 (en) 2007-07-03 2012-11-07 株式会社日立製作所 RFID tag mounting board
JP4520491B2 (en) 2007-07-09 2010-08-04 オリンパス株式会社 Capsule medical system
US8340750B2 (en) 2007-07-19 2012-12-25 Medtronic, Inc. Mechanical function marker channel for cardiac monitoring and therapy control
AU2008282451B2 (en) 2007-07-27 2013-09-26 Second Sight Medical Products Implantable device for the brain
GB0714807D0 (en) 2007-07-30 2007-09-12 Oxford Biosignals Ltd Method and apparatus for measuring breathing rate
KR100863064B1 (en) 2007-08-03 2008-10-13 한국전자통신연구원 Garment for measuring physiological signals and method of fabricating the same
KR101080423B1 (en) 2007-08-03 2011-11-04 삼성전자주식회사 Multi module combination type portable electronic device
US9179864B2 (en) 2007-08-15 2015-11-10 Integrity Tracking, Llc Wearable health monitoring device and methods for fall detection
US20090048498A1 (en) 2007-08-17 2009-02-19 Frank Riskey System and method of monitoring an animal
US8926509B2 (en) 2007-08-24 2015-01-06 Hmicro, Inc. Wireless physiological sensor patches and systems
US20090062670A1 (en) 2007-08-30 2009-03-05 Gary James Sterling Heart monitoring body patch and system
US10561336B2 (en) 2007-09-05 2020-02-18 Sensible Medical Innovations Ltd. Method and system for monitoring thoracic tissue fluid
JP5602629B2 (en) 2007-09-07 2014-10-08 フローレ,インゴ Diagnostic sensor unit
US20090069642A1 (en) 2007-09-11 2009-03-12 Aid Networks, Llc Wearable Wireless Electronic Patient Data Communications and Physiological Monitoring Device
US20090076342A1 (en) 2007-09-14 2009-03-19 Corventis, Inc. Adherent Multi-Sensor Device with Empathic Monitoring
WO2009036333A1 (en) 2007-09-14 2009-03-19 Corventis, Inc. Dynamic pairing of patients to data collection gateways
DK2192946T3 (en) 2007-09-25 2022-11-21 Otsuka Pharma Co Ltd In-body device with virtual dipole signal amplification
US20090087483A1 (en) 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US20090088618A1 (en) 2007-10-01 2009-04-02 Arneson Michael R System and Method for Manufacturing a Swallowable Sensor Device
CL2008003007A1 (en) 2007-10-12 2009-10-02 Bigtec Private Ltd A microchip with layers of low temperature firing ceramics (ltcc) forming a reaction chamber, conductive rings that surround the reaction chamber and a heater that supplies heat to the rings, the microchip manufacturing method and a micro polymerase chain reaction (pcr) device.
US20090105561A1 (en) 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8134459B2 (en) 2007-10-19 2012-03-13 Smiths Medical Asd, Inc. Wireless telecommunications system adaptable for patient monitoring
US20090105567A1 (en) 2007-10-19 2009-04-23 Smiths Medical Pm, Inc. Wireless telecommunications network adaptable for patient monitoring
US8139225B2 (en) 2007-10-24 2012-03-20 Siemens Medical Solutions Usa, Inc. System for processing patient monitoring power and data signals
GB0721117D0 (en) 2007-10-26 2007-12-05 T & Medical Ltd system for assisting in drug dose optimisaion
US20090112626A1 (en) 2007-10-30 2009-04-30 Cary Talbot Remote wireless monitoring, processing, and communication of patient data
WO2009063377A1 (en) 2007-11-13 2009-05-22 Koninklijke Philips Electronics N.V. Ingestible electronic capsule
CN101926097B (en) 2007-11-27 2016-10-05 普罗透斯数字保健公司 Use communication channel wears body communication system
US20090149839A1 (en) 2007-12-11 2009-06-11 Hyde Roderick A Treatment techniques using ingestible device
US20090157113A1 (en) 2007-12-18 2009-06-18 Ethicon Endo-Surgery, Inc. Wearable elements for implantable restriction systems
JP5535936B2 (en) 2007-12-20 2014-07-02 コーニンクレッカ フィリップス エヌ ヴェ Capacitance detection and communication
JP5091657B2 (en) 2007-12-21 2012-12-05 株式会社東芝 Wireless communication apparatus and wireless communication method
US20090171180A1 (en) 2007-12-28 2009-07-02 Trevor Pering Method and apparatus for configuring wearable sensors
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
EP2230993B1 (en) 2008-01-15 2018-08-15 Cardiac Pacemakers, Inc. Implantable medical device with antenna
WO2009091910A1 (en) 2008-01-15 2009-07-23 Cardiac Pacemakers, Inc. Implantable medical device with wireless communications
US20090182207A1 (en) 2008-01-16 2009-07-16 Tenxsys Inc. Ingestible animal health sensor
GB2456567B (en) 2008-01-18 2010-05-05 Oxford Biosignals Ltd Novelty detection
JP5132335B2 (en) 2008-01-29 2013-01-30 富士フイルム株式会社 Capsule endoscope and capsule endoscope system
JP5156427B2 (en) 2008-02-13 2013-03-06 富士フイルム株式会社 Capsule endoscope system
EP3235491B1 (en) 2008-03-05 2020-11-04 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems
EP2249919B1 (en) 2008-03-06 2019-05-22 Stryker Corporation Foldable, implantable electrode array assembly
US7983189B2 (en) 2008-03-12 2011-07-19 Embarq Holdings Company, Llc System and method for tracking performance and service level agreement compliance for multipoint packet services
US20090243833A1 (en) 2008-03-31 2009-10-01 Ching Ching Huang Monitoring system and method for patient care
WO2009146082A2 (en) 2008-04-01 2009-12-03 The Research Foundation Of The State University Of New York Rfid monitoring of drug regimen compliance
EP2319389B1 (en) 2008-04-03 2014-02-26 Olympus Medical Systems Corporation Antenna unit and receiving apparatus for capsule medical apparatus
DE102009002450A1 (en) 2008-04-18 2009-10-22 Korsch Ag Method and device for inserting inserts (cores) in dies of a rotary tablet press
WO2009131664A2 (en) 2008-04-21 2009-10-29 Carl Frederick Edman Metabolic energy monitoring system
CA2724890A1 (en) 2008-06-18 2009-12-23 The Smartpill Corporation System and method of evaluating a subject with an ingestible capsule
US20090318303A1 (en) 2008-06-20 2009-12-24 International Business Machines Corporation Microfluidic selection of library elements
US9014778B2 (en) 2008-06-24 2015-04-21 Biosense Webster, Inc. Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
CH699071A2 (en) 2008-07-02 2010-01-15 Flakes S A A braking and / or mechanical locking.
US20100001841A1 (en) 2008-07-07 2010-01-07 Cardullo Mario W Dynamically distributable nano rfid device and related method
SG10201702853UA (en) 2008-07-08 2017-06-29 Proteus Digital Health Inc Ingestible event marker data framework
EP2320875B1 (en) 2008-07-23 2019-07-03 I-Property Holding Corp. Secure tracking of tablets
AU2009281876B2 (en) 2008-08-13 2014-05-22 Proteus Digital Health, Inc. Ingestible circuitry
US20100056878A1 (en) 2008-08-28 2010-03-04 Partin Dale L Indirectly coupled personal monitor for obtaining at least one physiological parameter of a subject
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US20100063841A1 (en) 2008-09-05 2010-03-11 Vital Data Technology, Llc System and method of notifying designated entities of access to personal medical records
US8224596B2 (en) 2008-09-09 2012-07-17 International Business Machines Corporation Portable device battery optimization routing system
US20100069002A1 (en) 2008-09-16 2010-03-18 Vcan Sports, Inc. Method and apparatus for a wireless communication device utilizing bluetooth technology
JP5411943B2 (en) 2008-11-13 2014-02-12 プロテウス デジタル ヘルス, インコーポレイテッド Ingestible therapy activation system and method
AU2009324536A1 (en) * 2008-12-11 2011-07-14 Proteus Digital Health, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
TWI503101B (en) 2008-12-15 2015-10-11 Proteus Digital Health Inc Body-associated receiver and method
SG196787A1 (en) 2009-01-06 2014-02-13 Proteus Digital Health Inc Ingestion-related biofeedback and personalized medical therapy method and system
SG172847A1 (en) 2009-01-06 2011-08-29 Proteus Biomedical Inc Pharmaceutical dosages delivery system
CN105380650A (en) 2009-01-06 2016-03-09 普罗秋斯数字健康公司 High-throughput production of ingestible event markers
JP4576462B2 (en) 2009-01-30 2010-11-10 株式会社バッファロー Router device
US8395521B2 (en) 2009-02-06 2013-03-12 University Of Dayton Smart aerospace structures
US8073401B2 (en) 2009-02-17 2011-12-06 Rfaxis, Inc. Multi mode radio frequency transceiver front end circuit with inter-stage matching circuit
WO2010099268A1 (en) 2009-02-25 2010-09-02 Xanthia Global Limited Wireless physiology monitor
US8452366B2 (en) 2009-03-16 2013-05-28 Covidien Lp Medical monitoring device with flexible circuitry
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
US8805528B2 (en) 2009-03-31 2014-08-12 Medtronic, Inc. Channel assessment and selection for wireless communication between medical devices
SG10201810784SA (en) 2009-04-28 2018-12-28 Proteus Digital Health Inc Highly Reliable Ingestible Event Markers And Methods For Using The Same
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US8200321B2 (en) 2009-05-20 2012-06-12 Sotera Wireless, Inc. Method for measuring patient posture and vital signs
EP2437850B1 (en) 2009-06-04 2014-11-19 Morgan Advanced Ceramics, Inc. Co-fired metal and ceramic composite feedthrough assemblies for use at least in implantable medical devices and methods for making the same
BR112012003745A2 (en) 2009-08-21 2019-09-24 3M Innovantive Properties Company fabric lighting methods and products
US20110230732A1 (en) 2009-09-14 2011-09-22 Philometron, Inc. System utilizing physiological monitoring and electronic media for health improvement
US8207731B2 (en) 2009-09-30 2012-06-26 Thermofisher Scientific Apparatus and method for automatic product effect compensation in radio frequency metal detectors
UA109424C2 (en) 2009-12-02 2015-08-25 PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS
WO2011112972A2 (en) 2010-03-11 2011-09-15 Philometron, Inc. Physiological monitor system for determining medication delivery and outcome
TWI638652B (en) 2010-04-07 2018-10-21 波提亞斯數位康健公司 Miniature ingestible device
US9872637B2 (en) 2010-04-21 2018-01-23 The Rehabilitation Institute Of Chicago Medical evaluation system and method using sensors in mobile devices
CN106408309A (en) 2010-06-14 2017-02-15 特鲁塔格科技公司 System for verifying an item in a package using a database
KR101760663B1 (en) 2010-06-14 2017-08-04 트루테그 테크놀로지스, 인코포레이티드 System for verifying an item in a package
WO2011159337A1 (en) 2010-06-14 2011-12-22 Trutag Technologies, Inc. Labeling and verifying an item with an identifier
CN106296226A (en) 2010-06-14 2017-01-04 特鲁塔格科技公司 For producing the system of the packaging article with identifier
US20120016231A1 (en) 2010-07-18 2012-01-19 Medical Scan Technologies, Inc. System and method for three dimensional cosmetology imaging with structured light
CN103180801B (en) 2010-09-13 2016-08-03 诺基亚技术有限公司 Haptics communications
WO2012071280A2 (en) 2010-11-22 2012-05-31 Proteus Biomedical, Inc. Ingestible device with pharmaceutical product
WO2012129256A1 (en) 2011-03-21 2012-09-27 Purafil, Inc. Systems and methods for detecting and identifying contaminants in a gaseous environment
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9158890B2 (en) 2011-07-27 2015-10-13 At&T Mobility Ii Llc Mobile applications and methods for conveying performance information of a cardiac pacemaker
US20130129869A1 (en) 2011-11-23 2013-05-23 Hooman Hafezi Compositions comprising a shelf-life stability component
BR112015001388A2 (en) 2012-07-23 2017-07-04 Proteus Digital Health Inc techniques for making ingestible event markers comprising an ingestible component
EP2898297A4 (en) 2012-09-21 2016-05-25 Proteus Digital Health Inc Wireless wearable apparatus, system, and method
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US20150127738A1 (en) 2013-11-05 2015-05-07 Proteus Digital Health, Inc. Bio-language based communication system
WO2015112604A1 (en) 2014-01-22 2015-07-30 Proteus Digital Health, Inc. Edible adhesives and ingestible compositions including the same
US20160345906A1 (en) 2014-02-04 2016-12-01 Proteus Digital Health, Inc. Enhanced ingestible event indicators and methods for making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2731497A4 *

Also Published As

Publication number Publication date
WO2013009781A3 (en) 2013-04-04
CN103781411B (en) 2016-01-06
US9439582B2 (en) 2016-09-13
US20120007734A1 (en) 2012-01-12
MX2014000482A (en) 2014-08-27
HK1196239A1 (en) 2014-12-12
AU2017202754B2 (en) 2019-01-24
KR20140066996A (en) 2014-06-03
EP2731497B1 (en) 2016-04-27
AU2012282776A1 (en) 2014-01-30
AU2012282776B2 (en) 2017-02-02
RU2014104519A (en) 2015-08-20
BR112014000624A2 (en) 2017-02-14
EP2731497A4 (en) 2015-04-01
CA2841904A1 (en) 2013-01-17
EP2731497A2 (en) 2014-05-21
TW201320962A (en) 2013-06-01
US8912908B2 (en) 2014-12-16
US20150173646A1 (en) 2015-06-25
CN103781411A (en) 2014-05-07
JP2014522695A (en) 2014-09-08
IN2014CN00509A (en) 2015-04-03
AU2017202754A1 (en) 2017-05-18
MX337132B (en) 2016-02-12

Similar Documents

Publication Publication Date Title
AU2017202754B2 (en) Communication system with remote activation
EP2731496B1 (en) Communication system incorporated in an ingestible product
AU2012282772A1 (en) Communication system with multiple sources of power
AU2012282777A1 (en) Communication system with enhanced partial power source and method of manufacturing same
EP2731494A2 (en) Communication system using an implantable device
WO2013078405A1 (en) Communication system incorporated in a container
AU2011204798C1 (en) Communication system with partial power source

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12811425

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 2014520263

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2841904

Country of ref document: CA

Ref document number: 2014/1985

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2012811425

Country of ref document: EP

Ref document number: MX/A/2014/000482

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2012282776

Country of ref document: AU

Date of ref document: 20120710

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 20147003474

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2014104519

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014000624

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 112014000624

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140110